| Title | Collaboration Type | HHS Participating Agencies | NIH Participating Institutes, Centers, and Offices | Description |
|---|---|---|---|---|
| 10th Annual Conference on the Science of Dissemination and Implementation | Meeting/ Workshop | AHRQ | NHLBI, NCCIH, NCI, NIAAA, NIAID, NIDA, NIDDK, NIMH, NINR | A forum for discussing the science of dissemination and implementation, the 10th annual conference aimed to grow the research base by bridging the gap between evidence, practice, and policy in health and medicine. http://www.academyhealth.org/events/site/10th-annual-conference-science-dissemination-and-implementation-health |
| 2016 NCI SBIR Workshop on Facilitating the Development of Molecularly Targeted Radiotherapy | Training Initiative | FDA | NCI | As part of its continued effort to support awardee companies'' journey to commercialization, NCI SBIR Development Center hosted a specialized workshop for awardee companies developing molecularly targeted radiotherapy. The Workshop on Facilitating the Development of Molecularly Targeted Radiotherapy (hereinafter TRT Workshop) brought together experts from the SBIR program, NCI Radiation Research program, Food and Drug Administration''s Center for Drug Evaluation and Research (FDA CDER), and Department of Energy''s Isotope program to introduce the regulatory and clinical processes relevant to workshop participants. https://sbir.cancer.gov/programs/2016TRT |
| 2018 Physical Activity Guidelines Advisory Committee Report | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/ODP, NCI | The 2018 Physical Activity Guidelines Advisory Committee submitted its Scientific Report to the Secretary of Health and Human Services in February 2018. The report summarizes the scientific evidence on physical activity and health and will be used by the government to develop the second edition of the Physical Activity Guidelines for Americans. The HHS ODPHP coordinates the overall effort for this activity and oversees the FACA. The NIH ODP coordinates NIH input on this effort. https://health.gov/paguidelines/ |
| A Pilot Study of Urinary Carcinogen Biomarkers in the Golestan Cohort Study | Research Initiative | CDC, FDA | NCI | A pilot study in the Golestan Cohort to compare exposure to different types of carcinogens (nicotine metabolites, polycyclic aromatic hydrocarbons [PAHs], tobacco-specific nitrosamines [TSNAs], and volatile organic compounds [VOCs]) and creatine in the urine of self-reported cigarette, chewing nass, water pipe, and opium users, and those who never use these products. The study will examine the stability of these markers over time by taking advantage of repeated samples that were collected from a subset of participants. Results from the pilot study will then be used to evaluate the potential of future studies and evaluate their design. |
| A Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews | Research Initiative | CDC | NCI | NCI and CDC are collaborating on a cross-sectional study of 83 airline pilots and 50 university faculty to assess the relation of stable chromosome translocations with cosmic radiation exposure. |
| A Working Group to Consider the Question of Federal Public Health and Medical Resource Allocation | Committee, Work group, Advisory group, or Task Force | OS | CC | THe NIH Clinical Center is participating in a working group to consider the question of federal public health and medical resource allocation. The group developed a framework for allocation of federal resources during scarcity after engaging with stakeholders in ethics, disaster preparedness, and emergency management. |
| A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial | Research Initiative | CDC | NIAID | The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using new regimens, including high-dose rifapentine. |
| Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) | Research Initiative | FDA | NIDA | Abuse Liability Evaluation for Research, Treatment, and Training (ALERTT) is part of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration (FDA). The mission of the (ACTTION) is to identify, prioritize, sponsor, coordinate, and promote innovative activities with a special interest in optimizing clinical trials that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of public health. http://www.acttion.org/news/3_1_12.html |
| Accelerating Medicines Partnership | Other | FDA | OD/OSP, NIA, NIAMS, NIDDK, NINDS | The Accelerating Medicines Partnership (AMP) is a public-private partnership, between NIH, FDA, 10 biopharmaceutical companies and multiple non-profit organizations, and managed by the Foundation for NIH (FNIH), to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics. The ultimate goal is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them. AMP was launched in February 2014, with projects in three disease areas (Alzheimer’s disease; type 2 diabetes; and autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus). Steering committees for each of the three disease areas, with representation from all partners, meet regularly to review ongoing progress and milestones. The steering committees are managed by FNIH under the direction of an AMP Executive Committee comprised of representatives from NIH, participating industry leaders, FDA, and non-profit organizations. https://www.nih.gov/research-training/accelerating-medicines-partnership-amp |
| AccessGUDID | Resource Development | FDA | NLM | The Global Unique Device Identification Database (GUDID) contains key device identification information submitted to the FDA about medical devices that have Unique Device Identifiers (UDI). The National Library of Medicine (NLM), in collaboration with the FDA, has created the AccessGUDID portal to make device identification information in the GUDID available for everyone, including patients, caregivers, healthcare providers, hospitals, and industry. https://accessgudid.nlm.nih.gov |
| Action for Health in Diabetes (Look AHEAD) | Research Initiative | CDC, IHS | NIDDK, NIA | This study is a 16-center, randomized clinical trial investigating the long-term health consequences of weight loss. Enrollment occurred between 2001-2004 with a planned follow-up of up to 13.5 years. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. The study intervention was discontinued in Sept. 2012 on the recommendation of the Data and Safety Monitoring Board (DSMB), as there were no differences between the two groups after up to 11 years of follow-up. The study will continue to follow participants for study outcomes. http://www.lookaheadtrial.org |
| Adjuvant Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA | NIAID, NCI | Staff from all National Institute of Allergy and Infectious Diseases (NIAID) Divisions, program staff from the Biomedical Advanced Research and Development Authority (BARDA), and regulatory staff from the Food and Drug Administration (FDA) exchange information about ongoing programs related to novel adjuvants for infectious disease vaccines, identify high priority research areas (and gap areas), and discuss ideas to accelerate progress in adjuvant research through better access to information and resources. |
| Administrative Supplements on HIV Pre-Exposure Prophylaxis Implementation Science in CDC-Funded Public Health Demonstration Projects | Research Initiative | CDC | NIMH | The National Institute of Mental Health (NIMH), in collaboration with the Centers for Disease Control and Prevention (CDC), developed a request for applications to call for administrative supplements to currently funded NIH grants. These supplements would support implementation science research related to a CDC-funded public health initiative to reduce HIV infections in men who have sex with men (MSM) and transgender individuals through improved HIV pre-exposure prophylaxis (PrEP) planning, outreach, and delivery. Eight supplements were awarded. https://grants.nih.gov/grants/guide/pa-files/PA-16-199.html |
| Adolescent Brain Cognitive Development (ABCD) Study | Research Initiative | CDC | NIDA, NCI, NIAAA, NICHD, NIMH, NIMHD, NINDS, OD/DPCPSI/OBSSR | The Adolescent Brain Cognitive Development (ABCD) project, a landmark longitudinal study of brain development and child health, will increase our understanding of how diverse experiences during adolescence interact with changing biology to influence brain, cognitive, and social/emotional development of youth. In partnership with area public and private schools, researchers at twenty-one research sites across the country will recruit 10,000 children at age 9-10 from diverse races and ethnicities, education and income levels, and living environments and follow them through their teens and into early adulthood. Throughout this period, researchers will assess each child’s physical and mental health, substance use, sleep patterns, genetics, childhood experiences, and cultural/environmental influences, as well as track brain and cognitive development with non-invasive magnetic resonance imaging scans at regular intervals. To enrich the value of the study, ABCD will release anonymized data annually to the research community in an open science model to allow scientists from all over the world to conduct analyses and pool resources to rapidly expand the types of scientific questions that can be answered. The actionable information coming out of this study will enable education, substance use prevention, and other health promotion policies to ensure the wellbeing and success of the Nation’s children. http://abcdstudy.org/ |
| Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) | Committee, Work group, Advisory group, or Task Force | CDC | FIC, NIAID, NICHD, NIMH, OD/DPCPSI/OAR | The Adolescent HIV Prevention and Treatment Implementation Science Alliance (AHISA) aims to enhance the effective use of evidence and help overcome implementation challenges related to prevention, screening, and treatment of HIV among adolescents (ages 15 to 24) in sub-Saharan Africa by catalyzing collaboration and communication among implementation scientists, program implementers, and policymakers. The goals of the Alliance are to: 1) provide a platform for cross-fertilization and exchange of ideas and information among implementation scientists and other stakeholders focusing on different aspects of HIV in adolescents; 2) enable the research to be better informed by programmatic challenges and questions; 3) inform policymakers of promising evidence and encourage use of the data in decision making; and 4) extend the reach and impact of implementation science related to adolescent HIV prevention and treatment. https://www.fic.nih.gov/About/center-global-health-studies/Pages/adolescent-hiv-prevention-treatment-implementation-science-alliance.aspx |
| Advanced Anticonvulsant System Interagency Product Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS | The Advanced Anticonvulsant System Interagency Product Team is a Department of Defense-led effort to facilitate activities, both research and regulatory, related to the FDA approval of midazolam for use in treating nerve agent exposure. |
| Adverse Event Reporting and Medical Countermeasures | Resource Development | FDA | NLM | NLM is working with the FDA to provide advice on key mobile technologies for targeted adverse event reporting and medical countermeasures in emergency settings. The group helped direct the design and development of the mobile app that was co-developed with programmers from Booz Allen Hamilton (BAH), the FDA contractor. BAH was responsible for the Web app that could be encapsulated within Android or iOS frameworks. NLM focused on the iOS framework and developed plugins for encryption, data caching and communications, audio capture, and overall app development. The app can send data to a cloud-based server under the aegis of the FDA. The app was demonstrated to the FDA leadership in June, 2014, and future R&D directions were outlined at the meeting. In addition to the design of the mobile app, NLM advised the FDA team on usability issues and provided guidance on distribution strategies. |
| Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | CC, NHLBI | The Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) is a 31-member federal advisory committee that provides advice to the Secretary of Health and Human Services through the Assistant Secretary for Health on a range of policy issues related to blood, blood products, and tissues. https://www.hhs.gov/ohaidp/initiatives/blood-tissue-safety/advisory-committee/index.html |
| Advisory Committee on Heritable Disorders in Newborn and Children | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD | The Advisory Committee on Heritable Disorders in Newborns and Children was established under the Public Health Service Act, Title XI, § 1109 (42 USC 300b-10), as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (PL 113-240). The mission of the Advisory Committee on Heritable Disorders in Newborns and Children is to reduce morbidity and mortality in newborns and children who have or are at risk for heritable disorders. The Committee recommends that every newborn screening program include a Uniform Screening Panel that screens for 32 core disorders and 26 secondary disorders. The Committee advises the Secretary, US Department of Health and Human Services on the most appropriate application of universal newborn screening tests, technologies, policies, guidelines, and standards. Specifically, the committee provides to the Secretary, the following: Advice and recommendations concerning grants and projects authorized, awarded, or funded related to screening heritable disorders in newborns and children; technical information to develop Heritable Disorders Program policies and priorities that will enhance the ability of the state and local health agencies to provide screening; counseling and health care services for newborns and children who have or are at risk for heritable disorders, and recommendations; and advice and information to enhance, expand, or improve the ability of the Secretary to reduce mortality and morbidity from heritable disorders in newborns and children. The committee was chartered on May 7, 2015. http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/ |
| Advisory Committee on Organ Transplantation (ACOT) | Committee, Work group, Advisory group, or Task Force | HRSA | NIAID | The Advisory Committee on Organ Transplantation (ACOT) was established to assist the HHS Secretary in enhancing organ donation, ensuring that the system of organ transplantation is grounded in the best available medical science, and assuring the public that the system is as effective and equitable as possible, thereby increasing public confidence in the integrity and effectiveness of the transplantation system. http://organdonor.gov/legislation/advisory.html |
| AHRQ - Systematic Evidence Reviews | Other | AHRQ | NHLBI | Develop systematic evidence reviews on topics and questions through an Evidence-based Practice Center (EPC). https://effectivehealthcare.ahrq.gov/ |
| AHRQ evidence report on Comparative Effectiveness of Interventions to Manage Labor and AHRQ evidence report on Labor Dystocia | Committee, Work group, Advisory group, or Task Force | AHRQ | NICHD | AHRQ sponsors the development of various reports to assist public- and private-sector organizations in their efforts to improve the quality of healthcare in the United States. These reports provide comprehensive, science-based information on common, costly medical conditions and new health care technologies and strategies. The EPCs review all relevant scientific literature on a wide spectrum of clinical and health services topics. EPCs also produce technical reports on methodological topics and other types of evidence synthesis-related reports. NIH scientists serve as expert advisors and collaborators in the development of some of these reports. |
| AHRQ National Guidelines Clearinghouse/National Quality Measures Clearinghouse (NQMC/NGC) Editorial Board | Committee, Work group, Advisory group, or Task Force | AHRQ | NLM | The AHRQ’s National Guidelines Clearinghouse/National Quality Measures Clearinghouse (NQMC/NGC) Editorial Board is composed of healthcare professionals with collective expertise in evidence-based quality measures and clinical practice guidelines. This is an expert public-private panel that provides guidance concerning the content and presentation of the related but distinct AHRQ resources, the National Guidelines Clearinghouse, and the National Quality Measures Clearinghouse. The Board also serves as a resource for feedback and guidance on developments in health care that inform future work. NLM is a member of this editorial board. http://www.qualitymeasures.ahrq.gov/index.aspx |
| AHRQ Patient Safety Workgroup | Committee, Work group, Advisory group, or Task Force | AHRQ | NLM | AHRQ Patient Safety Network (PSNet) is a national web-based resource featuring the latest news and essential resources on patient safety. The AHRQ Patient Safety Workgroup is an expert public-private panel that provides guidance to AHRQ concerning the implementation of legislation related to patient safety reporting and monitoring, including the “AHRQ Patient Safety Common Formats” for reporting patient safety events. NLM serves on this workgroup. https://psnet.ahrq.gov/ |
| AHRQ Registry of Patient Registries (RoPR) | Resource Development | AHRQ | NLM | The Registry of Patient Registries (RoPR) is a database of registry-specific information intended to promote collaboration, reduce redundancy, and improve transparency. ClinicalTrials.gov worked with RoPR to implement a mechanism for patient registries to be registered in ClinicalTrials.gov and additional information provided directly at RoPR. https://patientregistry.ahrq.gov/ |
| AIDSinfo/InfoSIDA | Public Education Campaign | CDC, FDA, HRSA | NLM, NIAID, OD/DPCPSI/OAR | AIDSinfo, a service of the US Department of Health and Human Services (HHS), offers access to the latest, federally approved HIV/AIDS medical practice guidelines, HIV treatment and prevention clinical trials, and other research information for health care providers, researchers, people affected by HIV/AIDS, and the general public. https://aidsinfo.nih.gov/ |
| Alaska Native Tumor Registry | Resource Development | CDC, IHS | NCI | In collaboration with CDC, IHS, and NCI, and with technical assistance from the Surveillance, Epidemiology, and End Results Program (SEER), the Alaska Native Tumor Registry collects information on cancer cases among Alaskan Native populations residing in Alaska. http://seer.cancer.gov/registries/alaska.html |
| Alcohol Clinical Trial Initiative (ACTIVE) | Committee, Work group, Advisory group, or Task Force | FDA | NIAAA, NIDA | A workgroup was formed under the auspices of the American College of Neuropsychopharmacology, known as the ACTIVE (Alcohol Clinical Trials Initiative) and consists of academic experts, industry representatives, and staff from the Food and Drug Administration, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse. The purpose is to explore methodological issues of conducting alcohol clinical trials and to provide the FDA, pharma, and the academic community evidence-based analyses into aspects of alcohol clinical trials such as endpoints, durations of trials, the placebo effect, handling of missing data, and grace periods. ACTIVE provides analyses for the FDA to use in developing evidence-based guidelines. http://www.ncbi.nlm.nih.gov/pubmed/21900883 |
| Alzheimer''s Disease Neuroimaging Initiative (ADNI) | Research Initiative | FDA | NIA, NIBIB | The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease. ADNI researchers collect, validate and utilize data such as MRI and PET images, genetics, cognitive tests, CSF, and blood biomarkers as predictors of the disease. Data from the North American ADNI’s study participants, including Alzheimer’s disease patients, mild cognitive impairment subjects and elderly controls, are available on a website run by NLM. http://adni.loni.usc.edu/ |
| America''s Children Forum on Health and Family Statistics | Resource Development | SAMHSA | NIDA | As a member of this collaboration, NIDA contributes data from the, “Monitoring the Future Survey on Illicit Drugs, Alcohol and Tobacco Trends”. http://www.childstats.gov/index.asp |
| American Academy of Pediatrics (AAP) Committee on Drugs | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The AAP Committee on Drugs reviews all aspects of pediatric pharmacology, including drug indications, contraindications, absorption rates, routes of administration, dosing, use precautions, and mode of action as they apply to children. The Committee also advises the Board of Directors in matters related to drug labeling, safety, and efficacy for both prescription and over-the-counter drugs; monitors federal legislation related to the drug approval process; and promotes the need for expanded pediatric drug trials. https://www.aap.org/en-us/about-the-aap/Committees-Councils-Sections/pages/Committee-on-Drugs.aspx |
| American Academy of Pediatrics (AAP) Council on Genetics | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD | The AAP Council on Genetics (COG) studies and makes recommendations to the AAP Board of Directors on recent advances in genetics and provides support to chapters on state legislative issues as they relate to genetics. http://pediatrics.aappublications.org/collection/council-genetics |
| American Academy of Pediatrics (AAP) Council on Injury, Violence and Poison Prevention (COIVPP) | Committee, Work group, Advisory group, or Task Force | ACF, HRSA, IHS | NICHD | The AAP Council on Injury, Violence, and Poison Prevention was formed on July 1, 2011, with the merging of the former Section and Committee on Injury, Violence, and Poison Prevention. This new leadership body addresses all facets of injury prevention policy, programs, advocacy, and education of general pediatricians, pediatric subspecialists, and families as a unified group. http://www2.aap.org/sections/ipp/ |
| American Community Survey (ACS) Content Review Working Group | Committee, Work group, Advisory group, or Task Force | OS | NICHD | The American Community Survey (ACS) is an ongoing survey that provides vital information on a yearly basis about our nation and its people. Information from the survey generates data that help determine how more than $400 billion in federal and state funds are distributed each year. Public officials, planners, and entrepreneurs use this information to assess the past and plan the future. https://www.census.gov/programs-surveys/acs/about.html |
| American Conference for the Treatment of HIV (ACTHIV) | Meeting/ Workshop | CDC, FDA, HRSA | OD/DPCPSI/OAR, NICHD, NIMH | The American Conference for the Treatment of HIV (ACTHIV) is a state-of-the-science conference for frontline health care professionals, in scientific collaboration with multiple federal and independent agencies. The conference is designed for all frontline clinicians providing HIV care for various population groups. In addition, this conference serves to provide guidance to less experienced HIV clinicians based on the Federal HIV Treatment Guidelines. http://acthiv.org |
| American Conference for Treatment of HIV (ACTHIV) Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NIAID, OD/DPCPSI/OAR | The purpose of this steering committee was to plan for the conference "American Conference for the Treatment of HIV (ACTHIV)”, now in its eleventh year. The ACTHIV is a state-of-the-science conference specifically targeted toward US frontline providers of care to persons at risk of or with HIV infection. http://www.acthiv.org/default.asp |
| Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks | Research Initiative | FDA | NINDS, NCATS, NCI, NIAAA, NIDA | The mission of the Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership funded by the US Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic treatments for the benefit of the public health. http://www.acttion.org/ |
| Antimicrobial Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of infectious diseases and disorders and makes appropriate recommendations to the FDA Commissioner. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/default.htm |
| Antiretroviral Pregnancy Registry | Resource Development | CDC, FDA, HRSA | NICHD | This is a registry of use of antiretroviral drugs in pregnancy that is sponsored by various pharmaceutical companies and has a committee of external experts and government staff from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA). The registry provides a resource for clinicians and researchers to improve the healthcare quality and patient safety for HIV infected mothers and their infants. http://www.apregistry.com/ |
| Arthritis Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the FDA for drug approval. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/default.htm |
| Asia-Pacific Economic Cooperation (APEC) Cervical Cancer Initiative | Meeting/ Workshop | OS | NCI | On August 24-25, 2017, the US National Cancer Institute’s Center for Global Health (NCI/CGH), working in collaboration with the US Departments of State and Health and Human Services, led a Policy Dialogue and Workshop on Human Papillomavirus (HPV) and Cervical Cancer Control during the APEC meetings in Ho Chi Minh City, Vietnam. The primary goal this dialogue was to jointly promote strategies for implementation of the APEC Roadmap to Promote Sustainable Economic Advancement for Women through Cervical Cancer Prevention and Control (2016-2021), a guiding document approved by the APEC Health Working Group in early 2017 with a key goal of enhancing knowledge exchange opportunities. Specifically, this practical workshop focused on current evidence of cost-effectiveness and the investment benefits of HPV vaccination programs as well as how to collect and use data from pilot and large-scale programs to inform future decision-making. http://www.cancer.gov/about-nci/organization/cgh/research/apec |
| Assay Guidance Workshop For High Throughput Screening And Lead Discovery | Meeting/ Workshop | FDA | NCATS, NCI, NIAAA, NIDDK | More than 40 participants attended the “Assay Guidance Workshop for High-Throughput Screening and Lead Discovery” on August 7, 2017, in Potomac, Maryland. Supported by NCATS, the workshop was designed to provide participants with a broad and practical perspective on how to develop and implement robust assays for early-stage drug discovery projects. Participants included researchers from four NIH centers, FDA, industry, and academia. Workshop leaders with more than 20 years of drug discovery experience covered a broad range of critical concepts underlying robust assay development and screening strategies. There were also open discussions for participants to share experiences and seek practical advice about individual research interests. https://ncats.nih.gov/expertise/preclinical/agm/training |
| Assessment of Occupational Exposure to Coal Tar Pitch Volatiles Containing Polycyclic Aromatic Hydrocarbons (PAHs) in Coal Tar Sealant Applications | Research Initiative | CDC | NIEHS | This study is to conduct exposure assessment in occupational populations for chemicals of interest to the National Toxicology Program. |
| Assessment of Occupational Exposure to Flame Retardants | Research Initiative | CDC | NIEHS | Conduct exposure assessment in occupational populations for chemicals of interest to the National Toxicology Program. |
| Assisted Outpatient Treatment | Research Initiative | HRSA, SAMHSA | NIMH | This collaboration supports the development and implementation of a rigorous and objective cross-site impact evaluation of an Assisted Outpatient Treatment (AOT) Grant Program for Individuals with Serious Mental Illness. The Department of Health and Human Services, Assistant Secretary for Planning and Evaluation (ASPE) has primary responsibility for the solicitation, management, and implementation of the evaluation contract in consultation with the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute of Mental Health (NIMH). The Center for Behavioral Health Statistics and Quality (CBHSQ), an entity within SAMHSA that serves as a focal point for data collection, analysis, and the dissemination of critical public health data, will provide consultation on the cross-site evaluation of the AOT grant program. ASPE, in consultation with the NIMH, brings expertise in evaluation design and implementation that benefits SAMHSA in its priority of having a rigorous multi-site evaluation. The initial Phase I Implementation Evaluation was completed in FY2017. Results of the Implementation Evaluation will inform the data collection plan for the Phase II Outcome Evaluation, which is scheduled to begin in FY2018. |
| Association Between Urinary PAH and Esophageal Squamous Dysplasia in the STEP study in Western Kenya | Research Initiative | CDC | NCI | This activity is a collaboration between NCI and CDC that aims to measure metabolites of polycyclic aromatic hydrocarbons (PAHs), cotinine and creatinine in the urine samples from individuals with and without precancerous lesions of the esophagus. |
| ASTM International F-2529-13--Standard Guide for In-Vivo Evaluation of Osteoinductive Potential for Materials Containing Demineralized Bone (DBM) | Research Initiative | FDA | NIDCR | Provide a guide based on a consensus of viewpoints used to determine the osteoinductive potential of a DBM containing products utilizing the arrhythmic rodent model. http://www.astm.org/Standards/F2529 |
| Autoimmune Diseases Coordinating Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NIAID, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR | The purpose of the Autoimmune Diseases Coordinating Committee (ADCC) is to provide a forum for the coordination of research efforts in autoimmunity and autoimmune diseases among various stakeholders including the NIH, other federal agencies such as the FDA and the CDC, and private organizations with an interest in autoimmune diseases. The ADCC meets twice yearly to discuss a broad range of basic, preclinical, and clinical endeavors. https://www.niaid.nih.gov/about/autoimmune-diseases-committee |
| Bacteriophage Therapy: Scientific and Regulatory Issues Public Workshop | Meeting/ Workshop | FDA | NIAID | The purpose of the public workshop is to exchange information with the medical and scientific community about the regulatory and scientific issues associated with bacteriophage therapy. https://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm544294.htm |
| Best Pharmaceuticals for Children Act (BPCA) Data Monitoring Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Best Pharmaceuticals for Children Act (BPCA) Data Coordinating Center (DCC) is responsible for managing all aspects of BPCA clinical trials including developing trial design, collecting and analyzing trial data, monitoring data quality, conducting site monitoring, collecting and preparing safety reports, organizing and submitting documentation to the FDA, and managing the Data Monitoring Committee. |
| Best Pharmaceuticals for Children Act (BPCA) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | This working group supports the goals of the Best Pharmaceuticals for Children Act (BPCA). The BPCA seeks to improve the level of information—in scientific publications and on the label—about pharmaceuticals used to treat children. The BPCA requires that the NIH identify the drugs of highest priority for study in pediatric populations and publish a list of drugs/needs in pediatric therapeutics. https://bpca.nichd.nih.gov/prioritization/status/Documents/Priority_List_07082014.pdf |
| Biological Select Agents and Toxins Interagency Policy Committee (BSAT IPC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Coordinating group with senior level leadership from CDC, FDA, and NIH that discusses appropriate oversight of Select Agents and Toxins. |
| Biological Select Agents and Toxins sub-Interagency Policy Committee (BSAT Sub-IPC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | Coordinating sub-group of FDA, CDC, and NIH staff that discuss the appropriate oversight of Select Agents and Toxins. This is a Subcommittee of the Biological Select Agents and Toxins Policy Coordination Committee (BSAT PPC). |
| Bioresource Development, Validation Tools, and Integrating High-Throughput Screening Technology Standards in Complementary and Alternative Medicine (CAM) Product Use in Children | Research Initiative | CDC, HRSA, SAMHSA | NCCIH, NICHD | Collaborative efforts between the FDA and NIH for substantiating health benefit claims for probiotics under Investigational New Drug Applications (IND) were placed in the framework of U01 Cooperative Agreements that began in 2008. The successful evaluation of the initiative has recently developed into an invitation to develop a Memorandum of Understanding (MoU) to promote resource sharing and exchange of research expertise; development of demonstration project(s); and the initiation of trans-agency research initiatives focused on the integration of advanced molecular technologies that lead to harmonization standards and improved diagnostics for safety and substantiation of the health benefits of probiotic interventions. In 2011, a collaboration with FDA was initiated to expand the validation tool. In 2012, a Materials Transfer Agreement [MTA] was approved and the FDA received the entire data collection to undergo testing employing their novel microarray multi-loci sequence testing system [MLST]. |
| Blood Products Advisory Committee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | CC, NHLBI | The FDA Blood Products Advisory Committee (BPAC) reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the Food and Drug Administration has regulatory responsibility. The committee also advises the Commissioner of Food and Drugs of its findings. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ |
| Blood, Organ, and Tissue Safety Committee (BOTSEC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | CC, NHLBI | The Blood, Organ, and Tissue Senior Executive Council (BOTSEC) is an advisory forum for senior leadership from HHS organizational components, as well as liaison representatives from Department of Defense and Veterans’ Health Administration, that are involved in blood, organ, and tissue safety and availability. The HHS Assistant Secretary for Health serves as the Council Chair, and the OASH Senior Advisor for Blood and Tissue Policy serves as the BOTSEC Executive Director. https://www.hhs.gov/ohaidp/initiatives/blood-tissue-safety/blood-organ-and-tissue-senior-executive-council/index.html |
| Board of Scientific Counselors of the CDC''s National Center of Injury Prevention and Control | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, SAMHSA | NICHD, NIA, NIDA, NIMH | The BSC advises the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NCIPC regarding surveillance, basic epidemiologic research, intervention research, and implementation, dissemination, and evaluation of promising and evidence-based strategies for the prevention of injury and violence. The Board makes recommendations regarding policies, strategies, objectives, projects, and priorities, and reviews progress toward injury and violence prevention. https://www.cdc.gov/injury/bsc/index.html |
| Botulism Guidelines Working Group | Committee, Work group, Advisory group, or Task Force | CDC | CC | The NIH Clinical Center is participating in a working group with CDC to develop clinical guidelines for treatment of botulism and use of botulism antitoxin. |
| Brain Attack Coalition | Committee, Work group, Advisory group, or Task Force | CDC | NINDS | The Brain Attack Coalition (BAC) is a group of public and private entities representing medical, scientific, advocacy, and government professionals from across the stroke continuum. The BAC is dedicated to setting direction, advancing knowledge, and communicating best practices to improve our ability to prevent and combat stroke. http://www.brainattackcoalition.org |
| Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative | Research Initiative | FDA | NINDS, NCCIH, NEI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIMH, OD/DPCPSI/OBSSR | The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is part of a new Presidential focus aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. Long desired by researchers seeking new ways to treat, cure, and even prevent brain disorders, this picture will fill major gaps in our current knowledge and provide unprecedented opportunities for exploring exactly how the brain enables the human body to record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought. http://braininitiative.nih.gov/ |
| Brownfields Federal Intergency Network/Working Group | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC | NIEHS | The purpose of this group is to share and exchange information, tools, and resources around EPA’s Brownfields Program among Federal Agencies. The Brownfields Program provides grants and technical assistance to communities, states, tribes, and others to assess, safely clean up and sustainably reuse contaminated properties. https://www.epa.gov/brownfields |
| Burkholderia Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OS | NIAID | This interagency working group coordinates activities related to the Burkholderia research portfolios of NIAID, the Biomedical Advanced Research and Development Authority (BARDA), and Defense the Threat Reduction Agency, and shares data related to the regulatory pathway of existing and novel medical countermeasures against melioidosis and glanders. |
| Cancer and Women''s Health Interagency Agreement | Research Initiative | FDA | NCI | This formal agreement establishes the framework and procedures to enhance collaborations and exchange of information between the FDA’s Office of Women’s Health (OWH) and NCI’s Center to Reduce Cancer Health Disparities (CRCHD). Working together, FDA and NCI seek to increase scientific knowledge and understanding of cancer in women through targeted basic, clinical, bio-behavioral, translational, and community-based participatory research approaches/efforts. FDA and NCI both recognize the need for a unified approach to advancing scientific knowledge related to cancer and women’s health. This harmonized approach will aid in advancing the public health of all women through innovation in cancer research and medical therapies. https://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm400985.htm |
| Cancer Control Plan, Link, Act, Network with Evidence-Based Tools (P.L.A.N.E.T) | Resource Development | AHRQ, CDC, SAMHSA | NCI | Cancer control planners, program staff, and researchers have the same goals: to reduce cancer risk, the number of new cancer cases, and the number of deaths from cancer, as well as enhance the quality of life for cancer survivors. While many share the same goals, all do not have easy access to resources that can facilitate the transfer of evidence-based research findings into practice. This Cancer Control Plan, Link, Act, Network with Evidence-based Tools (PLANET) portal provides access to data and resources that can help planners, program staff, and researchers to design, implement and evaluate evidence-based cancer control programs. https://cancercontrolplanet.cancer.gov/planet/index.html |
| Cancer Moonshot Blue Ribbon Panel | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP, NCI | The Cancer Moonshot Blue Ribbon Panel led the efforts of seven working groups that developed recommendations to accelerate the pace of cancer research, so as to achieve a decade''s worth of progress in just five years. The panel and the working groups consisted of scientific experts from various fields that span academia, industry, government, and advocacy organizations. https://www.cancer.gov/brp |
| CDC Chronic Kidney Disease Surveillance | Health Survey | CDC | NIDDK | NIDDK assists CDC in its surveillance program of chronic kidney disease. http://nccd.cdc.gov/ckd/ |
| CDC Community Guide | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NIDA | The Guide to Community Preventive Services (The Community Guide) is a collection of evidence-based findings of the Community Preventive Services Task Force (CPSTF). It is a resource to help select interventions to improve health and prevent disease in each state, community, community organization, business, healthcare organization, or school. Community Guide reviews are designed to answer three questions: (1) What has worked for others and how well?; )2) What might this intervention approach cost, and what am I likely to achieve through my investment?; and (3) What are the evidence gaps? https://www.thecommunityguide.org/about/about-community-guide |
| CDC Elimination of Pediatric HIV in US Stakeholders Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NICHD, NIAID | The CDC Elimination of Pediatric HIV in US Stakeholders Group is a working group of federal and non-federal individuals to assist the CDC in developing initiatives to eliminate mother to child HIV transmission in the United States. |
| CDC Integration with GrantSolutions | Resource Development | ACF | OD/OER | Collaboration with GrantSolutions to allow CDC Research programs to seamlessly use eRA research grant support services, including the eRA Commons grantee portal and the eRA Peer Review suite while having grants management staff process awards within GrantSolutions. |
| CDC Office of Public Health Genomics | Public Education Campaign | CDC | NHLBI | This collaboration seeks to define and implement a translational trajectory for scientific discoveries in genomics and related fields to population health benefits in health areas relevant to NHLBI including, heart, lung, blood, and sleep disorders. |
| CDC Surveillance to Support Implementation of the National Action Plan for Chronic Obstructive Pulmonary Disease (COPD) | Health Survey | CDC | NHLBI | To provide surveillance support for the public health implementation of the new National Action Plan for chronic obstructive pulmonary disease (COPD). NHLBI will provide funds in FY2017 and FY2018 to CDC/NCCDPHP/DPH for implementation of the Respiratory Health Module in the CDC Behavioral Risk Factor Surveillance System (BRFSS) 2017. https://www.cdc.gov/brfss/index.html |
| CDC-NHLBI Urine Biomarker Collaboration | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI, NCI, NIDDK, NINDS | The purpose of this work group is to conduct research on sodium and potassium biomarkers in the CDC''s NHANES and NHLBI cohort studies to improve monitoring of sodium intake in the US population. Research has included calibration studies on prediction of usual sodium intake and estimation of usual sodium intake in the US population. |
| CDC-NIH Lyme Disease Serum Sample Repository | Resource Development | CDC, OS | NIAID | Initiated in 2008, this resource was made available to the scientific community on a broad basis in late 2011. Lyme disease and related serum samples are available upon request for testing and comparison of new and current diagnostic tests with a common serum sample set for standardization. Samples are distributed by the CDC. CDC and NIH both provided support to acquire the samples and continue to work together to ensure the scientific community has access to samples needed for Lyme disease diagnostic test development. |
| CDC/ National Center for Health Statistics (NCHS) Balance/Dizziness Problems | Health Survey | CDC | NIDCD | The purpose of this agreement is for NIDCD to provide financial support to the National Center for Health Statistics (NCHS) for the inclusion of Balance/Dizziness Supplements for a representative sample of US adults (age 18+ years) and children (age 3–17 years) in the 2016 National Health Interview Survey (NHIS). Previously, NIDCD negotiated an IAA with NCHS for collaboration and funding of the 2008 Adult Balance/Dizziness Supplement and the 2012 Child Balance/Dizziness Supplement to the NHIS. The current fiscal year funds will provide partial support for the renewal of this collaborative effort between NCHS and NIDCD to fund the 2016 Adult and Child Balance/Dizziness Supplements to the NHIS. The new NHIS Supplements will include many of the same questions on Balance/Dizziness included in the earlier 2008 and 2012 studies, although revisions have been made to eliminate some questions in order to include new ones that higher on the current priority list. These questions on the new Balance/Dizziness Supplements will assist NIDCD to make program planning decisions on priorities with respect to the funding of research on the prevention of falls related to dizziness and balance. The results will also be analyzed for use in tracking the Department of Health and Human Services’ (DHHS) objectives in Healthy People 2020. Results from this nationally-representative survey of the US non-institutionalized, civilian population will help NIDCD make budget allocations to subject areas where needs are found to be most critical. http://www.cdc.gov/nchs/nhis.htm |
| CDC/HRSA Advisory Committee (CHAC) for HIV/AIDS, Viral Hepatitis, STD and TB prevention | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NICHD, OD/DPCPSI/OAR | The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment shall advise the Secretary, HHS; the Director, CDC; and the Administrator, HRSA, regarding objectives, strategies, policies, and priorities for HIV, Viral Hepatitis, and STD prevention and treatment efforts including surveillance of HIV infection, AIDS, Viral Hepatitis, other STDs, and related behaviors; epidemiologic, behavioral, health services, and laboratory research on HIV/AIDS, Viral Hepatitis, and other STDs; identification of policy issues related to HIV/Viral Hepatitis/STD professional education, patient healthcare delivery, and prevention services; agency policies about prevention of HIV/AIDS, Viral Hepatitis and other STDs, treatment, healthcare delivery, and research and training; strategic issues influencing the ability of CDC and HRSA to fulfill their missions of providing prevention and treatment services; programmatic efforts to prevent and treat HIV, Viral Hepatitis, and other STDs; and support to the agencies in their development of responses to emerging health needs related to HIV, Viral Hepatitis, and other STDs. https://www.cdc.gov/maso/facm/facmchachspt.html |
| CDC/National Institute of Occupational Safety and Health (NIOSH) for Audiometric Support for 3 NIDCD-Sponsored, Population-Based Surveys | Health Survey | CDC | NIDCD | The purpose of this agreement is to provide funding for scientific and technical support as well as quality assurance of three large audiometric examination surveys funded by NIDCD. These health surveys are: (1) The National Health and Nutrition Examination Survey (NHANES), (2) Age, Gene/Environment Susceptibility Study–Reykjavik Study (AGES–RS), and (3) the Early Childhood Longitudinal Study – Kindergarten Class of 2010/2011 (ECLS–K:2010/2011). http://www.cdc.gov/niosh/ |
| CDC’s Division of Select Agents and Toxins (DSAT) Work Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the CDC’s manual “Biosafety in Microbiological and Biomedical Laboratories.” http://www.cdc.gov/phpr/dsat.htm |
| CDC’s Field Epidemiology Training Program (FELP) Cancer Curriculum | Training Initiative | CDC | NCI | CDC and NCI (Center for Global Health and Cancer Prevention Fellowship Program) are collaborating to add a cancer curriculum to CDC’s Field Epidemiology Training Program. |
| Center for AIDS Research (CFAR) Implementation Science Workshop | Meeting/ Workshop | CDC | OD/DPCPSI/OAR, NIMH | This is an activity that began in 2017, leading to the workshop in 2018. The workshop is focused on clarifying and furthering NIH''s and the Center for AIDS Research (CFAR) network''s roles in advancing HIV-related implementation science research. The workshop will include representatives from NIH, CDC, USAID, State representatives and other non-Federal partners. |
| Centers for Disease Control and Prevention (CDC)/Health Resources and Services Administration (HRSA) Advisory Committee on Human Immunodeficiency Virus (HIV), Viral Hepatitis and Sexually Transmitted Diseases (STD) Prevention and Treatment (CHACHSPT) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR | The CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment advises the Secretary; the Director, CDC; the Administrator and Associate Administrator for HIV/AIDS, and HRSA regarding objectives, strategies, policies, and priorities for HIV and STD/hepatitis prevention and treatment efforts. These efforts include surveillance of HIV infection, AIDS, STDs/hepatitis, and related behaviors; epidemiologic, behavioral, health services, and laboratory research on HIV/AIDS and STDs/hepatitis; identification of policy issues related to HIV/STD/hepatitis professional education, patient healthcare delivery, and prevention services; agency policies about prevention of HIV/AIDS and other STDs, treatment, healthcare delivery, and research and training; strategic issues influencing the ability of CDC and HRSA to fulfill their missions of providing prevention and treatment services; programmatic efforts to prevent and treat HIV and STDs/hepatitis; and support to the agencies in their development of responses to emerging health needs related to HIV and other STDs/hepatitis. https://www.cdc.gov/maso/facm/facmchachspt.html |
| Characterize Emerging HIV Strains from Blood Donors and Patients | Resource Development | FDA | NIAID | This initiative will characterize emerging HIV strains from blood donors and patients to determine viral tropism based on co-receptor usage strains. It will update the global viral panels to analyze multiple, diverse isolates from different parts of the world. This activity is part of NIAID’s ongoing efforts to develop a well-characterized repository for diagnostics, and drug and vaccine studies. https://eqapol.dhvi.duke.edu/ |
| CHEMM (Chemical Hazards Emergency Medical Management) | Resource Development | ATSDR, CDC, OS | NLM, NICHD | This activity is to develop and maintain a comprehensive web resource and mobile app (in conjunction with the Wireless Information System for Emergency Responders [WISER]). Chemical Hazards Emergency Medical Management (CHEMM) is a tool designed to provide access to comprehensive sets of information about chemical hazards and emergency medical management via a user-friendly interface. https://chemm.nlm.nih.gov |
| Children’s HHS Interagency Leadership on Disasters (CHILD) Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, OS, SAMHSA | NICHD, NIAID, NIDA, NIGMS, NIMH | ASPR and ACF created the CHILD Working Group in February 2010 to integrate the needs of children across all HHS disaster planning activities and operations. The CHILD Working Group assessed current capabilities and facilitated coordination at the policy and response levels. The CHILD Working Group also developed a set of recommendations that could enhance how the Department provides and facilitates care to address the disaster-related health and human services needs of children (birth through age 17) during and after disasters or public health emergencies. The 2011 Update on Children and Disasters (2011 Summary) reported on the following areas: (1) mental and behavioral health; (2) medical countermeasures; (3) child physical health, emergency medical services, and pediatric transport; and (4) child care and child welfare. The 2012-2013 CHILD Report provided updates on those topics and added three additional areas of focus: (1) pregnant and breastfeeding women and newborns; (2) children with special health care needs and other subpopulations of children at heightened risk and historically under-represented in disaster planning efforts; and (3) enhancing collaboration across government and with non-governmental organizations (NGO). https://www.phe.gov/Preparedness/planning/abc/Documents/child-2014-2015.pdf |
| Chronic Fatigue Syndrome Advisory Committee (CFSAC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | NINDS | The Chronic Fatigue Syndrome Advisory Committee (CFSAC) provides advice and recommendations to the Secretary of Health and Human Services via the Assistant Secretary for Health of the US Department of Health and Human Services on issues related to myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS). These include: 1) factors affecting access and care for persons with ME/CFS; 2) the science and definition of ME/CFS; and 3) broader public health, clinical, research, and educational issues related to ME/CFS. http://www.hhs.gov/advcomcfs/ |
| Clinical and Translational Research Course for PhD Students | Training Initiative | FDA | CC, NCATS, NCI, NHLBI, NIAID, NIDA, NIDCR, NIDDK, NIGMS, NIMH, NINDS | The Clinical and Translational Research Course for PhD Students is a two-week intensive introductory course for graduate students in the basic biomedical sciences who have at least one year of graduate study. The purpose of the course is to demonstrate and highlight the roles of PhD scientists in clinical and translational research, to provide an overview and examples of how basic science and clinical observations lead to translational research, and to increase awareness and access to PhD role models, research resources, and potential career opportunities at the NIH. http://www.cc.nih.gov/training/phdcourse |
| Clinical Decision Support (CDS) Federal Collaboratory and Inventory of Federal Clinical Decision Support Activities | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, HRSA, IHS, OS | NLM, CC | A federal community of interest focused on clinical decision support (CDS), and a compilation of project summaries describing CDS activities that are either funded by the US Federal government or that are being executed by agencies of the government. CDS encompasses a variety of tools and technologies that are used within electronic clinical information systems to improve the quality, safety, efficiency, and effectiveness of patient care. CDS provides clinicians, staff, patients, and other key decision makers with knowledge and person-specific information, intelligently filtered at appropriate times, to enhance health and health care. CDS encompasses computerized alerts and reminders, clinical guidelines, order sets, order entry feedback, patient data reports and dashboards, documentation templates, diagnostic support, and the presentation of contextually relevant reference information within clinical information systems. NLM has submitted to the Collaboratory and Inventory summaries of NLM projects involving Clinical Decision Support. |
| Clinical Investigator Interagency Working Group for the Development of Antiviral Influenza Therapeutics | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | This working group discusses a range of issues relevant to the development of antiviral drugs for the treatment of influenza. |
| Clinical Islet Transplantation Consortium | Research Initiative | CMS, FDA | NIDDK, NIAID | The Clinical Islet Transplantation (CIT) Consortium is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in people with type 1 diabetes. Studies conducted by the CIT Consortium will focus on improving the safety and long-term success of methods for transplanting islets, the insulin-producing cells of the pancreas, in people whose own islets have been destroyed by the autoimmune process that characterizes type 1 diabetes. One clinical trial, in particular, is studying the efficacy of islet transplantation after kidney transplantation. Participants may include Medicare beneficiaries. This study was mandated in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. http://www.citisletstudy.org |
| Clinical Research Using Medicare Data from the Virtual Research Data Center (VRDC) | Research Initiative | CMS | NLM | NLM is working with CMS and other NIH ICs to demonstrate the value of the CMS Virtual Research Data Center (VRDC) as a source of Big Data. https://www.resdac.org/cms-data/request/cms-virtual-research-data-center |
| Clinical Utilization Plan for Anthrax Medical Countermeasure Use in a Mass Casualty Event (CUPAC) Medical Countermeasures Workgroup | Committee, Work group, Advisory group, or Task Force | CDC | CC | The NIH Clinical Center is participating as a member of the Medical Countermeasures Work Group to provide clinical algorithms that will assist clinicians to evaluate, triage, diagnose and treat large numbers of patients presenting with symptoms of anthrax. It will also provide a clinical prioritization schema for the use of medical countermeasures specific to anthrax and outline unique critical care issues that may require special consideration. |
| Clinical Vocabulary and Standards Development for Meaningful Use of Electronic Medical Records | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, OS | NLM | NLM is collaborating with OS and HHS Office of the National Coordinator for Health Information Technology (ONC) on developing and disseminating regulatory language related to health information technology, meaningful use, and standards and certification criteria related to electronic health records and messaging. The collaboration includes serving as members of the Content Standards Workgroup, and Semantic Standards Workgroup of the Health IT (HIT) Standards Committee. The HIT Standards Committee is a Federal advisory committee that was created by the Health Information Technology for Economic and Clinical Health (HITECH) Act to provide input to HHS on the policies and technologies needed to improve health and care. http://www.nlm.nih.gov/healthit.html |
| ClinicalTrials.gov | Resource Development | FDA | NLM, CC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/OER, OD/OSP | ClinicalTrials.gov is an NLM-operated database containing summary protocol and results information from publicly and privately funded clinical research. As of December 2016, the database included summary protocol information on more than 230,000 clinical studies conducted in over 195 countries, with nearly 24,000 records displaying summary results. NLM originally collaborated with FDA on implementing Section 113 of the Food and Drug Administration Modernization Act of 1997. It subsequently collaborated with FDA and NIH OD to implement the statutory requirements of Section 801 of the Food and Drug Administration Amendments Act of 2007 through rulemaking. The final rule (42 CFR Part 11) was issued in September 2016. NLM is currently collaborating with FDA and other parts of NIH to implement the regulatory requirements of 42 CFR Part 11. https://www.clinicaltrials.gov/ |
| CMS End-stage Renal Disease (ESRD) Affinity Group | Committee, Work group, Advisory group, or Task Force | CMS | NIDDK | CMS has established a number of affinity groups to focus groups of individuals interested in and working on particular topics -- in this case, end-stage renal disease (ESRD). NIDDK Program staff have participated in meetings, bringing domain expertise and perspectives on current research findings. |
| CMS-FDA-NIH Trilateral Council | Committee, Work group, Advisory group, or Task Force | CMS, FDA | OD/OSP, NIA, OD/OER | The CMS-FDA-NIH Trilateral Council provides a forum for agency leaders to discuss policy issues, programs, and research initiatives of mutual interest and determines appropriate interfaces and collaborations that may inform NIH-funded research, FDA guidance and regulations, and CMS policies and programs. The Council formed in April 2016 and meets at the request of the Chairs: the NIH Director, FDA Commissioner, and CMS Administrator. |
| CMS-NIH Senior Leadership Council | Committee, Work group, Advisory group, or Task Force | CMS | OD/OSP, NIA, OD/OER | The CMS-NIH Senior Leadership Council provides a forum for agency leaders to discuss policy issues, programs, and research initiatives of mutual interest and determines appropriate interfaces and collaborations that may inform NIH-funded research and CMS policies and programs. The Leadership Council is co-chaired by the NIH Director and CMS Administrator and meets at the request of the Chairs. |
| CMS/CDC/FDA/NIH Opioid Abuse Collaboration | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA | NIA, NIDA, NINDS | The purpose of this collaboration is to discuss agency activities surrounding the HHS Secretary’s opioid abuse initiatives. |
| Collaboration With Indian Health Service Institutional Review Board (IRB) In Training IRB Interns From Native Communities | Committee, Work group, Advisory group, or Task Force | IHS | CC, NHGRI | The Clinical Center’s Department of Bioethics, in collaboration with NHGRI, piloted an Institutional Review Board (IRB) internship program for Native Americans. http://www.ihs.gov/Research/index.cfm?module=hrpp_about |
| Collaborative Islet Transplant Registry Ad Hoc Scientific Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NIAID | This Advisory Committee provides scientific direction to the Collaborative Islet Transplant Registry on an ad hoc basis. |
| Collaborative Use Repurposing Engine (CURE) | Research Initiative | FDA | NCATS | CURE is a new tool designed to centrally capture and organize real-world information about how healthcare practitioners use existing drugs in novel ways to treat patients with neglected tropical diseases (NTDs), emerging infections, and drug-resistant infections when treatment options are limited or inadequate. It is currently publicly available in “beta” as an open-access website that enables healthcare practitioners throughout the world to contribute to the database by using a simple online form, a smartphone or other mobile device. In addition to submitting their own case reports, practitioners are also able to query and retrieve information from the database. Neglected Tropical Diseases (NTDs) are a group of parasitic and bacterial diseases that cause substantial illness for more than one billion people globally. Patients with NTDs, emerging or drug-resistant infections may lack adequate treatment options due to the limited number of drugs approved for these conditions. Out of necessity, healthcare practitioners try to use existing drugs in novel ways to treat these patients. At present, much of this clinical experience, regardless of whether the patient outcomes are positive or negative, is never reported or shared, and the knowledge is therefore lost. https://www.hhs.gov/idealab/projects-item/collaborative-use-repurposing-engine/ |
| Combating Antibiotic Resistant Bateria (CARB) | Resource Development | CDC, FDA | NLM, NHGRI, NIAID | The National Action Plan for Combating Antibiotic-resistant Bacteria is a multi-agency initiative to deal with the threat of increasing antibiotic resistance. NCBI has a part in Sub-Objective 2.1.4: Develop and maintain a national sequence database of resistant bacteria. https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf |
| Committee on Emerging Science for Environmental Health Decisions | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA, OS | NIEHS, NCATS, NCI, NHGRI, NICHD | This National Academy of Sciences (NAS) Committee facilitates communication among government, industry, environmental groups, and the academic community about scientific advances that may be used in the identification, quantification, and control of environmental impacts on human health. New methods and approaches that can be used to identify and control environmental impacts on human health are explored in regular workshops that provide a public venue for exchanging information and discussing potential implications for environmental health decisions. http://nas-sites.org/emergingscience/ |
| Common Data Elements (CDE) for Patient-Centered Outcomes Research | Resource Development | OS | NLM, CC, CIT, NCATS, NCI, NEI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NIMH, NINDS, NINR, OD/OER | Led by NLM, a Task Force of the NIH Scientific Data Council and others are working to promote the use of common data elements in research, surveillance, and patient registries to facilitate data sharing and reuse. Work to date has produced a portal of NIH projects that use Common Data Elements (CDEs) and, with the assistance of funding to develop data infrastructure to promote patient-centered outcomes research (OS Patient-Centered Outcomes Research Trust Fund), will contribute to development of a search, retrieval, and repository mechanism that will support and reflect the standards work of the Standards & Interoperability (S&I) Framework Structured Data Capture Initiative. This project contributes to efforts to develop a repository and search tool for identification of CDEs for Patient-Centered Outcomes Research. Initially formed as a work-group of the Trans-NIH BioMedical Informatics Coordinating Committee (BMIC), and changed to SDC Task Force in 2016. https://www.nlm.nih.gov/cde/ |
| Community Guide Cardiovascular Coordination Team | Committee, Work group, Advisory group, or Task Force | CDC | NHLBI | The purpose of the workgroup is to assess the feasibility of and conducting an evidence-based review to assess the effectiveness of interventions using community health workers for cardiovascular disease prevention and other relevant topics. The completed reviews will be included in, “The Community Guide sponsored by the Community Preventive Services Task Force”. https://www.thecommunityguide.org/ |
| Community Preventive Services Task Force (CPSTF) | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/ODP, OD/DPCPSI | The Community Preventive Services Task Force (CPSTF) is an independent, non-federal panel of prevention experts that conducts rigorous systematic reviews and provides public health recommendations to the CDC to inform decision-making about policy, practice, and research priorities for community preventive services. Recommendations from the CPSTF are published in The Guide to Community Preventive Services. The Office of Disease Prevention (ODP) represents NIH as an official liaison member and works with the CDC and CPSTF members to ensure that recommendations represent the views, concerns, and needs of the NIH and our constituents. ODP staff also serve on, or recommend NIH scientists to serve on systematic review teams, and help translate CPSTF recommendations into actions. http://www.thecommunityguide.org |
| Computational Toxicology for NIH Medications Discovery | Research Initiative | FDA | NIDA | Through an inter-agency agreement, the FDA provides structure-activity, relationship-based toxicity predictions for compounds that are under evaluation in the NIDA Addiction Treatment Discovery Program. On a limited basis, other NIH ICs may utilize this resource by working through NIDA. |
| Computer-aided Diagnosis for Radiology Images | Research Initiative | FDA | CC | This collaboration focuses on the improvement of computer-aided diagnosis for radiology images. Specific applications include computer-aided polyp detection for CT colonography, improvements in the conduct and analysis of observer performance experiments using radiology images, and the use and development of advanced machine learning and receiver operating characteristics methods with application to computer-aided diagnosis. |
| Conducting Comprehensive Toxicological Assessments | Research Initiative | FDA | NIEHS | The purpose of the Conducting Comprehensive Toxicological Assessments Agreement is to conduct comprehensive toxicological assessments on FDA priority chemicals/agents nominated to the National Toxicology Program at the FDA''s National Center for Toxicological Research. Studies can include range finding sub-chronic and chronic, compound-specific mechanistic studies, and consideration of the use of alternate test systems. This combination of studies is designed to facilitate the interpretation of study results in support of comprehensive quantitative human health risk assessments. The primary goal of this program is to develop a comprehensive scientific database that can be utilized to reduce the uncertainty in risk assessment/risk-benefit analysis for specific chemicals with high FDA impact. |
| Consensus-Based Entity (CBE) Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA | NLM | The Consensus-Based Entity (CBE) Committee is an HHS-wide entity, chaired by ASPE, to provide oversight and input into the execution of ASPE’s legislation-mandated contract with the National Quality Forum (the Consensus-Based Entity) for establishing quality and performance measures. NLM participates as an invited member. |
| Contact Lens Safety Campaign | Public Education Campaign | CDC | NEI | The NEI helped CDC disseminate contact lens safety information via social media during its spring break campaign in March. Additionally, NEI added CDC resources to its Pinterest page. https://www.pinterest.com/neinih/contact-lens-safety |
| Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee | Committee, Work group, Advisory group, or Task Force | OS | NLM | The Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to ONC on standards, implementation specifications, and certification criteria for the electronic exchange and use of health information. |
| COPD National Action Plan | Meeting/ Workshop | AHRQ, CDC, CMS, HRSA, IHS | NHLBI, NCI, NIA, NIEHS, NINR | The Chronic Obstructive Pulmonary Disease (COPD) National Action Plan is the first-ever blueprint for a multi-faceted, unified fight against the disease. Developed at the request of Congress with input from the broad COPD community, it provides a comprehensive framework for action by those affected by the disease and those who care about reducing its burden. https://www.nhlbi.nih.gov/health-topics/education-and-awareness/COPD-national-action-plan |
| Council on Emergency Medical Care | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, HRSA, OS, SAMHSA | NIMH, NCATS, NHLBI, NICHD, NIGMS, NINDS, NLM | The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policymakers in emergency medical care from organizations across the Federal Government. The CEMC contributes to the development, advancement, and coordination of federal strategies, policies, and priorities relating to emergency medical care to improve the nation’s emergency care system. |
| Countering Biothreats PCC on Gene Editing and Synthesis (CBT PCC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP | A coordinating group comprised of senior-level leadership from NIH, CDC, and OS that discuss policy options related to gene editing and synthesis. |
| Countering Biothreats sub-PCC on Gene Editing and Synthesis (CBT sub-PCC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP | A coordinating group of staff from NIH, OS, and CDC that discuss policy options related to gene editing and synthesis. This sub-PCC supports the Countering Biothreats PCC on Gene Editing and Synthesis (CBT PCC) group. |
| Countermeasures Against Chemical Threats (CounterACT) Research Network | Research Initiative | CDC, FDA, OS | NINDS, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, NLM | The CounterACT program is a translational research program supporting basic, translational, and clinical research aimed at the discovery and identification of better therapeutic medical countermeasures and diagnostic technologies against chemical threat agents, which facilitates their movement through the regulatory process in collaboration with other federal departments and agencies, such as the Biomedical Advanced Research and Development Authority (HHS BARDA). The program includes a comprehensive network of Research Centers of Excellence, individual co-operative research projects, small business innovation research grants, contracts, and interagency agreements with the Department of Defense. Among other activities, NINDS organizes an annual meeting of investigators supported by the program allowing researchers to share information, encourage collaboration, and enable NIH staff to evaluate the group’s progress on themes such as nerve agents, seizure detection technology, cyanide, and sulfur mustard. https://www.ninds.nih.gov/Current-Research/Trans-Agency-Activities/CounterACT |
| Country Work in Cancer Research and Cancer Control Planning Strengthening – Kenya | Other | CDC | NCI, FIC, NIAID | Kenya has an estimated population of over 42 million. Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus, and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in the country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have a significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M, and USAID invested $700 million in Kenya in FY2011. At least six NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH) partnership, along with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012. |
| Critical Path to Tuberculosis (TB) Drug Regimens (CPTR) Rapid Drug Sensitivity Testing (DST) Consortium | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The purpose of the Critical Path to Tuberculosis (TB) Drug Regimens (CPTR) Rapid Drug Sensitivity Testing (DST) Consortium is to support and sustain discussion, share information, and to coordinate clinical trials of new TB drug combinations. The overall goal is to rapidly advance new cost-effective therapies while maintaining the highest standards of scientific rigor. The Consortium will work to coordinate planning among the major non-commercial sponsors and their research groups to ensure rapid and efficient Phase II evaluations of drug combinations. |
| DailyMed | Resource Development | FDA | NLM | DailyMed provides high-quality information about marketed drugs, including FDA labels (package inserts). The website provides health information providers and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. NLM provides this DailyMed as a public service, free of advertising. http://www.dailymed.nlm.nih.gov |
| Data Access for Grantees | Resource Development | CMS | NIA | NIA has an Inter-Agency Agreement (IAA) to assist grantees with accessing Centers for Medicare & Medicaid Services (CMS) data. It is anticipated that this initiative will create a more user-friendly and more cost-efficient means for grantees to access CMS data, especially the need to access Part D data. Specifically, this agreement gives CMS''s Privacy Board justification to release Part D data to NIA grantees with Data Use Agreements. Researchers pay for data use. This includes activities for remote access data enclave. |
| Demand Reduction Interagency Working Groups | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, OS, SAMHSA | NIAAA, NIDA | These working groups aim to prevent substance abuse and related negative consequences by implementing a prevention framework to serve as a foundation for collaboration among Federal agencies in the development of joint initiatives that serve States and communities across the Nation. |
| Department of Defense Resuscitation and Transfusion Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | This committee oversees DoD research in resuscitation and transfusion. |
| Developing a Strategically Coordinated Registry Network (CRN) for Women’s Health Technologies | Committee, Work group, Advisory group, or Task Force | AHRQ, FDA, OS | NLM | This project is funded by the Office of the Secretary Patient Centered Outcomes Research Trust Fund for Data Infrastructure. The project goal is to create a strategically Coordinated Registry Network (CRN) for women’s health technologies that will collect patient-reported outcomes and employ the standards for Structured Data Capture (SDC) from EHRs for data collection and exchange to both enhance existing registries and enrich PCOR data infrastructure pertinent to women’s health conditions. https://aspe.hhs.gov/os-pcortf-funded-projects |
| Developing Clinical Vocabulary Standards for Public Health Reporting | Resource Development | CDC | NLM | This collaboration between NLM and CDC is to develop Logical Observation Identifiers Names and Codes (LOINC) for use in public health reporting, including tumor registry reporting and reportable disease reporting. https://phinvads.cdc.gov/vads/SearchVocab.action |
| Development and Use of a Non-human Primate Model of Pertussis Disease and Transmission | Other | FDA | NIAID | NIH has been working with the FDA towards the development and use of a non-human primate model of pertussis disease and transmission. The unique model helps to test novel vaccines and to understand host immunity. |
| DHHS Health Care Personnel Influenza Vaccination Interagency Working Group | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee is charged with developing strategies to increase the number of healthcare professionals who are vaccinated with the influenza vaccine. http://www.hhs.gov/ash/initiatives/hai/hcpflu.html |
| DHHS Healthcare Infection Control Practices Advisory Committee (HICPAC) | Committee, Work group, Advisory group, or Task Force | OS | CC | This committee serves as the major policy advisory committee in the nation for healthcare epidemiology. |
| DHHS Medical Claims Review Panel | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | CC | The MCRP assists the DHHS in meeting its responsibility to provide quality health care in its facilities and by its practitioners. The MCRP reviews paid claims against DHHS facilities and providers to determine if the care provided met the standard of care and makes quality improvement recommendations to health care facilities and individual providers. The Panel meets monthly and includes two NIH representatives; the current Chair of the Panel is an NIH physician. |
| DHHS Office on Women’s Health, Section on Pregnancy and Newborn Care, womenshealth.gov | Committee, Work group, Advisory group, or Task Force | OS | NICHD | NIH scientists work together with other HHS experts to develop and review content for HHS public-facing websites, including the womenshealth.gov website. http://www.womenshealth.gov |
| DHHS Steering Committee for the Prevention of Healthcare-Associated Infections | Committee, Work group, Advisory group, or Task Force | OS | CC | This steering committee is charged with developing a national action plan for addressing the important problem of healthcare-associated infections. https://health.gov/hcq/prevent-hai-action-plan.asp |
| Diabetes Mellitus Interagency Coordinating Committee (DMICC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NIDDK, CSR, NCATS, NCCIH, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM | The DMICC facilitates cooperation, communication, and collaboration on diabetes among the participating government entities. DMICC meetings, held several times a year, help members identify emerging issues and opportunities and develop ways in which different government components can work together and build upon each other’s expertise and resources. This approach helps ensure that federal diabetes activities are coordinated and not duplicated, as well as stimulates collaborations where appropriate. http://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee/Pages/background.aspx |
| Diabetes Prevention Program (DPP) and Diabetes Prevention Program Outcomes Study (DPPOS) | Research Initiative | CDC, IHS | NIDDK, NCATS, NCI, NCMHD, NEI, NHLBI, NIA, NICHD | The Diabetes Prevention Program (DPP) showed that lifestyle change or the drug metformin delay the development of type 2 diabetes. The Diabetes Prevention Program Outcomes Study is studying the long-term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the DPP. https://dppos.bsc.gwu.edu/web/dppos/about |
| Diabetic Eye Disease Information Dissemination | Public Education Campaign | CDC | NEI | CDC''s National Diabetes Education Program is part of the National Eye Health Education Program Partnership. This past year, NEI and CDC worked outlets and conference calls, and circulated information in phConnect and among each other''s stakeholder groups. |
| Diabetic Retinopathy Clinical Research Network | Research Initiative | OS | NEI, NIDDK | The Diabetic Retinopathy Clinical Research Network (DRCR.net) is a collaborative network dedicated to facilitating multicenter clinical research of diabetic retinopathy, diabetic macular edema, and associated conditions. The DRCR.net supports the identification, design, and implementation of multicenter clinical research initiatives focused on diabetes-induced retinal disorders. Principal emphasis is placed on clinical trials, but epidemiologic outcomes and other research may be supported as well. The network is funded by the NEI, and co-funded by OS, through NIDDK, with the Special Funding Program for Type 1 Diabetes Research. http://drcrnet.jaeb.org/ViewPage.aspx?PageName=Home |
| Diagnosis, Treatment, and Medical Service Utilization in Medicare and Medicaid Population | Research Initiative | CMS | CC | Centers for Medicare and Medicaid Services (CMS) and NIH CC Rehabilitation Medicine (RMD) agreed to collaborate in data-sharing for research, the results of which may be helpful to improve medical-service quality, utilization, and effectiveness for Medicare and Medicaid beneficiaries. CMS will provide electronic data to the NIH Clinical Center, which will perform analyses that are agreed to by both parties. |
| Diagnostic Integrated Program Team (IPT) under Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) | Committee, Work group, Advisory group, or Task Force | BARDA, CDC, FDA | NIAID | Integrated Program Teams (IPT) are established by PHEMCE. This IPT is focused on diagnostics related to medical countermeasures requirements and development. http://www.phe.gov/Preparedness/mcm/phemce/Pages/mission.aspx |
| Diet-Induced Hypomethylation in Preneoplastic Liver | Research Initiative | FDA | NCI | The Food and Drug Administration (FDA) National Center for Toxicological Research and the National Cancer Institute (NCI) Division of Cancer Prevention, Nutritional Sciences Research Group are collaborating on an Interagency Agreement in which NCI will provide funds to examine the role of epigenetic mechanisms as factors that predetermine individual susceptibility to the development of hepatocellular carcinoma and to provide evidence that epigenetic alterations may be used as markers of susceptibility to disease development, and that correction of those epigenetic abnormalities during hepatocarcinogenesis may be a crucial decisive factor in cancer prevention strategies. |
| Dietary Supplements Ingredient Database (DSID) | Research Initiative | CDC, FDA | OD/DPCPSI/ODP, NCI, NHLBI, NIDDK, OD/DPCPSI/ODS | The NIH Office of Dietary Supplements (ODS) leads this program, which provides a database of basic information about the nutrient content of selected ingredients in commonly consumed types of dietary supplements, compared to label-reported ingredient levels. ODS, with collaboration from USDA, develops and maintains this database of statistical estimates—based on chemical analysis—of the nutrient content of selected ingredients in dietary supplements, compared with label-reported ingredient levels. Currently, the Dietary Supplements Ingredient Database (DSID) provides estimated levels of 18 vitamin and mineral ingredients derived from analytical data for 115 representative unspecified adult multivitamin/multimineral supplements (MVMs). Ingredients studied include children''s multivitamin/mineral supplements, non-prescription prenatal supplements, and omega-3 fatty acids. Additional dietary supplement ingredients will be included in future releases of the database. https://dietarysupplementdatabase.usda.nih.gov/ |
| Dietary Supplements Label Database (DSLD) | Resource Development | CDC, FDA | OD/DPCPSI/ODP, NLM, OD/DPCPSI/ODS | In response to a congressional mandate, the NIH Office of Dietary Supplement (ODS), in collaboration with the National Library of Medicine (NLM), takes the lead on the development and maintenance of the Dietary Supplements Label Database (DSLD). The database now contains over 72,000 labels, with new data accumulating at the rate of 1,000 labels per month. The DSLD will grow to include nearly all of the dietary supplement products in the United States. All labels are verified yearly to ensure they remain current. The DSLD provides product information that can be organized and searched by users. The primary users of this database are researchers who use the DSLD to help determine total nutrient intakes from food and supplements in populations they study. Health care providers use it to find the content of products their patients are taking. https://www.dsld.nlm.nih.gov/dsld/index.jsp |
| Digital Quantitation of Plasma Cells in Marrow Biopsies | Research Initiative | FDA | CC | This project is a collaboration between the NIH Clinical Center and the FDA that consists of developing software and establishing validations for the automated determination of marrow cellularity and enumeration of plasma cells identified by immunohistochemistry (IHC) using a CD138 antibody. This initial effort should serve as proof of principle for a broader plan to utilize IHC-based automated quantitation of different types of cells in bone marrow core biopsies for diagnosis, prognosis, and therapy monitoring of marrow disorders. |
| Disaster Research Response Project | Research Initiative | ATSDR, CDC, FDA, OS | NIEHS, NLM | The NIH Disaster Research Response (DR2) Project is a pilot project aimed at creating an environmental health disaster research system through platforms of ready-to-go research data collection tools and a network of specially trained research responders. This project was developed and will be administered by the NIEHS and NLM. Elements of the system include epidemiologic questionnaires and clinical protocols, specially trained disaster researchers, environmental health disaster research networks, a reach-back roster of subject matter experts, and a support infrastructure that can be activated and deployed during public health emergencies and declared disasters. This effort will not only serve as a model for enhancing environmental health research responses but will also provide invaluable lessons and platforms for others interested in advancing timely post-disaster research activities. http://disasterinfo.nlm.nih.gov/ |
| Dominantly Inherited Alzheimer''s Network (DIAN): International Network for the Identification, Evaluation, and Follow up of Families with Early Onset of Dominantly Inherited Alzheimer''s Disease | Research Initiative | FDA | NIA | This collaboration aims to set up an international network consisting of a consortium of scientific investigators that will have the responsibility to identify, recruit, evaluate, and follow-up individuals from families with early onset dominantly inherited Alzheimer’s Disease [i.e., families with the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) mutations or duplications or others still to be discovered]. https://dian.wustl.edu/our-research/observational-study/ |
| Drug Induced Liver Injury Network (DILIN) | Resource Development | FDA | NIDDK | Both a prospective and retrospective database containing cases of drug-induced liver disease, the Drug-Induced Liver Injury Network (DILIN) is funded by a cooperative agreement and includes eight clinical centers and a central data coordinating center. One of the goals of the DILIN is to establish a database of well-characterized cases of drug-induced liver injury along with serum, DNA, and tissue samples that will facilitate research on the mechanisms of hepatic injury due to drugs. Cases of liver injury due to herbal medications are also included. The DILIN will develop standardized definitions of drug-induced liver disease and standardization of scoring systems for causality. Three employees of FDA serve as ad hoc members on the committee overseeing the network activities. http://www.dilin.org/ |
| Early Hearing Detection and Intervention | Meeting/ Workshop | CDC, HRSA | NIDCD | This is Federal collaboration program involving NIDCD, CDC, and HRSA. NIDCD collaborates on early identification and diagnosis of hearing loss and intervention services for newborns and infants. HRSA funds awards to states and healthcare providers to screen newborns and young children for hearing loss. CDC funds states to develop data systems to track hearing loss. NIDCD also funds research grants to scientists throughout the US to study early hearing detection and intervention services. http://www.cdc.gov/ncbddd/hearingloss/index.html |
| East Asia Viral Hepatitis and Liver Cancer Consortium | Other | CDC | NCI, NIAID, NIDDK | The consortium aims to coordinate and share human, financial, and technical resources to effectively and efficiently address research and public health action needs in the prevention and control of viral hepatitis and liver cancer. This is a trans-HHS collaboration working with the World Health Organization Western Pacific Region Office WHO/WPRO and Ministries of Health of several partner countries. |
| Ebola and Infectious Disease Worker Training Program | Public Education Campaign | CDC | NIEHS | The Ebola Biosafety and Infectious Disease Response Worker Training Program began June 1, 2016, and will run through May 31, 2019. NIEHS is building federal capacity for biosecurity, bio-preparedness, and rapid response to emerging infectious diseases, including developing an infrastructure of trainers and organizations who can be a resource during emergencies. https://tools.niehs.nih.gov/wetp/index.cfm?id=2542 |
| Ebola Clinical Research Response in West Africa | Research Initiative | CDC, FDA | NIAID | This is a research collaboration between FDA, NIH, and CDC to respond to the Ebola emergency in West Africa. |
| Emergency Preparedness, Medical Countermeasures | Resource Development | OS | NCI | NCI provides expertise in radiation biology and radiation oncology to help guide the research and development of medical countermeasures for radiation injury and for biomarkers for assessing injury, dose, and who needs treatment. http://www.phe.gov/about/barda/Pages/default.aspx |
| Empowered Communities for Healthier Nation Initiative | Other | OS | NHLBI | Review of obesity grant applications for DHHS staff. https://www.grants.gov/web/grants/view-opportunity.html?oppId=294314 |
| End-stage Renal Disease (ESRD) Collaboration | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIDDK, NIBIB | Participating agencies and patient and physician groups are collaborating to help the medical product development community to understand the challenges and milestones needed to achieve the goal of a successful alternative to dialysis. Research, regulatory, and reimbursement needs for such a product are discussed in phone calls and structured meetings. |
| Endocrinologic and Metabolic Drugs Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the FDA for drug approval. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/default.htm |
| Enhanced NIH Reporting on Research Spending | Resource Development | CDC | OD/OSP, OD/OER | In early 2016, in response to a Congressional request from the FY16 Omnibus budget, NIH collaborated with the National Center for Health Statistics (NCHS) at the CDC to post federally sourced data on prevalence, from the National Health Interview Survey, and mortality, from the National Vital Statistics system, leveraging NCHS expertise to match these data sources to disease categories for which NIH reports spending totals. NIH intends to update these data on an annual basis, in regular consultation with NCHS, in order to maintain as accurate and comprehensive a dataset as possible. These data are posted alongside the RCDC spending categories on the NIH RePORT website. NIH provided mortality data for 103 RCDC categories, and prevalence for 36, out of 265 total RCDC categories. https://report.nih.gov/categorical_spending.aspx |
| Evaluation of Patient Reported Outcomes Following LASIK Surgery | Research Initiative | FDA | NEI | In October 2009, the FDA, the National Eye Institute (NEI), and the Department of Defense (DoD) launched the LASIK Quality of Life Collaboration Project (LQOLCP) to help better understand the potential risk of severe problems that can result from LASIK. The project published three manuscripts in 2016 on the new questionnaire developed by the group that can be used to assess the percent of patients who develop difficulties performing their usual activities following LASIK, and to identify predictors for those patients. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/SurgeryandLifeSupport/LASIK/ucm190291.htm |
| Evaluation of the Association between Maté Consumption and urinary PAH in Brazil | Research Initiative | CDC | NCI | This collaboration between CDC and NCI will measure metabolites of polycyclic aromatic hydrocarbons (PAHs) in the urine samples from individuals with different amounts of daily maté drinking. |
| Executive Committee for the Interagency Committee on Disability and Rehabilitation | Committee, Work group, Advisory group, or Task Force | ACL, CDC, IHS, OS | NICHD, NIMH, NINDS | This committee was established to promote coordination and cooperation among federal departments and agencies conducting disability, independent living, and rehabilitation research programs—including those that relate to assistive technology research, and research that incorporates the principles of universal design. https://icdr.acl.gov/committee/executive-committee |
| Executive Committee for the Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, SAMHSA | NICHD, NIAAA, NIDA | The Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD) was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that NIAAA chair an effort to coordinate Federal activities on Fetal Alcohol Syndrome (FAS) and other disorders associated with prenatal alcohol exposure. ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FAS and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and frequently arranges special conferences. https://www.niaaa.nih.gov/about-niaaa/our-work/interagency-coordinating-committee-fetal-alcohol-spectrum-disorders |
| Exposure Science in the 21st Century (ES21) Working Group | Research Initiative | CDC, FDA | NIEHS, NCI | ES21 is a working group chartered by the Toxics and Risk subcommittee of the OSTP Committee on Environment, Natural Resources, and Sustainability. The group focuses on coordinating efforts to advance exposure science through research and development. The primary emphasis is on information sharing and cataloging federal activities on biomonitoring, community engagement, data management, environmental monitoring, modeling, and the development of sensors and dosimeters. https://www.epa.gov/innovation/exposure-science-21st-century-federal-working-group |
| Extracellular Ribonucleic Acid (RNA) Communication | Research Initiative | FDA | OD/DPCPSI, NCATS, OD/DPCPSI/OSC | Recent advances have indicated that ribonucleic acids (RNAs) can play a role in a variety of complex cellular functions, including newly discovered mechanisms of cell-to-cell communication. RNA can be exported from cells in extracellular vesicles or bound to lipids or proteins, to circulate through the body and affect cells at a distance. However, the actual impact of the extracellular RNAs, or exRNAs, is currently unknown. NIH and FDA have coordinated efforts on the preclinical and clinical use of exRNAs to address human health and disease. To date, several PIs have had pre-pre-IND meetings with FDA/CBER. They have been provided information necessary to submit applications, for example, a biomarkers device. http://commonfund.nih.gov/Exrna/index |
| Extracting Adverse Reactions and Indexing the Content of Structured Product Labels (SPLs) | Resource Development | FDA | NLM | The objective of this initiative is for NLM to assist the US Food and Drug Administration (FDA) in indexing the content of structured product labels (SPL) for drugs. Natural language processing technology is used to extract drug-drug interaction information from SPLs which will be validated by FDA subject matter experts. Transforming the narrative text to structured information encoded in national standard terminologies is a prerequisite to the effective deployment of drug safety information in drug labels for clinical decision support. Starting in FY16, LHC and FDA/CDER collaborate on advancing automated extraction of Adverse Reactions (ARs) from drug listing information companies have submitted to FDA in the form of Structured Product Labels (SPLs). The goals of the initial agreement were to develop optimal MetaMap settings for extracting ARs from SPLs and provide FDA with the software necessary to replicate the results. To evaluate the extraction quality, LHC and FDA needed to develop a test collection of SPLs annotated with ARs. Working together, LHC and FDA have developed annotation guidelines. LHC have annotated 200 SPLs and coded the results to MedDRA, the official controlled vocabulary used by FDA to normalize the labeled ARs. In FY17, the collaboration continues with the goals to conduct a community-wide evaluation of the available AR extraction tools. The evaluation venue is NIST Text Analysis Conference (TAC). http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm |
| Extreme Events and the Elderly: Scientific Evidence, Cultural Considerations and Sustainable Solutions | Meeting/ Workshop | CDC | NIEHS, NIA | The purpose of this workshop was to explore research, service, and policy needs of the elderly in the context of extreme events (natural and man-made catastrophes such as hurricanes, floods, oil spills, and fires). The workshop highlighted existing resources and sustainable solutions for the elderly within the context of specific cultural needs of a variety of elderly populations (African American, Hispanic, Native American, Asian, rural/remote, and low SES elderly). This workshop was held from June 13 to 14, 2017. https://www.epa.gov/research-grants/trans-federal-workshop-extreme-events-environmental-health-and-elderly-scientific |
| Eye Research Collaboration | Other | FDA | NEI | The National Eye Institute (NEI) is collaborating with the Food and Drug Administration (FDA) on uveitis research and on the ocular manifestations of Zika virus and Ebola virus. Uveitis is an autoimmune disease that targets the eye. If left untreated the disease can cause permanent vision loss. Current treatments consist of steroids to suppress the immune system. However, chronic use of these drugs has many side-effects and complications. Recent outbreaks of Ebola virus and Zika virus have highlighted the unique immunological responses to these infections in the “immune privileged” eye. The virus persists in ocular fluids, even after virus is cleared from other parts of the body. |
| Fast Track Action Committee on Biosafety and Biosecurity | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | This Committee examines relevant biosafety regulations and further explores other options for biosafety oversight. |
| FDA Acute Radiation Syndrome (ARS) Action Team | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | The purpose of this collaboration is to inform members of the FDA ARS Action Team on key data from the radiation and nuclear countermeasures program (RNCP) drug development portfolio that will inform them in advancing products that may be brought forward for eventual licensure. A biweekly meeting takes place between NIAID (RNCP/Program Officer) and FDA (OCET/Senior Advisor) Senior Advisor to decide which MCMs will be presented to the Action Team. |
| FDA Cancer Imaging Program (CIP) Bi-annual Meeting | Meeting/ Workshop | FDA | NCI | This collaboration is a bi-annual meeting to enhance communication between the Cancer Imaging Program (CIP) and the Division of Medical Imaging Products of CDER in the FDA. This allows for a two-way exchange of information and discussion of issues that are important for each side. Topics that have been discussed include CIP''s standardization efforts of medical imaging scanners in NCI Cancer Centers, presentation and discussion of specific new molecular imaging modalities, and discussion of recent FDA decisions regarding new medical imaging innovations. |
| FDA Microbiology Devices Panel of the Medical Devices Advisory Committee | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This Committee provides expertise in the evaluation of evidence submitted by pharmaceutical companies to the FDA for drug approval. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/default.htm |
| FDA Substance Registry System Public Interface | Resource Development | FDA | NLM | The National Library of Medicine (NLM) and the Food and Drug Administration (FDA) established a collaborative effort to provide an interface for public access to the FDA’s Substance Registration System (SRS). The FDA SRS utilizes an existing NLM database backend architecture to provide public search capability for FDA substances and medicinal products. https://fdasis.nlm.nih.gov/srs/srs.jsp |
| FDA-NCI Every Other Month Meeting | Meeting/ Workshop | FDA | NCI | An every other month meeting to enhance communication between NCI and FDA, thereby expediting the development of new anti-cancer agents. General topics discussed include patient safety, clinical efficacy, and regulatory pathways to licensure, as well as an understanding of the operations of the sister agencies. |
| FDA/NIH Interagency Clinical Outcomes Assessments Working Group Meeting | Committee, Work group, Advisory group, or Task Force | FDA | NIMH, NCCIH, NCI, NHLBI, NIAMS, NINDS | The FDA and Institute representatives from NIH meet periodically to discuss the development of valid patient-oriented treatment outcomes, and relative measurements, for use in clinical trials of therapeutic interventions. |
| Federal Breastfeeding Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG | NICHD, NCI, NHLBI, NIDDK, NIEHS | The purpose of this workgroup is to develop strategies to implement the Surgeon General’s call to action to support breastfeeding. |
| Federal Consortium on the Substance Abusing Offender | Committee, Work group, Advisory group, or Task Force | SAMHSA | NIDA | Coordination of approximately a dozen agencies that work with substance abusing offenders. Staff meet by phone quarterly to provide updates on projects and initiatives at their agencies at the intersection of substance use and justice. |
| Federal Dietary Reference Intakes Steering Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, OS | NIDDK, NHLBI, OD/DPCPSI/ODS | This committee serves as an interagency forum to provide oversight on the process used to establish the Dietary Reference Intakes. These values serve as a basis for many federal nutrition programs and policies. |
| Federal Experts Security Advisory Panel (FESAP) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The Federal Experts Security Advisory Panel (FESAP) was established by Executive Order 13546 on July 2, 2010, to provide recommendations related to the security of biological select agents and toxins (BSAT) to the Secretaries of Health and Human Services and Agriculture and the Attorney General. https://www.phe.gov/Preparedness/legal/boards/fesap/Pages/default.aspx |
| Federal HIV/AIDS Web Council (HIV.gov) | Resource Development | CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR, CC, CIT, CSR, FIC, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/AoU, OD/DPCPSI | HIV.gov expands the visibility of timely and relevant Federal HIV policies, programs, and resources to the American public. It strives to increase the use of new media tools by government, minority, and other community partners to extend the reach of HIV programs to communities at greatest risk, as well as increase knowledge about HIV and access to HIV services for people most at-risk for, or living with, HIV. http://hiv.gov/ |
| Federal Interagency Forum for Child and Family Statistics | Research Initiative | ACF, AHRQ, CDC, HRSA, OS, SAMHSA | NICHD, NIMH | The purpose of this Interagency Agreement is to provide funds to support the work of the Federal Interagency Forum on Child and Family Statistics (Forum). The purpose of the Forum is to foster collaboration among Federal agencies that produce or use statistical data on children and families. Specifically, the Forum seeks to improve both the quality and use of data on children and families by investigating questions of data quality, data measurement, and data integration; identifying information gaps and data inconsistencies; widening access to information on children and families through the annual publication American’s Children: Key National Indicators of Well-Being and other means; coordinating the development and use of statistical data bases among Federal agencies; promoting communication among data producers, researchers, and public policymakers; and addressing concerns regarding collection, access, and dissemination of data. http://childstats.gov |
| Federal Interagency Forum on Aging Related Statistics | Resource Development | ACL, AHRQ, CDC, CMS, OS, SAMHSA | NIA | This Interagency Forum was formed with the goal of bringing together Federal agencies that share a common interest in improving aging-related data. The specific goals of the Forum are to improve both the quality and use of data on the aging population. https://agingstats.gov/about.html |
| Federal Interagency Health Equity Team (FIHET) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMHD, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NINR, OD/DPCPSI/ODP | Federal leadership for the National Partnership for Action to End Health Disparities (NPA) is provided by the Federal Interagency Health Equity Team (FIHET). The FIHET was established to foster communications and activities of the NPA within federal agencies and their partners; and to increase the efficiencies and effectiveness of related policies and programs at the national, state, tribal, and local levels. http://www.minorityhealth.hhs.gov/npa/ |
| Federal Interagency Healthy Homes Work Group (HHWG) | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The Healthy Homes Work Group (HHWG) developed a Strategy for Action that will capitalize on the collective expertise within the HHWG and the Task Force to advance the policy established in the United States Housing Act: “…to assist States and political subdivisions of States to remedy the unsafe housing conditions and the acute shortage of decent and safe dwellings for low-income families [and] to assist States and political subdivision of States to address the shortage of housing affordable to low-income families.” https://portal.hud.gov/hudportal/HUD?src=/program_offices/healthy_homes/advhh |
| Federal Interagency Task Force on the Arts and Human Development | Research Initiative | ACF, ACL, SAMHSA | NIA, NCCIH, NCI, NICHD, NIMH, OD/DPCPSI/OBSSR | Beginning in 2011, the National Endowment for the Arts (NEA) has convened a Federal Interagency Task Force on the Arts and Human Development to encourage more and better research on how the arts can help people reach their full potential at all stages of life. Task force members represent multiple units across the federal government, including the US Department of Health and Human Services, the National Institutes of Health, the National Science Foundation, and the US Department of Education, among others. To date, the Task Force has met quarterly to share ideas and information about research gaps and opportunities for understanding the arts'' role in improving health and educational outcomes throughout the lifespan. The Task Force has conducted a series of public webinars on compelling research and practices. Additionally, the group has begun a literature review of research on the arts and human development. In November 2012, four Task Force member agencies hosted a first-ever convening at the National Academy of Sciences to review the current state of research on the arts, health, and well-being in older Americans. https://www.arts.gov/partnerships/task-force |
| Federal Interagency Traumatic Brain Injury Research (FITBIR) Working Group | Resource Development | AHRQ, CDC, HRSA, OS, SAMHSA | NINDS, CIT, NCATS, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIGMS, NIMH | The charge of the Interagency Committee includes promoting collaboration among federal agencies. A goal of this committee is to develop a national “Roadmap” for Traumatic Brain Injury (TBI). This strategic planning effort will represent the collective expertise of providers, educators, advocates, federal/state/national organizations, and individuals with TBI and their families and will result in a consensus document outlining the critical elements of a successful system of care for TBI service delivery. Outcomes of the planning effort include the adoption of NINDS Common Data Elements for TBI research, and creation of the FITBIR Informatics System to store data from TBI patients and controls enrolled in studies funded by the DoD and NIH. The FITBIR Informatics System was developed to share data across the entire TBI research field and to facilitate collaboration between laboratories, as well as interconnectivity with other informatics platforms. https://fitbir.nih.gov/ |
| Federal Interagency Traumatic Brain Injury Research Working Group | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, HRSA, OS, SAMHSA | NICHD, CC, CIT, NCATS, NHLBI, NIA, NIAAA, NIBIB, NIDA, NIDCD, NIGMS, NIMH, NINDS | The FITBIR informatics system was developed to share data across the entire TBI research field. Our system is a combination of modules that supports sharing subject level de-identified data, rather than summaries or interpretations of the information. This work is done to help accelerate research progress by allowing re-analysis of data, as well as re-aggregation, integration, and rigorous comparison with other data, tools, and methods. https://fitbir.nih.gov/content/participating-organizations |
| Federal Interagency Work Group on Child Abuse and Neglect | Committee, Work group, Advisory group, or Task Force | ACF | NICHD, NIAAA, NIDA, NIMH, OD/DPCPSI/OBSSR | The Federal Interagency Workgroup on Child Abuse and Neglect meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning the prevention of child maltreatment and other related issues. http://www.acf.hhs.gov/cb/resource/fediawg |
| Federal Interagency Working Group for Diabetes | Committee, Work group, Advisory group, or Task Force | FDA | NIA | One of three Federal Interagency Working Groups formed as part of the National Action Plan to Prevent Adverse Drug Events. https://health.gov/hcq/pdfs/ade-action-plan-508c.pdf |
| Federal Interagency Working Group for Infants and Children Affected by Zika Virus | Committee, Work group, Advisory group, or Task Force | ACF, ACL, CDC, CMS, HRSA, OS, SAMHSA | NICHD | This working group brings scientists from multiple Federal agencies together to coordinate research and consider cross-cutting initiatives for children affected by Zika. |
| Federal Interagency Working Group for Research on Race and Ethnicity | Committee, Work group, Advisory group, or Task Force | CDC, CMS, OS | NICHD | The Working Group explores measurement of race and ethnicity. It prepares recommendations to OMB and other Federal agencies for the development, testing, and usage of race and ethnicity designations to more accurately describe minority populations. |
| Federal Interagency Working Group on Improving Measurement of Sexual Orientation and Gender Identity in Federal Surveys | Committee, Work group, Advisory group, or Task Force | ACF, CDC, CMS, HRSA, IHS, OS, SAMHSA | OD/DPSCSI/SGMRO, NICHD | The Working Group explores measurement of sexual orientation and gender identity (SOGI), considering multiple different dimensions of sex, gender, and sexuality. The Working Group examines variability in measurement by age, race, ethnicity, and cultural group. It prepares recommendations to OMB and other Federal agencies for the development, testing, and usage of SOGI measures to more accurately describe LGBT populations. |
| Federal Partners Committee on Women and Trauma | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, SAMHSA | NIDA, NIAID, NIMH, OD/DPCPSI/ORWH | Led by the Department of Labor (DOL) and Substance Abuse and Mental Health Services Administration (SAMHSA), the Women and Trauma workgroup includes more than three dozen federal agencies, departments, and offices one of the largest interagency collaborations in federal government history. https://www.nasmhpd.org/content/federal-partners-committee-women-and-trauma-report |
| Federal Partners in Bullying Prevention, Intervention, and Recovery | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS, SAMHSA | NIMH, NIAAA, NICHD, NIDA | This workgroup meets to provide a forum through which staff from relevant federal agencies can communicate and exchange ideas concerning how to prevent or stop bullying in schools and communities. http://www.stopbullying.gov/ |
| Federal RePORTER | Resource Development | ACF, ACL, AHRQ, CDC, FDA | OD/OER | Federal RePORTER is a searchable public database of scientific awards from federal agencies, which allows for portfolio analysis and metrics development across scientific domains. The trans-federal agency consortium called STAR METRICS (Science and Technology for America’s Reinvestment Measuring the Effects of Research on Innovation, Competitiveness, and Science) designed, created, and maintains Federal RePORTER. https://federalreporter.nih.gov |
| Federal Sudden Unexpected Infant Death/Sudden Infant Death Syndrome (SUID/SIDS) Workgroup | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS | NICHD | The Federal SUID/SIDS Workgroup represents multiple federal agencies that have established a partnership to coordinate activities, research, and outreach related to reducing infant mortality caused by SUID and SIDS. |
| Federal Supply and Demand of Isotopes | Committee, Work group, Advisory group, or Task Force | FDA | NIBIB, NCI | This workgroup was formed as a follow-up to the Inaugural Workshop on Isotope Federal Supply and Demand, a workshop now held annually. The workgroup consists of representatives of Federal agencies with the aim of providing a forum for interaction between agencies and departments to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. DOE is charged with the production of isotopes that are not commercially available, and coordinates the informational and production efforts. Dr. Roderic Pettigrew, Director of NIBIB is the NIH point of contact on this topic. The workgroup holds an annual workshop that includes all Federal agencies that use isotopes; the workshop promotes discussion on the use, supply and demand of isotopes in various areas including homeland defense, medicine, agriculture, and basic and applied research. The fifth workshop was held in November 2016. An NIH representative participated as a panel member at a congressional briefing on this topic in December 2014. The event was co-sponsored by the American Chemical Society and Research America! http://science.energy.gov/np/community-resources/workshops/2015-workshop-on-isotope-federal-supply-and-demand/ |
| Federal Working Group on Bone Diseases | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA | NIAMS, CSR, NCCIH, NCI, NEI, NIA, NIAAA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ODS, OD/DPCPSI/ORWH | An interagency committee focusing on osteoporosis and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency''s mission. |
| Federal Working Group on Dietary Supplements (FWGoDS) | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, HRSA, IHS, OS | OD/DPCPSI/ODP, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ORWH | The Office of Dietary Supplements (ODS) leads the Federal Working Group on Dietary Supplements (FWGoDS) which is comprised of individuals from federal agencies that share information and discuss issues, initiatives, and research related to dietary supplements. The FWGoDS facilitates communication and collaboration between NIH and its federal partners in several ways: co-funding research investigations within the NIH, expanding opportunities for research-investigator training, and strengthening collaborative efforts involving dietary supplement research, education, and communication. The FWGoDS meets twice a year and serves as a means of communication between ODS and its federal partners. |
| FedTel: Cross-Federal work group on telehealth | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NIBIB, NLM, OD/DPCPSI/OBSSR | The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. Current topics of emphasis include Telehealth and Health Information Technology (HIT); Technology, Innovation and Standards; Public Education of Telehealth; and Access to Health Care. |
| Filovirus Animal Non-Clinical Group (FANG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories. |
| FNIH Biomarkers Consortium | Research Initiative | CMS, FDA | NIMH, NCATS, NCI, NEI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDDK, NIEHS, NINDS | The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics. http://biomarkersconsortium.org |
| FNIH PACT (Partnership for Accelerating Cancer Therapies) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $215 million launched by the National Institutes of Health, the FNIH (Foundation for the NIH) and 11 leading pharmaceutical companies as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the FNIH, with the Food and Drug Administration serving in an advisory role. https://fnih.org/what-we-do/current-research-programs/partnership-for-accelerating-cancer-therapies |
| Fogarty HIV Research Training Program and AIDS International Training and Research Program (AITRP) | Training Initiative | CDC | FIC, NIDA | The goal of the Fogarty HIV Research Training Program (AITRP) is to build multi-disciplinary bio-medical, behavioral, and social science research capacity for the prevention, care, and treatment of HIV/AIDS and HIV-related conditions in adults and children in low- and middle- income countries (LMIC). Research training will be provided to scientists at institutions in countries defined by the World Bank criteria as LMIC. In FY15, PEPFAR/CDCCOP funded one supplement to a parent AITRP award in Ukraine through SUNY Medical Center Downstate. Also, research training activities in Uganda continued to be supported in FY15 through the FY14 PEPFAR/CDC-COP funded supplement to the Fogarty HIV Research Training award at the University of California, Berkeley. http://www.fic.nih.gov/Programs/Pages/hiv-aids-research-training.aspx |
| Forum on Regenerative Medicine | Committee, Work group, Advisory group, or Task Force | FDA | NIDCR, NHLBI, NIAMS, NIBIB, NIDDK, NINDS | Six NIH institutes and FDA are participating in a multi-year National Academy of Medicine (NAM)-led activity entitled "Forum on Regenerative Medicine". The objective of the Forum is to engage key stakeholders of regenerative medicine in a dialogue about opportunities and challenges facing translation of regenerative medicine science and technologies to the clinic. The setting of the NAM provides a neutral convening mechanism for interactions between academia, industry, government, regulators, patients’ organizations, foundations, and others. In addition to science, ethical, legal, and societal issues related to regenerative medicine are discussed. In October 2016 the Forum supported a highly successful interdisciplinary workshop that examined the current state of science in regenerative medicine. Further activities are currently being planned. http://www.nationalacademies.org/hmd/Activities/Research/RegenerativeMedicine.aspx |
| Full-text health-related documents at NLM (includes HSTAT) | Resource Development | AHRQ, ATSDR, CDC, CMS, FDA, OSG, SAMHSA | NLM | The National Library of Medicine of the National Institutes of Health provides a free, web-based resource of full-text documents that provide information on health-care decision making. https://www.ncbi.nlm.nih.gov/books/?term=intra_hhs_collaborations%5bfilter%5d |
| Funding Opportunity Announcement Module (FOAM) | Resource Development | ACF | OD/OER, NHLBI | The Funding Opportunity Announcement Module (FOAM) allows NIH Institutes and Centers and HHS Operating Divisions to develop content for and perform the needed approvals to publish funding opportunity announcements. The system has a flexible configuration to meet all of the needs for HHS Operating Divisions. Furthermore, FOAM achieves economies of scale by preventing the need for individual agencies to develop duplicate systems at a cost much greater than that of developing a unified system. |
| Gabriella Miller Kids First Common Fund Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NCATS, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAID, NIAMS, NIDA, NIDCR, NIDDK, NIEHS, NINDS, OD/DPCPSI/ORIP, OD/DPCPSI/OSC, OD/ECHO | The NIH Gabriella Miller Kids First Common Fund Working Group supports the goals and initiatives of the NIH Gabriella Miller First Common Fund Pediatric Research Program. The Common Fund’s Gabriella Miller Kids First Pediatric Research program (Kids First) is developing a data resource for the pediatric research community of well-curated clinical and genetic sequence data that will allow scientists to identify genetic pathways that underlie specific pediatric conditions but that may also be shared between apparently disparate conditions. A representative from CDC participates in the Kids First Working Group. https://commonfund.nih.gov/kidsfirst/overview |
| Genetic Studies in the National Birth Defects Prevention Study | Research Initiative | CDC | NHGRI | This study is a collaboration between CDC and NHGRI to carry out DNA sequencing and genotyping on samples collected as part of the National Birth Defects Prevention Study. https://www.cdc.gov/ncbddd/birthdefects/nbdps.html |
| GeT-RM Browser | Resource Development | CDC | NLM | The GeT-RM Coordination Program is a CDC project for establishing a community process to create reference materials, quality control measures, and proficiency testing for genetic testing. The GeT-RM Browser is provided by NCBI to facilitate access to the data generated by this project, which is intended to aid evaluation of the analytical validity of next-generation sequencing assays. https://www.ncbi.nlm.nih.gov/variation/tools/get-rm/ |
| Global Change Research Program (GCRP) Interagency Climate Change and Human Health Group (CCHHG) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIEHS, FIC | NIEHS co-chairs along with CDC and NOAA the interagency working group under the Global Change Research Program (GCRP) that plans, coordinates, and executes many federal science activities on climate change and human health. |
| Global Environmental and Occupational Health (GEOHealth) | Research Initiative | CDC | FIC, NCI, NIEHS | FIC, NCI, NIEHS, CDC''s National Institute for Occupational Safety and Health (NIOSH), Canada’s International Development Research Centre (IDRC), and the Global Alliance for Clean Cookstoves are supporting Global Environmental and Occupational Health (GEOHealth) Hubs. These are regional hubs based at low- or middle-income country (LMIC) institutions focused on collaborative research, data management, training, curriculum development, and policy support around high-priority local, national, and regional environmental and occupational health threats. The expectation is that GEOHealth Hubs will become the lead resources for environmental and occupational health, attract and retain the best talent in the region, and provide the scientific evidence for policy formulation. Together all regional hubs supported will form the GEOHealth Network, a platform for coordinated environmental and occupational health research and research training activities. FIC and its partners are supporting linked U2R and U01 awards to US and LMIC institutions, respectively. All partners contribute funds to the program. http://www.fic.nih.gov/Programs/Pages/environmental-occupational.aspx |
| Global Health - Household Air Pollution Investigation Network (HAPIN) | Research Initiative | CDC | OD/DPCPSI, FIC, NCI, NHLBI, NICHD, NIEHS, OD/DPCPSI/OSC | The Household Air Pollution Investigation Network (HAPIN) is a large NIH initiative designed to tackle the challenge of reducing the burden of disease from household air pollution (HAP). Within HAPIN, an Implementation Science Network (ISN) was formed to advance the science of uptake and scale-up of clean cooking technology in the developing world. The ISN steering committee is composed of HAP experts from across NIH and various government and non-government agencies. https://commonfund.nih.gov/globalhealth/HAPINresources |
| Global Health Security Advisory Group (GHSAG) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID, NINDS | The Global Health Security Advisory Group (GHSAG) is a committee composed of high-level representatives of the national health authorities for the G-8 block of countries. The GHSAG was formed to develop and implement concrete actions to improve global health security and serve as a network for rapid response to biological, chemical, radio-nuclear terrorism (CBRN) crises. http://www.ghsi.ca/english/index.asp |
| Global Health Security Agenda (GHSA) Action Package Prevent 3 (APP3), Biosafety and Biosecurity Working Group | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP | The purpose of the APP3 WG is to promote awareness and implementation of comprehensive national-level biosafety and biosecurity frameworks within the Global Health Security Agenda. https://www.ghsagenda.org/ |
| Global Ingredient Archival System (GINAS) | Research Initiative | FDA | NCATS | The Global Ingredient Archival System is a project that aims to provide a common identifier for all of the substances used in medicinal products, utilizing a consistent definition of substances globally, including active substances under clinical investigation, consistent with the ISO 11238 standard. The FDA is utilizing software from this project to meet their obligations under the Identification of Medicinal Products (IDMP) global regulatory scheme. In 2016, the software was deployed onto FDA internal systems and FDA’s existing data was migrated into their instance (internally called Global Substance Registration Service (GSRS)). A public version of FDA’s substance definitions for use by researchers outside the agency was made available through NCATS’ website for the project. https://ncats.nih.gov/expertise/preclinical/ginas |
| Global Initiative for Cancer Registry Development | Other | CDC | NCI | Cancer incidence and mortality are rising rapidly worldwide, particularly in low- and middle-income countries. There is an overwhelming need for countries to adopt and implement cancer control actions. Yet only one in five low- and middle-income countries have the necessary data to drive policy and reduce the burden and suffering due to cancer. The Global Initiative for Cancer Registry Development (GICR) is a coordinated, multi-partner approach to deliver the required change. Its objective is to make cancer data count. http://gicr.iarc.fr/ |
| Global Strategic Plan to Prevent Harms Associated with Alcohol Misuse | Meeting/ Workshop | CDC, SAMHSA | NIAAA | NIAAA represented HHS at the World Health Organization, coordinating with officials at CDC and SAMHSA to review Global Strategies to Prevent Harms Associated with Alcohol Misuse. |
| Go4Life | Public Education Campaign | ACL, AHRQ, CDC, OS, OSG | NIA, NCCIH, NEI, NHLBI, NIAMS, NIDDK, NIMH, NINDS | Go4Life is an exercise and physical activity campaign from the National Institute on Aging at the National Institutes of Health (NIH), It is designed to help individuals fit exercise and physical activity into their daily life. Motivating older adults to become physically active for the first time, return to exercise after a break in their routines, or build more exercise and physical activity into weekly routines are the essential elements of Go4Life. Go4Life offers exercises, motivational tips, and free resources to help individuals get ready, start exercising, and keep going. The Go4Life campaign includes an evidence-based exercise guide in both English and Spanish, an exercise video, an interactive website, and a national outreach campaign. http://www.nia.nih.gov/Go4Life |
| Grants management with AHRQ | Other | AHRQ | CSR | CSR works with AHRQ to perform receipt and referral services. |
| Grants management with CDC | Other | CDC | CSR | CSR works with CDC to receive and peer review some of their grant applications. |
| Grants management with FDA | Other | FDA | CSR | CSR works with FDA through the Tobacco Regulatory Science Program in the Office of Disease Prevention under NIH OD to receive and review some of their grant applications. |
| Harmonization of Various Common Data Models and Open Standards for Evidence Generation | Committee, Work group, Advisory group, or Task Force | FDA, OS | NLM, NCATS, NCI | "This project is funded by the Office of the Secretary Patient Centered Outcomes Research Trust Fund for Data Infrastructure. This goal of this project is to facilitate the use of Real World Data (RWD) sources (e.g., claims, EHRs, registries, electronic Patient Reported Outcomes (ePRO)) to support evidence generation for regulatory and clinical decision making. This project will: (1) Develop common data architecture as the intermediary between various Common Data Models; (2) Create a sustainable, flexible, modifiable shared resource that can evolve over time with changing requirements; (3) Validate the common data architecture through a specific use case that would evaluate the safety of newly approved oncology drugs that help to allow the immune system to target cancers; and (4) Establish methods and develop processes, policies and governance for ongoing curation, maintenance, and sustainability of the common data architecture, building upon existing resources, standards, and tools." https://aspe.hhs.gov/os-pcortf-funded-projects |
| Harmonization of various Common Data Models and Open Standards for Evidence Generation | Resource Development | FDA | NCATS, NCI, NLM | The goal of this project is to build data infrastructure for conducting patient-centered outcomes research using data derived from the delivery of health care in routine clinical settings. These data are collectively referred to as observational data. The sources of these data may include, but are not limited to insurance billing claims, electronic health records (EHRs), and patient registries. The Common Data Model (CDM) organizes data into a standard structure, which may differ across networks. This project intends to harmonize several existing CDMs in order to support research and analyses across multiple data networks. The aim is to advance the utility of data and its interoperability across networks to facilitate patient-centered outcomes research. The enhanced data infrastructure created through this project will have the capacity to support evidence generation on patient-centered outcomes that can inform regulatory and clinical decision making within federal programs. |
| HCS Research Collaboratory | Research Initiative | AHRQ, CDC, FDA, OS | OD/DPCPSI, NCATS, NCCIH, NCI, NHLBI, NIA, NIAID, NIAMS, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NINDS, NLM, OD/DPCPSI/OSC | The Health Care Systems (HCS) Research Collaboratory program is strengthening the national capacity to implement cost-effective large-scale research studies that engage health care delivery organizations as research partners. The studies funded through this program, referred to as pragmatic clinical trials, engage medical centers across the country in addressing a wide range of pressing public health concerns. The HCS Collaboratory works with representatives from the FDA, AHRQ, OHRP, and CDC in order to bring expertise from across HHS to bare on the implementation of these complex pragmatic clinical trials. https://commonfund.nih.gov/hcscollaboratory |
| Health and Human Services Federal Interagency Working Group (FIW) - National HIV/AIDS Strategy (NHAS) Indicators: Young Men who have Sex with Men (YMSM) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA, IHS, SAMHSA | OD/DPCPSI/OAR | Three Federal Interagency Working Groups (FIWs) were formed to address the lack of progress on some of the National HIV/AIDS Strategy (NHAS) performance indicators. This subgroup is led by Drs. David Purcell of the Center for Disease Control and Prevention (CDC), Susannah Allison of the National Institutes of Health (NIH), and Timothy Harrison of the Office of HIV/AIDS and Infectious Disease Policy (OHAIDP). The FIW charge is to address the lack of progress regarding NHAS Indicator 3 (Reduce the percentage of young gay and bisexual men who have engaged in HIV-risk behaviors by at least 10 percent); further, the FIW is charged with reviewing the literature and developing two logic models to help illustrate how to improve upon these two indicators. The logic models are designed to capture inputs and outputs from a 30,000-foot level and drive a longer conversation about what we are doing right and where we are falling short. |
| Health and Retirement Study (HRS) | Research Initiative | CDC, CMS | NIA | This study follows more than 20,000 men and women over 50, offering insight into the changing lives of the older US population. Launched in 1992, this multidisciplinary, longitudinal study has become known as the Nation’s leading resource for data on the combined health and economic conditions of older Americans. http://hrsonline.isr.umich.edu/ |
| HealthMap: Knowledge Management for Emerging Infectious Disease Intelligence | Research Initiative | OS | NLM | Leveraging previous National Library of Medicine (NLM) funded work under the HealthMap project, the HHS Assistant Secretary for Preparedness and Response (ASPR) and OPEO co-funded an administrative supplement to an NLM/NIH grant to provide funding to Harvard University for a pilot project in which Harvard will develop real-time applications to collect, parse, analyze, and display open source data in order to address the national needs of emergency preparedness and response for hurricanes. http://www.healthmap.org |
| Healthy People 2020 | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/ODP, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NINDS | Healthy People provides science-based national goals and objectives with 10-year targets designed to guide national health promotion and disease prevention efforts to improve the health of all Americans. As part of its mission, Healthy People has established benchmarks and monitored progress over three decades in order to (1) engage multiple sectors to strengthen policies and improve practices that are driven by the best available evidence and (2) to increase public awareness of the determinants of health, disease, and disability and the opportunities for progress. Healthy People published a mid-course review in 2017 and can be found here: https://www.cdc.gov/nchs/healthy_people/hp2020/hp2020_midcourse_review… https://www.healthypeople.gov/ |
| Healthy People 2020 - Blood Disorders | Health Survey | CDC | NHLBI | The purpose of the collaborative activity is to support development and implementation by the National Health Interview Survey (NHIS) of measures that could be used to assess progress towards achieving Healthy People 2020 blood disorders and blood safety. The NHLBI and the National Center for Health Statistics collaborate on this activity. https://www.healthypeople.gov/2020/topics-objectives/topic/blood-disorders-and-blood-safety |
| Healthy People 2020 - Kidney Disease | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, OS | NIDDK | The Office of the Secretary of HHS leads the Healthy People 2020 initiative. The lead agency for most data activities is the CDC. However, for the kidney area, most of the information is provided by NIDDK through the US Renal Data System. http://www.healthypeople.gov |
| Healthy People 2020 - Older Adults | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA | NIA, NIMH, NINDS | This Healthy People 2020 topic is designed to develop an understanding of the health and health care needs and implications for older adults. The objectives overall will promote healthy outcomes in this population. The goal of these objectives is to improve the health, function, and quality of life of older adults. http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=31 |
| Healthy People 2020 - Sleep Health | Health Survey | CDC | NHLBI, NIA, NICHD, NIDA, NIDDK, NIMHD, NINDS, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS | The purpose of the collaborative activity is to support the identification of nationally representative measures that could be used to assess progress towards achieving Healthy People sleep health objectives. The National Heart, Lung and Blood Institute leads this activity. https://www.healthypeople.gov/2020/topics-objectives/topic/sleep-health |
| Healthy People 2020 - Social Determinants of Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, OS, SAMHSA | NIMHD, NCI, NHLBI, NIAAA, NIAMS | The overarching goals for Healthy People 2020 incorporate a focus on social determinants of health as well as on health outcomes and risk factors. The Working Group intends to develop objectives for the social determinants and methods to ensure their integration across all Healthy People 2020 objectives. https://www.healthypeople.gov/2020/about/history-development/Federal-Interagency-Workgroup |
| Healthy People 2020 - Structured Evidence Queries (SEQs) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS, SAMHSA | NLM | NLM is collaborating with ODPHP to develop structured PubMed searches for the HP 2020 objectives. Each PubMed search (a structured evidence query (SEQ) or "seek") is developed by medical librarians and reviewed by members of the HP 2020 working groups. The canned PubMed searches enable the public health workforce to find evidence-based information related to a specific HP 2020 objective. The SEQs are accessible from the HP 2020 website as well as the PHPartners.org website. http://phpartners.org/hp2020/index.html |
| Healthy People 2020 - Visual Health | Health Survey | AHRQ, CDC | NEI, OD/DPCPSI/ODP | Healthy People 2020 is a collaboration with NIH, CDC, and AHRQ to survey and measure public health outcomes for a variety of common diseases over the current decade. NEI''s goal for this program is to Improve the visual health of the Nation through prevention, early detection, timely treatment, and rehabilitation. https://www.healthypeople.gov/ |
| Healthy People 2020 Disability Representative | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. NIH and HHS staff collaborate on workgroups under the Healthy People framework to refine objectives, update information, and monitor progress towards Healthy People objectives. The goal of this group is to maximize health, prevent chronic disease, improve social and environmental living conditions, and promote full community participation, choice, health equity, and quality of life among individuals with disabilities of all ages. https://www.healthypeople.gov/2020/topics-objectives/topic/disability-and-health |
| Healthy People 2020 Nutrition Working Group | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, OS | NICHD, NIDDK | Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. NIH and HHS staff collaborate on workgroups under the Healthy People framework to refine objectives, update information, and monitor progress towards Healthy People objectives. The goal of this group is to promote health and reduce chronic disease risk through the consumption of healthful diets and achievement and maintenance of healthy body weights. https://www.healthypeople.gov/2020/topics-objectives/topic/nutrition-and-weight-status |
| Healthy People 2020 Oral Health Law and Health Policy Project | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA, IHS, OS | NIDCR | Highlight the state of laws and policies related to specific topic areas and provide practical information about the use of law and policy to address health factors. Each report will feature progress toward meeting the salient Healthy People 2020 objectives, focusing on state and local laws and policies, and highlighting laws that have demonstrated positive outcomes. |
| Healthy People 2020-Dementias, Including Alzheimer''s Disease | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA | NIA, NIMH, NINDS | This Healthy People 2020 topic will focus on increasing the awareness of the diagnosis of Alzheimer’s disease, and on reducing the proportion of preventable hospitalizations in persons with diagnosed Alzheimer’s disease and other dementias. The goal is to reduce the morbidity and costs associated with, and maintain or enhance the quality of life for, persons with dementia, including Alzheimer’s disease. http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=7 |
| Healthy Vision Month | Public Education Campaign | CDC | NEI | Each May the NEI sponsors Healthy Vision Month (HVM), which is a national observance designed to elevate eye health as a priority for Americans. NIH worked with CDC for the 2014 observance to disseminate disease information for CDC''s Vision Initiative website and provided online banners and buttons linking to the HVM site and to the NEI for additional information. http://www.nei.nih.gov/hvm/ |
| Hematopoietic Stem Cell Transplantation Interagency Working Group | Committee, Work group, Advisory group, or Task Force | FDA, HRSA | NCI, CC, NHLBI, NIAID, NIDDK | This working group reviews matters associated with hematopoietic stem cell transplantation. |
| Hepatitis B Research Network | Research Initiative | CDC | NIDDK | The Hepatitis B Research Network (HBRN) was established in 2008 to advance understanding of disease processes and natural history of chronic hepatitis B, as well as to develop effective approaches to treatment with currently available therapies. The Network brings together clinical centers from throughout the US and Canada. This multi-center Network is enrolling patients in multiple clinical trials in both adults and children with hepatitis B. http://www.hepbnet.org/ |
| HHS Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis Interagency Implementation Group (VHIG) | Research Initiative | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NIDA, NIAID, NIDDK, NIMHD | HHS agencies review the Institute of Medicine (IOM) recommendations and develop a comprehensive strategic viral hepatitis action plan that would: address IOM recommendations for viral hepatitis prevention, care, and treatment; set forth actions to improve viral hepatitis prevention and ensure that infected persons are identified and provided care and treatment; and improve coordination of all activities related to viral hepatitis across HHS and promote collaborations with other government agencies and nongovernmental organizations. http://www.hhs.gov/ash/ohaidp/initiatives/ |
| HHS Adolescent Health Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NIDA, NIAAA, NICHD, NIMH | This interagency working group, which was established in January 2010 within the Office of the Assistant Secretary for Health, provides a forum for HHS agencies and other federal agencies to learn from each other and support a full-range of evidence-based approaches to improve adolescent health, to address adolescents’ health risks, and highlight programs focused on positive youth development. This collaboration among many HHS agencies and offices serves as a forum for exchanging information relevant to improving adolescent health and well-being. |
| HHS Adult and Adolescents HIV Treatment Guidelines Panel | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NIAID, OD/DPCPSI/OAR | The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of the Office of AIDS Research Advisory Council (OARAC). The primary goal of the Panel is to provide HIV care practitioners with recommendations based on current knowledge of antiretroviral drugs (ARVs) used to treat adults and adolescents with HIV in the United States. The Panel reviews new evidence and updates recommendations when needed. These guidelines include recommendations on baseline laboratory evaluations, treatment goals, benefits of ART and considerations when initiating therapy, choice of the initial regimen for ART-naive patients, ARV drugs or combinations to avoid, management of treatment failure, management of adverse effects and drug interactions, and special ART-related considerations in specific patient populations. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf |
| HHS Antimicrobial Resistance Challenge Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID, OD/DPCPSI | Development and management of the HHS Antimicrobial Resistance Rapid Point of Need Diagnostic prize competition. http://www.cccinnovationcenter.com/challenges/antimicrobial-resistance-diagnostic-challenge/ |
| HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Communications | Committee, Work group, Advisory group, or Task Force | ACL, OS | NIDA, NIMH | A subcommittee of the HHS Behavioral Health Coordinating Committee is a coordinating body within the US Department of Health and Human Services (HHS) that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. This subcommittee of communication professionals collaborates on inter-departmental behavioral health initiatives and promotional efforts. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Committee (BHCC) Subcommittee on Opioids | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIDA | A subcommittee of the HHS Behavioral Health Coordinating Committee is a coordinating body within the US Department of Health and Human Services (HHS) that identifies and facilitates collaborative, action-oriented approaches to addressing the HHS behavioral health agenda. The National Institute of Drug Abuse (NIDA) Serves as Co-Chair with FDA on this inter-agency subcommittee addressing prescription drug abuse. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Committee (BHCC) Trauma and Early Intervention Subcommittee | Committee, Work group, Advisory group, or Task Force | ACF, SAMHSA | NIMH, NIAAA, NICHD, NIDA | The BHCC is tasked with assuring that agencies coordinate their activities related to addressing the needs of and services for persons with behavioral healthcare concerns, particularly but not exclusively those with serious mental illness (SMI). The new charge of the Trauma and Early Intervention Subcommittee is the creation of a Primer on Trauma-Informed Human Services that will summarize the practical implications of recent research about trauma, toxic stress, executive functioning, and related constructs for managers and administrators of HHS-supported human services programs. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Committee Subgroup on Trauma | Committee, Work group, Advisory group, or Task Force | ACF, OS, SAMHSA | NICHD, NIMH, OD/DPCPSI | The Behavioral Health Coordinating Committee Subgroup on Trauma aims to share information and identify and facilitate collaborative, action-oriented approaches to address the Department of Health and Human Services behavioral health agenda pertaining to trauma without duplication of effort across the Department. |
| HHS Behavioral Health Coordinating Council (BHCC) Subcommittee on Marijuana | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | NIDA | The Behavioral Health Coordinating Council (BHCC) Subcommittee on Marijuana develops projects with clear goals, provides guidance to achieve steady progress, and measurable outcomes, and develop key policy messages on issues related to marijuana. http://www.samhsa.gov/about-us/interagency |
| HHS Behavioral Health Coordinating Council (BHCC) Subcommittee On Primary Care And Behavioral Health Integration | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA | NIMH, NIAAA, NIDA | The BHCC is tasked with assuring that agencies coordinate their activities related to addressing the needs of and services for persons with behavioral healthcare concerns, particularly but not exclusively those with serious mental illness (SMI). The Behavioral Health/Primary Care Integration Subcommittee addresses the need to improve the integration of mental health and primary care services. This group convenes bi-monthly to share agency initiatives in this area and collaborate on new initiatives to promote this integration. http://www.samhsa.gov/about-us/interagency |
| HHS Biannual Dual Use Research of Concern (DURC) Inventory | Resource Development | CDC, FDA, OS | OD/OSP, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI | Development of the HHS Biannual Dual Use Research of Concern (DURC) inventory reports, as required by the USG Policy for Oversight of Dual Use Research of Concern. |
| HHS Biomedical Advanced Research and Development Authority (BARDA) Armed Forces-Radiobiology Research Institute (AFRRI) Good Laboratory Practices (GLP) Integrated Project Team | Committee, Work group, Advisory group, or Task Force | BARDA | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) participates on the HHS BARDA Armed Forces Radiobiology Research Institute (AFRRI) Good Laboratory Practices (GLP) Integrated Project Team to collaborate and provide subject matter expertise, advice, and guidance on establishing a quality assurance program at AFRRI for GLP compliance. |
| HHS Biomedical Advanced Research and Development Authority (BARDA) Radiological and Nuclear Threats Integrated Program Team | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This Interagency Working Group, established under the Biomedical Advanced Research and Development Authority (BARDA), determines overall radiation countermeasures strategy and priorities. The National Institute of Allergy and Infectious Diseases (NIAID) provides subject matter expertise, advice and guidance on medical countermeasure development, requirements, and preparedness/response. |
| HHS Biosafety and Biosecurity Coordinating Council (HHS BBCC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP | This Council serves as a high-level and formal mechanism to coordinate and collaborate on biosafety and biosecurity issues across the Department. |
| HHS Biovigilance Committee | Committee, Work group, Advisory group, or Task Force | CDC | CC, NHLBI | This committee develops systems for reporting adverse events resulting from blood transfusion or donation. |
| HHS Border Health Intra-agency Working Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, FDA, HRSA, IHS, OS | NICHD, NIA, NIAID, NIDDK, NIMH, NIMHD | This intra-agency workgroup allows for the exchange of information and cooperation among HHS agencies on issues related to border health. The purpose of this group is to convene HHS components that have a vested interest in US-Mexico border health issues to provide a platform for discussion, coordinate efforts, and potentially identify mutual areas of collaboration to improve the health and quality of life for border residents. |
| HHS Data Council | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OBSSR | Coordinates all health and human services data collection and analysis activities of the Department of Health and Human Services, including an integrated data collection strategy, coordination of health data standards and health and human services and privacy policy activities. https://aspe.hhs.gov/hhs-data-council-introduction#dcpurpose |
| HHS Dietary Guidance Review Committee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS | NIDDK | This committee reviews draft nutrition materials developed by all federal agencies and fulfills the legislative mandate (1990 NNMRRA) to ensure that Federal dietary guidance is consistent with the Dietary Guidelines for Americans and is scientifically accurate. |
| HHS ED Developmental and Behavioral Screening Working Group | Committee, Work group, Advisory group, or Task Force | ACF, ACL, CDC, CMS, HRSA, SAMHSA | NICHD | This committee supports the objectives of improving developmental and behavior screening. |
| HHS Environmental Justice Working Group | Public Education Campaign | CDC, FDA, HRSA, OS, SAMHSA | NIEHS, NIMHD | The Office of the Assistant Secretary for Health (OASH) is responsible for coordinating interdisciplinary programs within HHS and ensures that HHS works in concert with its federal partners, including the Environmental Justice Working Group. OASH staff lead the HHS Environmental Justice Working Group with bi-weekly meetings that provide time for sharing information and new approaches, identifying opportunities for collaboration, and updating progress toward advancing the actions of the 2012 HHS Environmental Justice Strategy and the Priority Areas of Focus. HHS EJ Working Group members are responsible for coordinating and reporting on activities related to environmental justice within their agencies. https://www.hhs.gov/environmental-justice/index.html |
| HHS Evidence & Evaluation Policy Council | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | OD/OSP | The HHS Evidence & Evaluation Policy Council was instituted in 2016. The aims of the Council are to develop and coordinate a community within HHS that can advise and consult with their agencies on evaluation and evidence activities. The council works toward improving efficiency and effectiveness in planning, conducting, and disseminating evaluations and evidence throughout HHS, and ensuring the integrity, rigor, and relevance of the information collected, analyzed, and disseminated for evaluation purposes. Activities focus on coordination and collaboration, emphasizing areas of common interest. Example topics include staff development, emerging issues like using administrative data for evaluation purposes, working effectively with leadership and agency partners, and adopting common principles and practices. https://aspe.hhs.gov/evaluation-evidence |
| HHS Global Health Collaborative | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMH | This interagency working group meets to provide a forum within the Department of Health and Human Services (HHS) that identifies Global Health issues relevant to the HHS Global mental health agenda. |
| HHS Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NIAID, OD/DPCPSI/OAR | These guidelines were prepared by the Opportunistic Infections Working Group under the auspices of the Office of AIDS Research Advisory Council (OARAC) of the NIH. Briefly, six co-editors selected and appointed by their respective agencies (i.e., NIH, CDC, IDSA) convened working groups of clinicians and scientists with subject matter expertise in specific HIV-associated opportunistic infections. The co-editors appointed a leader for each working group, which reviewed the literature since the last publication of these guidelines, conferred over a period of several months, and produced draft revised recommendations. Issues requiring specific attention were reviewed and discussed by the co-editors and the leaders from each working group at the annual meeting of the IDSA in Vancouver, Canada, in October 2010. After further revision, the guidelines were reviewed by patient care advocates and by primary care providers with extensive experience in the management of HIV infection. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf |
| HHS H5N1 Gain-of-Function Review Group (HHG Review Group) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The Framework for Guiding HHS Funding Decisions about Research Proposals with the Potential for Generating Highly Pathogenic Avian Influenza (HPAI) H5N1 Viruses that are Transmissible among Mammals by Respiratory Droplets requires that certain research proposals undergo additional review at both the funding agency and Departmental (HHS) levels prior to funding. The HHS Department-level review is performed by the HHG Review Group, which brings to bear multidisciplinary interagency expertise in science, countermeasure development and availability, national security, law, public health preparedness and response, biodefense, select agent regulations, and science and public health policy. The purpose of the HHS Department-level review includes review of the funding agency''s risk assessment, consideration of whether additional factors may alter assessment of whether the research can be funded, determination of which measures are needed to mitigate risks, consideration of the overall HHS influenza research portfolio, and determination of whether the proposal is acceptable for HHS funding. |
| HHS Health Disparities Council | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA | NIMHD | The HHS Health Disparities Council serves as the venue to share information, leverage HHS investments, coordinate HHS activities, reduce program duplication, and track progress on the strategies and actions of the HHS Disparities Action Plan. |
| HHS Healthy Weight, Nutrition and Physical Activity Work Group | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIDDK, NCI, NHLBI, NICHD, OD/DPCPSI/ODP | The Department of Health and Human Services (HHS) Healthy Weight, Nutrition and Physical Activity Work Group aims to improve dietary and physical activity behaviors through targeted sector initiatives. |
| HHS LGBT Policies Coordinating Committee | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | OD/DPSCSI/SGMRO, NCCIH, NICHD, NIMH, NIMHD | The HHS LGBT Policy Coordinating Committee is comprised of senior representatives from each division of HHS. This committee coordinates LGBT-related policies across the department and recommends future actions that HHS can take to improve the health and well-being of LGBT individuals. https://www.hhs.gov/programs/topic-sites/lgbt/reports/index.html |
| HHS Measurement Policy Council | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA | NLM | The HHS Measurement Policy Council was convened in early 2012 to begin the work of aligning measures across HHS. Composed of senior-level representatives from Agencies and operating divisions across HHS, the group also addresses new measure development and implementation, and measurement policy. The Council has so far reviewed nine topics to date: hypertension control, hospital-acquired conditions/patient safety, HCAHPs, smoking cessation, depression screening and care coordination, HIV/AIDS, perinatal, and obesity/BMI. While these measures are used for Federal programs, the Measurement Policy Council supports State and private-sector efforts to adopt core measure sets for further harmonization and alignment across the health and health care community. NLM serves on this council. http://www.ahrq.gov/workingforquality/about.htm |
| HHS Nutrition Policy Board | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, IHS, OS, SAMHSA | NIDDK | This Board coordinates the Department''s nutrition policy development and program implementation and is the principle point of contact with USDA for nutrition policy. |
| HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NIAID, OD/DPCPSI/OAR | Also called ''Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection''. These updated Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection address the use of antiretroviral therapy (ART) for infants, children, and adolescents living with HIV. In general, these guidelines are appropriate for the care and management of youth with sexual maturity rating (SMR, formerly Tanner staging) I to III, whereas the guidelines developed by the Panel for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents are suitable for the care and management of adolescents in late puberty (SMR IV-V). Guidance on the management of adverse events associated with the use of antiretroviral (ARV) drugs in children and a detailed review of information about safety, efficacy, and pharmacokinetics (PK) of ARV agents in children is also included. The Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel), a working group of the Office of AIDS Research Advisory Council (OARAC), reviews new data on an ongoing basis and provides regular updates to the guidelines. The Guidelines are available on the AIDSinfo website at http://aidsinfo.nih.gov. https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf |
| HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NIAID, OD/DPCPSI/OAR | Also called ''Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States''. These Guidelines update the October 2016 Perinatal Guidelines. The Department of Health and Human Services Panel on Treatment of Pregnant Women Living with HIV and Prevention of Perinatal Transmission (the Panel), a working group of the Office of AIDS Research Advisory Council, develops these guidelines. The guidelines provide health care providers with information for discussion with pregnant women living with HIV infection to enable collaborative, informed decision-making regarding the use of ARV drugs during pregnancy, use of scheduled cesarean delivery to reduce perinatal transmission of HIV, and decision-making around the use of ARV drugs for prophylaxis of infants exposed to HIV. The recommendations in these Guidelines are accompanied by a discussion of various circumstances that commonly occur in clinical practice and the factors that influence treatment considerations. The Panel recognizes that strategies to prevent perinatal transmission and concepts related to management of HIV in pregnant women are rapidly evolving and will consider new evidence and adjust recommendations accordingly. The updated guidelines are available from the AIDSinfo website http://aidsinfo.nih.gov. https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf |
| HHS Preparedness for Pregnant Women Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA, IHS, OS | NICHD, NIAID, NLM, OD/DPCPSI/ORWH | This HHS working group meets monthly to exchange information and consult on various agency programs related to preparedness for pregnant women. |
| HHS Secretary''s Initiative on Serious Mental Illness (SMI) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIMH | The Department of Health and Human Services (HHS) Action Plan includes activities addressing the needs of individuals with serious mental illness (SMI) as well as those at high risk for developing SMI. This plan targets three goals: reducing the duration of untreated SMI through early engagement in care; improving the quality of care through stronger measurement and accountability; and increasing access to community-based treatment and support services. |
| HHS Sickle Cell Disease Interest Group | Other | CDC, CMS, HRSA, OS | NHLBI | The HHS Sickle Cell Disease Interest Group is a collaboration to discuss and share information on each agency''s SCD program to move the science forward. |
| HHS Tick-Borne Diseases Working Group | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NIAID | The Tick-Borne Disease Working Group was established by Congress in 2016 as part of the 21st Century Cures Act to provide subject matter expertise and to review federal efforts related to all tick-borne diseases, to help ensure interagency coordination and minimize overlap, and to examine research priorities. The focus of this effort is the development of a report to the Secretary of Health and Human Services and Congress on the findings and any recommendations of the Working Group for the federal response to tick-borne disease prevention, treatment, and research, as well as how to address gaps in these areas. https://www.hhs.gov/ash/advisory-committees/tickbornedisease/index.html |
| HHS Tobacco Control Steering Committee and Cessation Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, CMS, FDA, HRSA, OS, SAMHSA | NHLBI, NCI, NIDA | This committee, led by the Department of Health and Human Services, coordinates and initiates tobacco control activities across agencies. Helped to develop the HHS Tobacco Control Strategic Action Plan and the Action Plan Progress Report. |
| HHS Viral Hepatitis Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIDDK, NIDA | The HHS Viral Hepatitis Interagency Working Group was created by the Office of the Assistant Secretary for Health to address a report sponsored by the Institute of Medicine entitled Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. The group meets to discuss collaborations and activities directed at achieving the goals for viral hepatitis research and control highlighted in the IOM report. (Although NIDDK and NIDA represent NIH as Working Group members, other NIH Institutes/Centers/Offices also provide input to the VHIG through their participation in the Trans-NIH Committee on Viral Hepatitis.) The working group developed a 2017-2020 National Viral Hepatitis Action Plan. http://www.hhs.gov/hepatitis/action-plan/u-s-viral-hepatitis-action-plan-overview/index.html |
| HIV/AIDS Cancer Match Study | Research Initiative | CDC | NCI | Investigators use data from the NCI HIV/AIDS Cancer Match Study, in conjunction with data from the CDC HIV surveillance program, to estimate the burden of cancer in HIV-infected people in the United States. http://hivmatch.cancer.gov/ |
| HPV Working Group for the Advisory Committee on Immunization Practices (ACIP) | Committee, Work group, Advisory group, or Task Force | CDC | NCI | The HPV Working Group for the Advisory Committee on Immunization Practices (ACIP) Work Groups (WGs) serves in a key scientific role in support of vaccine policy development by the ACIP. ACIP WGs conduct extensive background reviews of relevant research data to develop options for recommendations for use of vaccines in the civilian population of the United States. WGs are convened solely to gather scientific information related to vaccines and the diseases they prevent, to analyze relevant issues and data, and to draft policies or options for review, deliberation, and vote by the ACIP. |
| HRSA childhood obesity technology challenge | Other | HRSA | NHLBI | NIH reviews grant applications submitted in response to HRSA''s childhood obesity technology challenge. https://www.federalregister.gov/documents/2017/09/26/2017-20537/challenge-competition-using-technology-to-prevent-childhood-obesity-in-low-income-families-and |
| I-Corps @ NIH | Training Initiative | CDC | NCI, NCATS, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIMH, NINDS | The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. https://sbir.cancer.gov/programseducation/icorps |
| Identifying Early Psychosis in Primary Care and Connecting to Care | Research Initiative | HRSA | NIMH | The Health Resources and Services Administration (HRSA) and National Institute of Mental Health (NIMH) are supporting testing of a brief early psychosis screening instrument. This instrument may be used in a primary care setting to identify people with psychosis at the earliest possible opportunity and connect them to an early psychosis treatment program. https://projectreporter.nih.gov/project_info_description.cfm?aid=9502128&icde=37112614&ddparam=&ddvalue=&ddsub=&cr=3&csb=default&cs=ASC&pball= |
| Image-guided Interventional Therapeutics | Research Initiative | FDA | CC, NCI | This collaboration will lead to safer and more effective treatment planning and performance of image-guided interventions and therapeutic drug delivery. The results of all of these studies of image-guided interventions and related technologies and the models used to study them will have a direct impact on the effectiveness and consistency of the FDA Center for Devices and Radiological Health''s preclinical review of device applications while meeting the primary research goal of optimizing image-guided interventions and pre-clinical modeling of those interventions. Regulatory science and translational therapeutics have overlapping goals when it comes to drugs and devices combination therapies. |
| Immunology Interest Group | Meeting/ Workshop | FDA | NCI, CC, NCCIH, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, OD/OIR | The NIH Immunology Interest Group brings together immunologists from across all NIH institutes as well as the FDA. The two major activities of the IG are a Wednesday afternoon lecture series highlighting world-class immunologists and intramural immunologists and an annual workshop where up to 350 NIH/FDA immunologists get together to present their work to the community. https://ecollab.niaid.nih.gov/sites/IIG/_layouts/15/start.aspx#/SitePages/Welcome%20to%20the%20NIH%20Immunology%20Interest%20Group.aspx |
| Immunotoxicity of Workplace Xenobiotics | Research Initiative | CDC | NIEHS | The Immunotoxicity of Workplace Xenobiotics interagency agreement (IAG) functions to enhance the immunotoxicological evaluations of humans exposed to quantifiable levels of xenobiotics in the environment and workplace. To date work funded by this IAG has examined immune responses in diverse worker populations including farmers, healthcare and hospital workers, firefighters, and manufacturing workers (nanomaterials, lead batteries). A variety of occupational populations in the agriculture, forestry, service, and manufacturing sectors are at elevated risk of fungal exposures due to workers handling contaminated cellulose-based materials. The current projects focus on the growing concern of personal exposure to fungal bioaerosols and the potential toxicity of mold and mold-related xenobiotics from contaminated materials. |
| Implementing Early Intervention Services for Clinical High Risk for Psychosis in U.S. Community Settings: What Do We Know and What Do We Need to Know? | Meeting/ Workshop | SAMHSA | NIMH | NIMH collaborated with the Substance Abuse and Mental Health Services Administration (SAMHSA) in sponsoring this research meeting on July 27-28, 2017 in Bethesda, MD. The purpose of this meeting was to lay the groundwork for developing a national strategy to expand services for early psychosis to include evidence-based interventions for clinical high-risk states. Leading researchers in this field presented findings on the effectiveness of clinical high-risk interventions and directors of clinical programs presented on the challenges and opportunities in implementing these services in communities. |
| Improving Genomics/Omics Technical Standards and Molecular Tools for Prebiotic Probiotic Research and Development Working Group | Research Initiative | CDC, FDA, OS | NCCIH, NCI, NHGRI, NIDA, NLM | The overarching workgroup effort is to enhance research initiatives/resource development as IAA workgroup members committed to sustain and accelerate translatability of validation analytics and reference datasets using omic and other multi-omic substitutable [SMART] tools, devices, and HL-7 FHIR technologies to support rapid and efficient interoperability with electronic health records and clinical decision support systems. A second goal is to coordinate and plan trans-NIH and Inter-agency meetings, workshops and initiatives with greater efficiency of ICO resources and expertise between agencies. Innovative technologies like HL-7 SMART on FHIR have been demonstrated to enhance health information exchange, affordably and accurately. Novel device monitoring using reference standards including, FDA Precision and NIST nanofabrication, multi-omics and modeling strategies can be integrated to improve validation and standards biosafety, risk monitoring of adverse drug events, food safety, overuse and resistance to antibiotics, and emerging infection. The intent originated in April 2016 with an Initiative planning meeting that is now ongoing for IAA partnered PCORI; other IAA collaboratives in progress. |
| Improving steps in development and assessment of Fecal Microbiota for Transplantation products | Other | FDA | NIAID | The goals are to (1) examine the utility of pathogen detection methods in Fecal Microbiota for Transplantation (FMT), (2) understand the effect of manufacturing conditions on the viability and efficacy of FMT products, and (3) identify markers of potency for FMT products by leveraging a novel mouse strain (MAIT cell deficient) exhibiting unique resistance to C. difficile colonization. |
| Improving the Treatment for Allergic Rhinoconjunctivitis and Asthma Through Allergen Immunotherapy | Other | AHRQ | NIAID | NIAID and AHRQ collaborated in organizing a June 2015 workshop entitled “Improving the Treatment for Allergic Rhinoconjunctivitis and Asthma Through Allergen Immunotherapy." The goal of this meeting was to develop clinical trial protocols that could address some of the identified needs to improve the effectiveness of allergen immunotherapy, and to identify the need to improve the use of allergen immunotherapy in current medical practice. Two manuscripts, summarizing the workshop discussion and recommendations, are in preparation. |
| Inclusion Across the Lifespan | Meeting/ Workshop | FDA | NIA, NCI, NHLBI, NICHD, NIDCR, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/OER | In response to scientific need and a congressional mandate in the 21st Century Cures Act (P.L. 114-255), the National Institutes of Health (NIH) convened a workshop of experts on the appropriate inclusion of pediatric and older populations in research studies involving human subjects. The workshop brought together experts in clinical research to discuss barriers and opportunities for participation of these populations in clinical studies, including those supported by NIH. https://obssr.od.nih.gov/event/inclusion-across-the-lifespan-workshop/ |
| Influenza Risk Management Meeting | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza Risk Management Meetings provide members (including ASPR/BARDA, CDC, FDA, and NIH) with a venue to discuss issues relating to the US Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v. |
| Influenza Vaccine Manufacturing Improvement Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | The Influenza Vaccine Manufacturing Improvement Group aims to optimize donor strains, improve sterility assays, and develop alternative potency assays. |
| Intelligent Robotics and Autonomous Systems (IRAS) Interagency Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, OS | NICHD, NEI, NIA, NIBIB, NINDS, NINR | The IRAS Interagency Working Group coordinates Networking and Information Technology Research and Development (NITRD) Program research and development programs, budgets, and policy recommendations, focusing on the advancement of intelligent robotics and autonomous systems that complement, augment, enhance, or emulate human physical capabilities or embodied human intelligence. This includes identifying and pursuing current and emerging topics of mutual interest to the member agencies; launching of task forces to examine specific timely research topics and opportunities; coordinating major interagency outreach activities; and facilitating the development and sharing of data, models, software tools, and testbeds among NITRD agencies and stakeholders. https://www.nitrd.gov/nitrdgroups/index.php?title=IRAS |
| Inter-Agency Working Group on Technology Transfer | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OIR/OTT, OD/OIR | This working group recommends opportunities for improving technology transfer (TT) from Federal laboratories, including: (1) current technology transfer programs and standards for assessing the effectiveness of these programs; (2) new or creative approaches to technology transfer that might serve as model programs for Federal laboratories; (3) criteria to assess the effectiveness and impact on the Nation''s economy of planned or future technology transfer efforts; (4) an assessment of cooperative research and development venture programs; and (5) policy and guidance statements to support all Federal Agencies'' TT programs. |
| Inter-Agency Working Group on the National Healthcare Quality and Disparities Report | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, CMS, HRSA, IHS, OS | NIMHD, NCI, NHLBI, OD/DPCPSI | This working group provides expert scientific guidance for the National Healthcare Quality and Disparities Report. These annual reports measure trends in effectiveness of care, patient safety, timeliness of care, patient centeredness, and efficiency of care. The reports present, in chart form, the latest available findings on quality of and access to health care. https://www.ahrq.gov/research/findings/nhqrdr/index.html |
| Inter-Society Coordinating Committee (ISCC) for Practitioner Education in Genomics | Committee, Work group, Advisory group, or Task Force | HRSA | NHGRI, NCI, NEI, NHLBI, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIGMS, NIMH, NINDS, NINR, NLM | This education collaborative facilitates sharing interactions among professional societies, agencies, and health systems. It intends to enhance the accrual of knowledge and skill among practitioners applying genomic results to clinical care. In its start-up phase, the ISCC focused primarily on physicians and dentists. It has since expanded to engage and collaborate with allied practitioner groups such as nurse practitioners, physician assistants, pharmacists, genetic counselors, and nurses comprising integrated health care teams. It will continue to add other relevant professions and add to the reviewed and searchable educational resources on its website. http://www.genome.gov/27554614 |
| Interagency Agreement for Communications on Prevention of Underage Tobacco Use | Public Education Campaign | FDA | NCI | The FDA Center for Tobacco Products (CTP) and the NCI Office of Communications and Education are collaborating on an Interagency Agreement in which CTP will provide funds to NCI to provide planning, formative research, target messaging, creative content, outreach strategies, and communications support for a campaign to prevent underage tobacco use as it relates to FDA’s authorities under the Tobacco Control Act. Primary focus areas include multi-ethnic journalist training and outreach; development of a partnership strategy, digital strategy, and social marketing tools; digital gaming best practices; and formation of a CTP communications workgroup comprised of subject matter experts. |
| Interagency Artificial Pancreas Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NIBIB, NICHD | The Interagency Artificial Pancreas Working Group is a group of multi-disciplined scientists and clinicians from the Food and Drug Administration (FDA) and the NIH to support the Artificial Pancreas Initiative. The goals of this initiative are to provide infrastructure for narrowing the gap between basic biomedical knowledge and clinical application of novel technologies, and to cross-fertilize and partner with stakeholders in order to identify and overcome the clinical and scientific challenges to the development of an artificial pancreas. Through collaborative efforts, such as workshops, the group strives to develop innovative strategies to achieve their goals. |
| Interagency Autism Coordinating Committee (IACC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, CDC, CMS, FDA, HRSA | NIMH, NICHD, NIDCD, NIEHS, NINDS | The Interagency Autism Coordinating Committee (IACC) is a Federal advisory committee that coordinates all efforts within the Department of Health and Human Services (HHS) concerning autism spectrum disorder (ASD). Through its inclusion of both Federal and public members, the IACC helps to ensure that a wide range of ideas and perspectives are represented and discussed in a public forum. The committee reconvened in November 2015 to begin a new session under the Autism CARES Act. http://iacc.hhs.gov |
| Interagency Biorisk Management Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | This working group coordinates and collaborates on mechanisms to strengthen research laboratory bio-risk management and to promote outreach and education programs that inform scientists, biosafety professionals, institutional officials, and the public on bio-risk management. |
| Interagency Chemical Risk Assessment Working Group | Committee, Work group, Advisory group, or Task Force | OS | NINDS, NIAID | This working group is a Department of Homeland Security led effort to determine chemical hazards and develop Chemical Risk Threat Assessment list of priority chemicals. |
| Interagency Collaborative Animal Research Education (ICARE) Training Project | Training Initiative | BARDA, FDA | OD/OER | The Interagency Collaborative Animal Research Education (ICARE) Academies and Train the Trainer Institutes use active learning to train participants to meet their responsibilities for animal welfare oversight. The program empowers accountability for facts and conceptual understanding of Federal standards through the study of realistic problems encountered in animal care and use programs. Faculty includes subject matter experts from biomedical research institutions and federal agencies, including NIH and USDA. Institutional Animal Care and Use Committee members, staff, institutional officials, veterinarians, animal facility personnel, administrators, consultants, as well as compliance and regulatory personnel involved in the humane use of animals in research all may participate in the ICARE program. https://grants.nih.gov/grants/olaw/interagency_icare.htm |
| Interagency Collaborative to Advance Research in Epilepsy (ICARE) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NINDS, FIC, NCATS, NHGRI, NHLBI, NIA, NIAAA, NIAMS, NICHD, NIDA, NIMH | The Interagency Collaborative to Advance Research in Epilepsy (ICARE) is an interagency epilepsy working group that includes broad representation across the NIH ICs involved in epilepsy-related research, as well as across HHS and other Federal agencies and multiple epilepsy research and patient advocacy groups with a primary focus on biomedical research. The purpose of this group, which is led by the National Institute of Neurological Disorders and Stroke, is to increase communication among institutes and agencies sponsoring epilepsy-related research and to explore opportunities for increased coordination. The group’s annual meetings provide a forum for sharing information about ongoing and planned epilepsy research activities, highlighting advances, discussing needs and opportunities, and promoting increased collaboration toward common research goals. https://www.ninds.nih.gov/Current-Research/Focus-Research/Focus-Epilepsy/ICARE |
| Interagency Committee on Disability Research (ICDR) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIDCD | The Interagency Committee on Disability Research (ICDR) was established to promote coordination and collaboration among federal departments and agencies conducting disability, independent living, and rehabilitation research programs—including programs related to assistive technology research, and research that incorporates the principles of universal design. http://www.icdr.us/ |
| Interagency Committee on Smoking and Health | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, SAMHSA | NIDA, NCI | The Committee was chartered in 1985 and advises the Secretary, Department of Health and Human Services (DHHS), the Assistant Secretary for Health, and the Centers for Disease Control and Prevention on coordination of research, educational programs, and other activities within the Department that relate to the effect of smoking on human health, and on coordination of these activities with other Federal, State, local, and private agencies. The Committee established and maintains a liaison with appropriate private entities, other Federal agencies, and State and local public agencies respecting activities relating to the effect of cigarette smoking on human health. https://www.cdc.gov/tobacco/about/icsh/index.htm |
| Interagency Coordinating Committee for Newborn Screening | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD | This committee makes recommendations for screening certain disorders, developing a system to adjudicate newborn screening expansion, and assist states in implementing programs to test for the recommended conditions. |
| Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, SAMHSA | NIAAA, NICHD, NIDA | The Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD) was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that NIAAA chair an effort to coordinate Federal activities on Fetal Alcohol Syndrome (FAS) and other disorders associated with prenatal alcohol exposure. ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FAS and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and frequently arranges special conferences. http://www.niaaa.nih.gov/ICCFASD |
| Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDDK, NICHD, NINDS | The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, HHS to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from NIH, FDA, and CDC, and is chaired by the NIDDK Director. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/public-health-service/Pages/public-health-service-interagency-coordinating-committee-human-growth-hormone-creutzfeldt-jacob-disease.aspx |
| Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, IHS, OS, OSG, SAMHSA | NIDA, NIAAA | The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency. https://www.stopalcoholabuse.gov/default.aspx |
| Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) | Research Initiative | ATSDR, CDC, FDA | NIEHS, NCI, NEI, NIAID, NLM | The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) is an interagency committee of 15 Federal agencies that carries out specific duties prescribed by the ICCVAM Authorization Act, P.L. 106-545. The ICCVAM is administered by the National Toxicology Program''s Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), a component of the NIEHS. NICEATM, in collaboration with ICCVAM and its international collaborators in Japan, the EU, and Canada, conducts research studies to evaluate the scientific validity of proposed new safety testing methods. NICEATM and ICCVAM also conduct international scientific peer review evaluations of proposed safety methods, and forward recommendations on scientifically valid methods to Federal agencies, which must adopt the proposed methods or provide a basis for not adopting them. NICEATM and ICCVAM also organize scientific workshops to evaluate the current state of the science on a wide range of toxicological and other safety endpoints. https://ntp.niehs.nih.gov/pubhealth/evalatm/iccvam/index.html |
| Interagency Dual Use Outreach Working Group (IDOWG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | This working group develops strategies to educate the research community about Dual Use Research of Concern (DURC) and the DURC-related USG policies. http://www.phe.gov/s3/Pages/default.aspx |
| Interagency Epilepsy Working Group | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, HRSA, OS | NICHD, NIA, NIMH, NINDS | This working group identifies potential joint initiatives related to epilepsy and helps to coordinate epilepsy-related efforts and information exchange within the NIH and across the HHS. |
| Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA | NIA | This interagency group was established by HHS in response to the Congressional directive to address Alzheimer disease. Under the National Alzheimer’s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran’s Administration, National Science Foundation, and Department of Defense are also involved in this effort. http://aspe.hhs.gov/daltcp/napa/ |
| Interagency Midazolam Product Coordination Team | Committee, Work group, Advisory group, or Task Force | FDA, OS | NINDS | A collaboration led by the Department of Health and Human Services (HHS) to facilitate activities, both research and regulatory, related to the Food and Drug Administration (FDA) approval of midazolam for use in treating nerve agent exposure. |
| Interagency Modeling and Analysis Group (IMAG) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | NIBIB, CSR, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR | The Inter-agency Modeling and Analysis Group (IMAG) is comprised of program directors from over 10 government agencies in the US including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably the multi-scale modeling (MSM) initiative, which was originally a multi-agency funding opportunity announcement and supplemented by various IMAG agencies through other funding opportunity announcements. The most recent multi-agency funding opportunity was issued in 2015 and expires in 2018. IMAG held its tenth-anniversary consortium meeting in March 2017. http://www.nibib.nih.gov/research/featured-programs/interagency-modeling-and-analysis-group-imag |
| Interagency Pain Research Coordinating Committee (IPRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA | NINDS, NCCIH, NIDA, NIDCR, NINR | The Interagency Pain Research Coordination Committee is an Affordable Care Act-mandated committee to coordinate pain research activities across the government. http://iprcc.nih.gov/ |
| Interagency Precision Medicine Initiative Working Group (IPMI WG) | Committee, Work group, Advisory group, or Task Force | FDA, OS | OD/OSP | The IPMI WG coordinates activities across the Federal government to enhance innovation in precision medicine, with the ultimate goal of moving the United States into an era where medical care can be more precisely tailored to each patient and the best outcomes can be achieved for all. |
| Interagency Select Agent Review Group (ISARG) | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID, OD/OM/OB, OD/OSP | The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the NIH-OD and BARDA, advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed. |
| Interagency Task Force on Military and Veterans Mental Health (ITF) | Committee, Work group, Advisory group, or Task Force | ACL, OS, SAMHSA | NIMH | Executive Order 13625, Improving Access to Mental Health Services for Veterans, Service Members, and Military Families, was released on August 31, 2012, and directed the Departments of Defense (DoD), Veterans Affairs (VA), and Health and Human Services (HHS) to ensure that Veterans, Service Members, and their families have access to needed mental health services and support. The Executive Order also established the Interagency Task Force on Military and Veterans Mental Health (ITF) and directed it to provide an annual review of agency actions, to define specific goals and metrics to aid in measuring progress, and make additional recommendations as appropriate to the President to improve mental health and substance use disorder treatment services for Veterans, Service Members, and their families. The ITF, co-chaired by the DoD Assistant Secretary for Health Affairs, the VA Under Secretary for Health, and the HHS Administrator for the Substance Abuse and Mental Health Services Administration, tracks and reports progress in executing all activities resulting from recommendations made pursuant to the Executive Order. |
| Interagency Workgroup on Technology to Facilitate Aging in Place | Research Initiative | ACL, CMS, FDA | NIA, NCI, NHLBI, NIBIB, NINDS, NINR | The purpose of this Trans-NIH/Inter-Agency group is to develop new platforms for everyday life technology that will enhance the common goals of multiple NIH institutes and other federal government agencies by improving the capability to rapidly conduct peer-reviewed technology research to facilitate aging in place, with a special emphasis on people from underrepresented groups. A platform is a group of technologies that are used as a base upon which other applications, processes or technologies are developed. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-16-021.html |
| Interagency Working Group in the Glycosciences | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, NCI, NICHD, NIDCR, NIDDK | This group meets annually to identify synergies, discuss progress on the development of national standards for carbohydrates, and exchange information on the glycosciences being pursued at each agency |
| Interagency Working Group on Open Science | Committee, Work group, Advisory group, or Task Force | ACL, AHRQ, CDC, FDA, OS | OD/OSP, OD/OER | The Interagency Working Group on Open Science (IWGOS) was established in October 2016 to advance Federal efforts to support open science by increasing access to and use of the results of Federally funded research and development, including but not limited to scholarly publications and digital data. Among its responsibilities, the IWGOS aims to improve implementation of policies to increase access to the results of Federally funded scientific research as described in a February 2013 memorandum from the Director of the Office of Science and Technology Policy (OSTP) and to identify additional steps that Federal departments and agencies can take to enhance the preservation, discoverability, accessibility, quality, and utility of the outputs of Federally funded scientific research. http://www.hhs.gov/open/publicaccess/index.html |
| International Cancer Control Partnership | Other | CDC | NCI | The National Cancer Institute and the Union for International Cancer Control convened global partners including the Centers for Disease Control and Prevention (CDC) to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal. ICCP partners will assist countries by: (1) Creating a searchable database of current cancer control plans from around the globe; (2) Performing analysis of gaps and highlighting priority areas for inclusion in plans; (3) Training appropriate personnel to develop plans with targets and evaluation strategies; (4) Providing planners with relevant existing materials and tools; and (5) Offering technical assistance. ICCP partners will use their collective state, country, and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets. http://www.iccp-portal.org/ |
| International Neonatal Consortium | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | INC accelerates the development of safe and effective therapies for neonates. The consortium engages the global neonatal community – families, neonatal nurses, academic scientists, regulators, pharmaceutical investigators, advocacy organizations, and funders – to focus on the needs of the neonate. Through teams that share data, knowledge, and expertise, INC will advance medical innovation and regulatory science for this underserved population. https://c-path.org/programs/inc/ |
| International Rare Diseases Research Consortium (IRDiRC) Funders'' Committee | Committee, Work group, Advisory group, or Task Force | FDA | NICHD, NCATS, NCI, NEI, NHGRI, NIAMS, NINDS | The International Rare Diseases Research Consortium (IRDiRC) teams up researchers and organizations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases. A number of grand challenges are being addressed through collaborative actions to reach these 2020 goals such as establishing and providing access to harmonized data and samples, performing the molecular and clinical characterization of rare diseases, boosting translational, preclinical and clinical research, and streamlining ethical and regulatory procedures. http://www.irdirc.org/about-us/ |
| International TB Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | This is a working group of the Federal TB Task Force. The International TB Working Group is chaired and organized by USAID. It meets monthly to coordinate international TB support. |
| Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee | Committee, Work group, Advisory group, or Task Force | OS | NLM | The Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to ONC on standards and implementation specifications to promote interoperability of computer systems and health information. https://www.healthit.gov/facas/calendar/2017/01/17/standards-2017-interoperability-standards-advisory-task-force |
| Intra-Agency Agreement (IAA) The National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to purchase data from the Centers for Medicare & Medicaid Services (CMS) | Other | CMS | NIAID | This IAA enables NIAID to purchase data from the Centers for Medicare & Medicaid Services (CMS). These data are critical for NIAID''s research on disease prevalence in the Medicare population. |
| Intradepartmental Council for Native American Affairs (ICNAA) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NIMHD, NCATS, NCI, NHGRI, NHLBI, NIAID, OD/DPCPSI/THRO, OD/ECHO | NIMHD and THRO support the Intradepartmental Council for Native American Affairs (ICNAA), including tribal consultation sessions and development of the annual tribal consultation report. https://www.hhs.gov/about/agencies/iea/tribal-affairs/about-icnaa/index.html |
| Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NCI, NIAID | The Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC) makes technically-based recommendations to the APHIS/CDC Select Agent and Toxin Program on restricted experiments of Select Agents and Toxins and the exclusion and exemption of attenuated strains. The Committee also conducts a biennial review of the Select Agents and Toxins list for HHS and overlap agents and toxins. https://www.selectagents.gov/egd-requests.html |
| Investigations of Early Life Determinants of Pediatric and Adult Malignancies in a Population | Research Initiative | CDC | NCI | In collaboration with investigators from the US Centers for Disease Control and Prevention (CDC) and the China CDC, the National Cancer Institute (NCI) is assessing the risk of pediatric leukemia and other pediatric cancers in a large population of offspring of mothers enrolled in a community intervention program of peri-conception folic acid supplementation in China. Pediatric cancer risks will be compared in offspring of mothers treated vs offspring of mothers not treated with folic acid supplements. |
| It’s a Noisy Planet. Protect Their Hearing® Public Education campaign | Public Education Campaign | CDC | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) sponsors It’s a Noisy Planet Protect Their Hearing®, a national public education campaign to increase awareness among parents of children ages 8 to 12 about noise-induced hearing loss (NIHL) and how to prevent it. The campaign disseminates messages through print and digital materials, social media, community events, school presentations, and other methods. The CDC’s National Center for Environmental Health and National Institute for Occupational Safety and Health (NIOSH) have actively collaborated with the NIDCD for this campaign. https://www.noisyplanet.nidcd.nih.gov |
| Joint Agency Microbiome (JAM) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, CC, CIT, CSR, FIC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/OAR, OD/DPCPSI/ODS | The Joint Agency Microbiome (JAM) Working Group provides an interagency forum for discussion of microbiome-related topics and research. The working group includes members from various NIH Institutes and Centers and the FDA. |
| Joint Agency Nutrition (JAN) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIDDK, NICHD, OD/DPCPSI/ODP, OD/DPCPSI/ODS | This Working Group was established to address gaps and opportunities in the areas of dietary supplements and nutrition research related to pregnant women and children and chronic diseases. The Working Group reports to the NIH-FDA Joint Leadership Council. |
| Joint Committee and Joint Commission Meetings | Meeting/ Workshop | CDC, FDA, OS | NCI, FIC, NIAID | The US State Department establishes collaborative agreements with foreign governments in fields of science and technology. These Joint Committee and Joint Commission Meetings (JCMs) facilitate discussion on selected topics creating cross-talk among the equivalent government agencies leading towards future collaborations. The Office of Secretary (OS) of the Department of Health and Humans Services (DHHS), through the Office of Global Affairs (OGA), organizes the operational divisions of HHS. The Fogarty International Center (FIC) facilitates the participation of NIH Institutes and Centers. |
| Joint External Evaluation Working Group (JEEWG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NCI, NIEHS, NINDS | The purpose of the JEEWG is to support the Global Health Security Agenda activities related to International Health Regulations implementation to include internal and external joint evaluations, draft a National Action Plan (NAP) to address recommendations, and periodically review and report the status of the NAP. https://www.ghsagenda.org/ |
| Joint Fellowship Program | Training Initiative | FDA | NCI | The objective of the NCI-FDA Joint Fellowship Training Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set bridging the two disparate processes. Fellows learn to build awareness of regulatory requirements into the early stages of the medical product development process and develop strategies to improve planning throughout research and regulatory review. http://iotftraining.nci.nih.gov/ |
| Kaposi Sarcoma and HHV8 in Sickle Cell and Other Ugandan Populations | Research Initiative | CDC | NCI | Epidemiological studies are being conducted to assess small-area variation of Kaposi''s sarcoma-associated herpesvirus (HHV8) and to learn about socio-demographical and environmental risk factors for HHV8 and Kaposi sarcoma in Uganda. |
| Kidney Interagency Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NICHD, NIDDK | The Kidney Interagency Coordinating Committee (KICC) consists of Federal representatives involved in chronic kidney disease (CKD) programs and activities. KICC''s purpose is to encourage communication and collaboration to shape a more coordinated Federal response to CKD. Many Federal agencies lead an aspect of the multi-faceted and interconnected response to CKD. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/kidney-urologic-hematologic-diseases-interagency-coordinating-committee/federal-response-to-ckd/Pages/federal-response-to-ckd.aspx |
| Kidney, Urologic, & Hematologic Diseases Interagency Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, IHS | NIDDK, NCCIH, NCI, NHLBI, NIA, NICHD, NINDS | The Kidney, Urologic, and Hematologic Diseases Interagency Coordinating Committee (KUHICC) encourages cooperation, communication, and collaboration among all Federal agencies involved in kidney, urology, and hematology research and other activities. Section 429 of Public Law 99-158 created the KUHICC in 1987. The committee met for the first time in 1988, and has the following subcommittees: Kidney Interagency Coordinating Committee, Urology Subcommittee, and Hematology Subcommittee. Meetings focus on interagency collaboration to elicit ideas from meeting participants to enhance current research directions within the National Institutes of Health and to form partnerships among agencies. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/kidney-urologic-hematologic-diseases-interagency-coordinating-committee/Pages/default.aspx |
| Laboratory-Developed Tests (LDT) Interagency Task Force | Other | CDC, CMS, FDA | OD/OSP, NLM | The Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) put together an interagency task force to expand their collaboration around oversight of laboratory-developed tests (LDTs). FDA issued draft guidance in October 2014 for overseeing the quality of LDTs, proposing that the FDA oversee the tests alongside CMS, which regulates labs through the Clinical Laboratory Improvement Amendments (CLIA). |
| Leadership Forums in Cancer Control Planning and Project ECHO | Meeting/ Workshop | CDC | NCI | The goal of the Cancer Control Leadership Forums and Project ECHO Program is to increase the capacity of participating countries from target regions to initiate or enhance cancer control planning and cancer research implementation through a multi-sectoral and tele-learning approach. The Forum is the focal point of a three-part process, spanning approximately 18 months. It is an opportunity for each country to develop an action plan to move their cancer control planning efforts forward and to exchange experiences in creating and implementing comprehensive cancer control plans with other countries in the region. The ECHO sessions, which follow the leadership forum, are an opportunity for countries to engage with one another remotely, improve individual skills and knowledge in a case-based learning environment, and share experiences and challenges in basic cancer control and cancer research principles. https://www.cancer.gov/about-nci/organization/cgh/research/cancer-control-leadership-forums |
| Leprosy Research Support in Armadillos (Dasypus Novemcinctus) | Other | HRSA | NIAID | The Leprosy Research Support and Maintenance of an Armadillo Colony – Post Genome Era interagency agreement provides standardized research reagents to investigators worldwide to assist in the development of skin test antigens used to detect leprosy. This agreement supports collaborative research to continuously improve biochemical, microbiological, and immunological models for leprosy research in an effort to provide the most up-to-date resource and expertise for mycobacterial researchers. |
| Library of Integrated Network-based Cellular Signatures (LINCS) | Research Initiative | FDA | OD/DPCPSI, NHGRI, NHLBI, OD/DPCPSI/OSC | The Library of Integrated Network-based Cellular Signatures (LINCS) program is developing a library of data at the cellular level that describes how different types of cells respond to a variety of agents that disrupt normal cellular functions, called “perturbagens.” This library may help us better understand normal and diseased conditions in cells and how to alter them. The LINCS program engages with the Food and Drug Administration (FDA) regarding how LINCS data may be used to predict drug toxicity. https://commonfund.nih.gov/LINCS/index |
| Logical Observation Identifiers Names and Codes (LOINC) | Resource Development | AHRQ, CDC, CMS, HRSA, IHS, OS | NLM | This activity supports the maintenance, distribution, and continued development of LOINC®, a set of universal codes and names to identify laboratory and other clinical observations which facilitates the exchange and pooling of clinical results for clinical care, outcomes management, public health, and research. The Regenstrief Institute, Inc., an internationally renowned healthcare and informatics research organization, maintains the LOINC database and supporting documentation, and the RELMA mapping program. http://www.nlm.nih.gov/research/umls/loinc_main.html |
| Lupus Federal Working Group | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NIAMS, NCCIH, NHLBI, NIAID, NICHD, NIDCR, NIDDK, NIEHS, NIMHD, NINDS, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | The Lupus Federal Working Group, established on behalf of the HHS Secretary by the NIH, facilitates collaboration among NIH components, other Federal agencies, voluntary and professional organizations, and industry groups with an interest in lupus. http://www.niams.nih.gov/About_Us/Committees/lupus_fwg.asp |
| Lyme and Tick-borne Diseases Work Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This workgroup involves members from agencies including the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and the NIH with the purpose of continued coordination and communication of activities, policy updates, events, agency highlights, and other shared interests relating to Lyme disease and other tick-borne diseases. |
| Mapping of the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) and International Classification of Disease (ICD) Clinical Terminology | Resource Development | CDC, OS | NLM | The US Department of Health and Human Services (HHS) has set a goal for the nationwide implementation of an interoperable health information technology infrastructure to improve the quality and efficiency of healthcare. Achieving this goal will require that key clinical data elements are captured or recorded in detailed, standardized form (using standard vocabularies, codes, and formats) as close to their original sources (patients, healthcare providers, laboratories, diagnostic devices, etc.) as possible. If these standardized clinical data can also be used to generate HIPAA- compliant billing transactions automatically, this will provide another incentive for adoption of clinical data standards. For the automated generation of bills from clinical data to become a reality, robust mappings from standard clinical terminologies to the HIPAA code sets must be created. To support the transition to ICD-10-CM in 2015, a map from SNOMED CT to ICD-10-CM is being created. https://www.nlm.nih.gov/research/umls/mapping_projects/snomedct_to_icd10cm.html |
| Medical Countermeasures Surveillance Integrated Program Team | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | This team was created to identify the regulatory science research required for real‐time tracking and evaluation of medical countermeasures (MCMs) during public health emergencies. The team is developing a comprehensive Action Plan to identify and facilitate the development of systems that can be used to monitor MCM safety and clinical benefit during an event. |
| Medical Education Partnership Initiative (MEPI) | Training Initiative | CDC, HRSA | FIC, NINR, OD/DPCPSI/OSC | The Medical Education Partnership Initiative (MEPI) builds human capacity for health in Africa by strengthening the medical education system in an environment that values and nurtures research in President’s Emergency Plan for AIDS Relief (PEPFAR)-funded countries. MEPI aims to advance PEPFAR''s goal of increasing the number of new health care workers by 140,000; strengthen in-country medical education systems; and build clinical and research capacity in Africa as part of a retention strategy for faculty of medical schools and clinical professors. The 13 awards administered by FIC/NIH are either in a no-cost extension to complete their activities or they have completed. FIC recently issued two new Funding Opportunity Announcements that build on the success of the MEPI program and extend the education development goals to Medical and Nursing Schools: the African Association for Health Professions Education and Research and the Health-professional Education Partnership Initiative (HEPI). The first would support an association to continue networking activities among health educators in Africa and the second would fund efforts to strengthen training and retention of health care professionals; encourage research to improve and evaluate educational practices; and enhance capacity to develop, implement, and evaluate evidence-based services with an emphasis on HIV/AIDS. The new initiatives work in collaboration with State Department''s Global AIDS Coordinator. http://www.fic.nih.gov/Programs/Pages/medical-education-africa.aspx |
| Memorandum of Understanding (MOU) between the FDA Center for Devices and Radiological Health and NIH/NINDS | Other | FDA | NINDS | This MOU provides a mechanism for addressing cross-cutting issues related to the development of devices for neurological disorders, from bench science to clinical studies and FDA approval. http://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm446756.htm |
| Memorandum of Understanding (MOU) between the FDA/Center for Biologics Evaluation and Research (FDA/CBER) and NIH/NINDS | Other | FDA | NINDS | This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to therapy development for neurological disorders, from bench science to clinical trials and FDA approval and licensure. http://www.fda.gov/aboutfda/partnershipscollaborations/memorandaofunderstandingmous/domesticmous/ucm397727.htm |
| Memorandum of Understanding Between National Toxicology Program (NTP) and NIH/NIEHS, FDA, and CDC/NIOSH | Other | CDC, FDA | NIEHS | The interagency National Toxicology Program (NTP), established in 1978 and administratively headquartered at NIH/NIEHS, is an ongoing cooperative effort to evaluate substances of public health concern, develop improved methods, strengthen the science base in toxicology, and provide information important for decisions to safeguard public health. This MOU between FDA, NIH/NIEHS, CDC/NIOSH and NTP affirms a commitment to provide resources dedicated toward carrying out NTP’s mission and outlines various administrative and managerial actions the agencies will take to support NTP’s activities. http://ntp.niehs.nih.gov |
| Microbiological Testing of Live Biotherapeutic Products | Resource Development | FDA | NIAID | The goal is to bring the purity and potency assays using the novel recombinant protein reagents to scale, as well as to optimize these methods and tools for tech transfer to facilitate the development and regulation of LBPs for preventive and therapeutic use. |
| Microphysiological Systems for Drug Efficacy and Toxicity Testing | Research Initiative | FDA | NCATS, NCI, NEI, NHLBI, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIGMS, NINDS, NINR, OD/DPCPSI/ORWH, OD/DPCPSI/OSC | The Microphysiological systems initiative aims to develop 3-D human tissue chips that accurately model the structure and function of human organs, such as the lung, liver, and heart. Once developed, researchers can use these models to predict whether a candidate drug, vaccine, or biologic agent is safe or toxic in humans in a faster and more cost-effective way than current methods. More than 30 percent of promising medications have failed in human clinical trials because they are determined to be toxic despite promising pre-clinical studies in animal models. These organs-on-chips will enable scientists to predict more accurately how effective a therapeutic candidate would be in clinical studies. To help streamline the therapeutic development pipeline, NIH, in collaboration with the Defense Advanced Research Projects Agency (DARPA) and the US Food and Drug Administration (FDA), is leading this initiative to improve the process for predicting whether drugs will be safe in humans. https://ncats.nih.gov/tissuechip |
| Mind Your Risks | Public Education Campaign | CDC, CMS | NINDS | The Mind Your Risks campaign is designed to create awareness and action about the fact that risk factors for stroke, particularly hypertension, may be linked to cognitive impairment and dementia. http://www.mindyourrisks.nih.gov/ |
| Models of Infectious Disease Agent Study (MIDAS) | Research Initiative | CDC | NIGMS, FIC, NIAID | Models of Infectious Disease Agent Study (MIDAS) is a collaboration of research and informatics groups to develop computational models of the interactions between infectious agents and their hosts, disease spread, prediction systems, and response strategies. The models will be useful to public health workers and researchers who want to better understand and respond to emerging infectious diseases. If a disease outbreak occurs, the MIDAS network may be called upon to develop specific models to aid in our understanding of the disease and its spread. http://www.nigms.nih.gov/Research/SpecificAreas/MIDAS/Pages/default.aspx |
| Mortality Disparities in American Communities | Research Initiative | CDC | NHLBI, NCI, NIA | MDAC is an inter-agency agreement between NIH institutes and the US Census Bureau. The study links the large 2008 American Communities Survey to the national death Index along with CMS Medicare and Medicaid administrative health records. The purpose is to further knowledge in the factors contributing to health disparities in the United States. https://www.census.gov/about/adrm/linkage/projects/mdac0/mdac-pdo.html |
| mPower Workgroup | Committee, Work group, Advisory group, or Task Force | FDA | NHLBI, NCI, NIA, NIBIB | Discuss ongoing programs and initiatives for collaboration between agencies related to mobile health. |
| Multi-Agency Tissue Engineering Science (MATES) interagency working group | Committee, Work group, Advisory group, or Task Force | FDA | NHLBI, NCI, NEI, NIAMS, NIBIB, NICHD, NIDCR | This WG facilitates communication across departments and agencies through regular information exchanges and workshops. Members facilitate the development of standards, monitor technology developments, and develop funding opportunity announcements to advance the science and address gaps in the tissue engineering and regenerative medicine field. |
| Multinational Influenza Seasonal Mortality Study (MISMS) Research | Research Initiative | FDA, OS | FIC, NHLBI, NIAID, NLM | The Multinational Influenza Seasonal Mortality Study (MISMS) was originally initiated to analyze national and global mortality patterns associated with influenza virus circulation. The focus of MISMS has since expanded to evaluate the interaction between the epidemiology, ecology, and evolutionary dynamics of influenza and other rapidly transmissible respiratory viruses, including natural selection, reassortment, migration, and antigenic change. Multinational and bilateral collaborations developed by MISMS collect, analyze, and disseminate research findings through scientific publications, training workshops, and communication tools for investigators and decision-makers. Our research findings inform numerous national governments, multilateral organizations, and research stakeholders on interventions for both pandemic and seasonal influenza. To date, data have been acquired from more than 40 countries (representing ~3.2 billion people), resulting in over 220 publications. http://misms.net |
| Muscular Dystrophy Coordinating Committee (MDCC) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, FDA, HRSA | NINDS, NHLBI, NIAMS, NICHD | This Federal Advisory Committee coordinates activities relevant to the various forms of muscular dystrophy across NIH and other federal agencies. The committee also includes members from patient organizations. Strategic planning efforts by the coordinating committee led to the development of an Action Plan for the Muscular Dystrophies, which contains specific research objectives appropriate to the missions of all committee member agencies and organizations, and thus serves as a central focus for research coordination. The plan is available at the MDCC web site. https://mdcc.nih.gov/ |
| My Family Health Portrait | Resource Development | CDC, HRSA, OSG | NHGRI, NCI, NICHD, NLM | My Family Health Portrait (MFHP) is a web-based tool from NHGRI and the US Surgeon General’s Family History Initiative that helps individuals track their family health history. Using any computer, an Internet connection, and an up-to-date Web browser, individuals add health information to build a drawing of their family tree and a chart of their family health history while exploring disease calculators. The tool is designed to keep all data on the client side to maximize privacy using HTML, CSS, and client-side JavaScript as its principal platforms. Users interact with the tool in a browser to build family health history generating an XML data file (HL7v3 standard) that users store locally or in the cloud. Both the family tree and the chart can be printed and shared with family members and an individual’s doctor. https://familyhistory.hhs.gov/FHH/html/index.html |
| Nanotechnology Characterization Laboratory | Research Initiative | FDA | NCI, NIEHS | The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the preclinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers and facilitates the development and translation of nanoscale particles and devices for clinical applications. http://ncl.cancer.gov/ |
| NAS/NOWS Working Group for Behavioral Health Coordinating Council (BHCC) Opioids and Controlled Substances Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA, IHS, SAMHSA | NICHD, NIDA | This working group meets regularly to coordinate information and develop joint efforts to reduce the effects of neonatal opioid withdrawal syndrome/neonatal abstinence syndrome (NOWS/NAS). |
| National Academies of Sciences, Engineering, and Medicine Consensus Study on Accessible and Affordable Hearing Health Care for Adults | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIDCD, NIA | NASEM established an ad hoc committee to address how to improve accessibility to and affordability of hearing health care (HHC) for adults, with a focus on nonsurgical devices and services. NASEM considered HHC from the health care and population health perspective, including the regulatory environment, access, and affordability. http://www.nationalacademies.org/hmd/Activities/HealthServices/HearingHealthCareForAdults.aspx |
| National Action Alliance for Suicide Prevention (NAASP) | Committee, Work group, Advisory group, or Task Force | ACL, CDC, HRSA, IHS, OS, OSG, SAMHSA | NIMH, NIAAA, NIDA, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | "Founded in September 2010, the NAASP is a public-private partnership designed to advance the National Strategy for Suicide Prevention in the United States. The NAASP''s Research Prioritization Task Force (RPTF) was charged with developing a process to prioritize suicide prevention research efforts and consider ways to integrate science and service to ensure that suicide deaths decrease significantly within the next decade. The RPTF released the Nation''s first suicide research agenda, A Prioritized Research Agenda for Suicide Prevention: An Action Plan to Save Lives. The research agenda includes an overarching goal to advance suicide prevention research more rapidly, seeking ways to reduce suicide deaths and attempts by 20 percent in five years and by 40 percent or greater in ten years. In 2015, the RPTF produced the "U.S. National Suicide Prevention Research Efforts: 2008-2013 Portfolio Analyses." The analyses revealed that investments in suicide research are severely lagging, but there is a growing knowledge base of intervention research. In 2016, the NIH Office of Disease Prevention supported the Pathways to Prevention Workshop, Advancing Research to Prevent Youth Suicide in 2016, which further refined methodological challenges and data linkage needs relevant to multiple NIH Institutes and HHS agencies. The National Institute of Mental Health (NIMH) developed a request for information relevant to this workshop, and a federal partners meeting in the spring of 2017 considered additional actions in response to the workshop recommendations. Two multi-IC RFAs were issued in response to this effort (MH RFA 18-400; MH RFA 18-410). In 2016, NAASP adapted the goal of reducing US suicide rates by 20 percent in 10 years. NIMH supports this goal by identifying practice-ready suicide prevention research. For example, in May 2017, the NIMH led the meeting, the “State of Suicide Prevention in Emergency Care” with participation from the NIH Office of Emergency Care Research (NIGMS), SAMHSA and the CDC. Surveillance, policy and practices challenges, as well as research gaps were identified for further strategic efforts. http://actionallianceforsuicideprevention.org/ |
| National Action Plan for the Elimination of MDR TB | Other | CDC | NIAID, CC, FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NICHD, NIDA | Federal agencies involved in the National Action Plan for the Elimination of MDR-TB coordinate reporting across agencies. Annual reporting and regular updates on opportunities for cross-agency collaboration and information sharing are provided. https://www.usaid.gov/what-we-do/global-health/tuberculosis/resources/news-and-updates/national-action-plan-combating-mdr |
| National Advisory Board for Medical Rehabilitation Research | Committee, Work group, Advisory group, or Task Force | ACL | NICHD, NHLBI, NIA, NIAMS, NIDCD, NINDS, OD/DPCPSI | The National Advisory Board for Medical Rehabilitation Research (NABMRR) is a Federal Advisory Committee that is composed of researchers, clinicians, and members of the public that advise the Directors of the National Center for Medical Rehabilitation Research, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institutes of Health on issues related to research in medical rehabilitation. The Board includes Ex Officio members from various Federal Departments and Agencies (VA, DoD, NSF, NIDILRR, AHRQ, FDA) to aid in the coordination of Federal programs, activities, projects, and plans for the same with respect to the conduct of research related to rehabilitation of individuals with disabilities. In 2015, the Board provided advice and consultation on: the development of a NIH Rehabilitation Research Plan, the review and marketing of a Medical Rehabilitation Research Infrastructure Network, the structure and funding of training opportunities for rehabilitation scientists, and concept approval for programs planned by the NCMRR. http://www.nichd.nih.gov/about/advisory/nabmrr/pages/index.aspx |
| National Ambulatory Medical Care Survey (NAMCS) Asthma Supplement - Interagency agreement with CDC/NCHS | Health Survey | AHRQ, CDC | NIEHS, NHLBI, NIAID, NICHD | Developed a survey of a national sample of primary care health providers and specialists likely to see asthma patients in order to gauge implementation of the NHLBI Guidelines for Asthma Diagnosis and Management. http://www.cdc.gov/namcs/ |
| National Amyotrophic Lateral Sclerosis (ALS) Registry | Resource Development | ATSDR, CDC | NINDS | The National ALS Registry is a congressionally mandated registry for persons in the US with ALS. It is the only population-based registry in the US that collects information to help scientists learn more about who gets ALS and its causes. http://wwwn.cdc.gov/als/ |
| National Biomonitoring Network Steering Committee | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The National Biomonitoring Network is an effort coordinated by the Association of Public Health Laboratories (APHL) to formally link national, regional, state, and local laboratories conducting the analysis of environmental exposures in biological samples to ensure high-quality data for use in public health practice. The effort is led by a Steering Committee of experts from the public health laboratories and federal agencies supporting biomonitoring efforts and research, including NIEHS. https://www.aphl.org/aboutAPHL/publications/action/Pages/APHL-in-Action-Fall-2016-NBN.aspx |
| National Cancer Control Strategy | Meeting/ Workshop | CDC | NCI | The National Cancer Control Strategy is an NCI-funded study through the National Academies of Sciences, Engineering, and Medicine, which examines cancer control efforts in the United States. This study is expected to produce a report in 2018, which will recommend a national strategy to reduce the incidence, morbidity, and mortality from cancer and to improve quality of life for cancer survivors. |
| National Clinical Trials Network (NCTN) Scientific Steering Committees (SSCs) | Committee, Work group, Advisory group, or Task Force | FDA | NCI | Scientific Steering Committees (SSCs) are composed of leading cancer experts and advocates from outside the Institute as well as NCI senior investigators who meet regularly to: (1) increase the transparency and openness of the trial design and prioritization process; (2) enhance patient advocate and community oncologist involvement in clinical trial design and prioritization; (3) convene Clinical Trial Planning Meetings to identify critical questions, unmet needs, and prioritize key strategies. http://www.cancer.gov/about-nci/organization/ccct/steering-committees |
| National Coalition for Oversite of Assisted Reproductive Technologies (NCOART) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The National Coalition for Oversight of Assisted Reproductive Technologies (NCOART) has become a successful forum for discussion of issues by organizations involved in the assisted reproductive technologies (ART) in the United States. |
| National Collaborative on Childhood Obesity Research (NCCOR) | Research Initiative | CDC | OD/DPCPSI/ODP, NCI, NHLBI, NICHD, NIDDK, OD/DPCPSI/OBSSR | Launched in 2009, the National Collaborative on Childhood Obesity Research (NCCOR) brings together four of the nation’s leading research funders — the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Robert Wood Johnson Foundation (RWJF), and the U.S. Department of Agriculture (USDA) — to accelerate progress in reducing childhood obesity in America. These leading national organizations: work in tandem to manage projects and reach common goals; coordinate funding to make the most of available resources; and share insights and expertise to strengthen research. NCCOR focuses on efforts that have the potential to benefit children, teens, and their families, and the communities in which they live. http://www.nccor.org |
| National Committee on Vital and Health Statistics | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, OS | OD/DPCPSI/OBSSR | The National Committee on Vital and Health Statistics (NCVHS) is the statutory public advisory body to the Secretary of Health and Human Services on health information policy. Established in 1949, NCVHS provides advice and assistance on key health data issues related to community and population health, standards, privacy and confidentiality, quality, and data access and use. It reports regularly to Congress on HIPAA implementation, and serves as a forum for interaction between HHS and interested private sector groups. Members have distinction in such fields as public health, education, informatics, law, economics, and medicine. http://www.ncvhs.hhs.gov/ |
| National Coordinated Child Safety Initiative Steering Committee | Committee, Work group, Advisory group, or Task Force | ACF, CDC, HRSA | NICHD | The Child Safety Network is supported by the National Coordinated Child Safety Initiative Steering Committee, which works to create new synergy among public and private stakeholders and to support the activities of the Child Safety Collaborative Innovation and Improvement Network (CoIIN) strategy teams. The Steering Committee will provide advice to the Child Safety CoIIN and help communicate the lessons and accomplishments of the Child Safety CoIIN to a broad national audience that will include public health professionals, policymakers, funders, and families. https://www.childrenssafetynetwork.org/national-coordinated-child-safety-initiative |
| National Database for Resistant Pathogen | Resource Development | CDC, FDA | NIAID, CC, FIC, NCATS, NCI, NHLBI, NIA, NIAAA, NIDA | The objective of this collaboration is to produce a collection of high-quality genome sequences from antibiotic-resistant strains and to create and maintain a publicly accessible database -- National Database for AR, developed and housed at NCBI/NLM. |
| National Diabetes Education Program (NDEP) | Public Education Campaign | AHRQ, CDC, HRSA, IHS | NIDDK, NEI, NHLBI, NIA | Established in 1997, the National Diabetes Education Program (NDEP) is a federally-funded program sponsored by NIH and CDC and includes more than 200 partners at the federal, state, and local levels that work together to improve the treatment and outcomes for people with diabetes, promote early diagnosis, and prevent or delay the onset of type 2 diabetes. http://www.ndep.nih.gov |
| National Family Health History Group | Public Education Campaign | CDC, HRSA, OS, OSG | NHGRI, NICHD, NLM, OD/OSP | Federal, state, and other stakeholders focus on increasing awareness of the value of family health history in managing health risks. National Family History Day is designated by the Surgeon General for increasing awareness of the above. Members of this group coordinate public communications and resource development. |
| National Food and Nutrient Analysis Program (NFNAP) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, IHS | NCI, NEI, NHLBI, NIA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ODS | The generation of original analytical data for foods at the US Department of Agriculture (USDA) is conducted through the National Food and Nutrient Analysis Program (NFNAP) in collaboration with multiple groups including the Department of Health and Human Services (HHS) and other federal agencies. NFNAP includes statistically based sampling plans for Key Foods and analysis of foods by qualified laboratories. The five Specific Aims of the NFNAP are to: (1) establish a monitoring program for Key Foods and critical nutrients. Key Foods are frequently consumed foods and ingredients, which collectively contributed more than 75 percent of the intake of any specific nutrient for the US population; (2) conduct comprehensive analyses of selected Key Foods; (3) develop databases for high priority foods consumed by US ethnic subpopulations; (4) develop databases for new bioactive components; and (5) develop a validated database for ingredients in dietary supplements. Analytical data generated through the NFNAP are compiled and released in annual updates of the USDA National Nutrient Database for Standard Reference (SR). They are also used to calculate estimates for related foods not analyzed, to assess nutrient variability, and to evaluate methods for estimating the nutrient content of multi-ingredient foods. These values will be used by the Food Surveys Research Group (FSRG), Agricultural Research Service (ARS) to develop the Food and Nutrient Dataset for Dietary Surveys used in the “What We Eat in America” (WWEIA) component of the National Health and Nutrition Examination Survey (NHANES). http://www.ars.usda.gov/SP2UserFiles/Place/12354500/FactSheets/NDL_FactSheet_NFNAP.pdf |
| National Health and Aging Trends Study (NHATS) | Health Survey | CMS, OS | NIA | The National Health and Aging Trends Study (NHATS) will examine how the daily lives of older adults change as they age. This research will help scientists understand the social and economic consequences of late-life disability for individuals, families, and society. http://www.nhats.org/ |
| National Health and Nutrition Examination Survey (NHANES) | Health Survey | CDC, FDA, OS | OD/DPCPSI/ODP, NHLBI, NIAAA, NIAMS, NICHD, NIDCD, NIDCR, NIDDK, NIEHS, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS | A program of studies designed to assess the health and nutritional status of adults and children in the United States. This nationally representative survey is unique in that it combines interviews and physical examinations. ODS uses this survey mechanism to collect data on dietary supplement use and data on biomarkers of nutritional status. http://www.cdc.gov/nchs/nhanes.htm |
| National Health and Nutrition Examination Survey (NHANES) - Audiometric Exams and Hearing-Related Questions | Health Survey | CDC | NIDCD | To provide support to the CDC''s National Center for Health Statistics (NCHS) for audiometry testing and related questions on hearing loss and noise exposure in adults ages 20 to 69 years in the National Health and Nutrition Examination Survey (NHANES) for data collection years 2015–2016. The study collects pure-tone, air conduction hearing thresholds at .5, 1, 2, 3, 4, 6, and 8 kHz in each ear separately, as well as otoscopic exams, tympanometry, and acoustic reflexes on representative samples of the non-institutionalized US population in sound-treated booths meeting recommended ANSI standards. Questionnaire information about tinnitus (frequency and degree of burden), use of hearing aids and other assistive devices, as well as exposure to firearms or other sources of loud noise are collected in home interviews prior to the subjects’ visit to the mobile exam centers (MECs) for audiometric exams. A similar hearing component was part of earlier NHANES, 1999–2004, and NHANES 2011–2012 conducted on a representative sample of US adults, ages 20 to 69 years. One of the Healthy People 2010 goals is to assess (with the goal of reducing) noise-induced hearing loss in adults. For this purpose, audiograms are examined and “notches” identified in the higher frequency ranges at 3, 4, or 6 kHz as a surrogate marker of noise exposure. Computer algorithms to identify the notches have been developed. The NHANES, 1999–2004, data serve as a baseline, but to assess progress on this goal in Healthy People 2020, hearing thresholds of US adults must be measured again in NHANES. NCHS directs the data collection contractor (i.e., WESTAT) in establishing and revising protocols for the hearing component and in preparing training and field manuals. NCHS provides NIDCD with an opportunity to collaboratively review summary data for purposes of quality control during the data collection period and, also, provides NIDCD with a data file for quality review approximately three months before the Public Use data release. http://www.cdc.gov/nchs/nhanes.htm |
| National Health and Nutrition Examination Survey (NHANES) Cardiovascular Component | Health Survey | CDC | NHLBI, NCI, NIA, NIAAA, NICHD, NIDCD, NIDCR, NIDDK | The purpose of this collaboration is to inform the National Institutes of Health (NIH) and the Nation on the status of key measures of cardiovascular, pulmonary, and sleep health, such as blood pressure, serum lipid levels, risk factors for disease, airway flow limitation, reports of efforts to control weight, and reports of sleep disturbances, and disease prevalence in the US civilian population. NIH identifies key cost-effective basic measures for these conditions and behaviors, relevant to its mission and amenable to being utilized in a mobile hospital setting. NIH staff work with National Center for Health Statistics (NCHS) staff to implement the most cost-effective of the measures, to monitor and help manage the survey in progress, and to evaluate and publish the resulting data. http://www.cdc.gov/nchs/nhanes/about_nhanes.htm |
| National Health and Nutrition Examination Survey (NHANES) Oral Health Component | Health Survey | CDC | NIDCR | The periodic oral health component of the National Health and Nutrition Examination Survey (NHANES); included enamel fluorosis imaging study for inclusion in future NHANES. http://www.cdc.gov/nchs/nhanes.htm |
| National Health and Nutrition Examination Survey 2005-2006, Allergy Component, Interagency Agreement with CDC/NCHS | Health Survey | CDC | NIEHS, NIAID | This collaborative project developed and implemented an allergy/asthma focused component for the National Health and Nutrition Examination Survey (NHANES). The allergy component, included in NHANES 2005-2006, enabled a more robust and generalizable investigation of the role of allergen/endotoxin exposures and IgE-mediated sensitization in allergic diseases than previously possible, increasing the knowledge of complex relationships between allergen and endotoxin exposures, allergic sensitization and allergic diseases, including asthma. This survey component queried on allergy and asthma prevalence and symptoms, measured levels of common indoor allergens and endotoxin in household dust, and quantified total and 19 allergen-specific immunoglobulin E levels in serum of study participants. https://wwwn.cdc.gov/nchs/nhanes/2005-2006/AGQ_D.htm |
| National Health and Nutrition Examination Surveys Interest Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NHLBI, NIAID, NIDCR | The National Health and Nutrition Examination Survey (NHANES) is a program of studies designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it combines interviews and physical examinations. The interest group assesses the use of NHANES data and discusses ideas for additions and changes to NHANES to enhance the usefulness of this major database. |
| National Health Interview Survey (NHIS) | Health Survey | CDC | NCI, NCCIH, NIDDK | The National Health Interview Survey (NHIS) - started in 1957 - is a continuous, nationwide in-person survey of approximately 35,000 households, or about 87,500 persons, in the civilian non-institutionalized population. The NHIS oversamples African-American and Hispanic respondents. NCI periodically sponsors a Cancer Control Supplement (CCS) which is administered to a randomly selected sample of 39,000 adults. http://www.cdc.gov/nchs/nhis.htm |
| National Hispanic Science Network (NHSN) | Meeting/ Workshop | AHRQ, CDC, SAMHSA | NIDA, NIAAA, NIMH | The National Hispanic Science Network is dedicated to improving the health equity of Hispanics. It has broad representation from academic and government agencies, including several National Institutes of Health Institutes and Centers, the Centers for Disease Control and Prevention, the Substance Abuse and Health Services Administration, and the Agency for Healthcare Research and Quality. http://nhsn.med.miami.edu/ |
| National HIV Prevention Conference | Meeting/ Workshop | CDC, FDA, HRSA | OD/DPCPSI/OAR, NICHD, NIMH | The National HIV Prevention Conference (NHPC) is the preeminent HIV prevention conference in the United States involving state and local health departments, community-based organizations, federal agencies, researchers, clinicians, people living with HIV and others sharing the latest advancements, strategies, and accomplishments in HIV prevention. https://www.cdc.gov/nhpc/index.html |
| National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations | Resource Development | AHRQ, CDC, CMS | NIDCD | The National Institute on Deafness and Other Communication Disorders (NIDCD) Directory of Organizations is designed to help patients, health consumers, providers, and others find agencies and organizations with an interest in the diseases and disorders of human communication. The directory is maintained as an online database accessible to the public from the NIDCD website. Several US Department of Health and Human Services agencies are included. https://www.nidcd.nih.gov/directory/ |
| National Interagency Confederation for Biological Research | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIAID | The National Interagency Confederation for Biological Research (NICBR) is a consortium of eight agencies with a common vision of Federal research partners working in synergy to achieve a healthier and more secure nation. It serves as a framework for facilitating and encouraging interaction among the NICBR member organizations where there are areas of mutual interest. Members collaborate and share technical expertise and scientific services. This multiagency confederation operates by consensus to ensure a balanced direction and focus. The eight members include elements of the Department of Defense, Health and Human Services, Agriculture, and Homeland Security. The mission of NICBR is to develop unique knowledge, tools, and products by leveraging advanced technologies and innovative discoveries to secure and defend the health of the American people. http://www.nicbr.mil/ |
| National Kidney Disease Education Program (NKDEP) | Public Education Campaign | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NIDDK, NHLBI | The National Kidney Disease Education Program (NKDEP) is an initiative of the NIH National Institute of Diabetes and Digestive and Kidney Diseases. NKDEP aims to improve early detection of chronic kidney disease (CKD), facilitate identification of patients at greatest risk for progression to kidney failure, promote evidence-based interventions to slow progression of CKD, and support the coordination of Federal responses to CKD. The NKDEP Health Information Technology (HIT) Working Group is collaborating with the Office of the National Coordinator for Health Information Technology on a CKD Care Plan, the CKD-related elements that should be included in a comprehensive electronic care plan template. The template elements will enable patients and clinicians to access, create, record, change, and receive key patient information and goals across multiple conditions. The HIT Working Group also held a workshop on "Using Health IT to Identify and Manage CKD Populations: Efforts of the NKDEP Health IT Working Groups" in 2017. http://www.nkdep.nih.gov |
| National Mental Health Study Field Test | Other | SAMHSA | NIMH | The National Institute of Mental Health (NIMH) is collaborating with the Substance Abuse and Mental Health Services Administration (SAMHSA) to pilot methods necessary for conducting a cross-sectional national mental health study designed to (1) estimate the prevalence of a number of specific mental disorders, (2) investigate disorder correlates and patterns of care, and (3) provide a platform for follow-up studies on subgroups of interest. The currently funded project will execute the steps necessary to build the instrument, obtain Office of Management and Budget clearance, and field test all procedures that could inform a larger scale study in the future. |
| National Nanotechnology Initiative (NNI) Nanotechnology Signature Initiative on Nanotechnology for Sensors and Sensors for Nanotechnology: Improving and Protecting Health, Safety, and the Environment | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB | This interagency effort to coordinate and stimulate the creation of the knowledge, tools, and methods necessary to develop and test nanosensors and to track the fate of engineered nanomaterials in the body, consumer products, the workplace, and the environment. http://www.nano.gov/SensorsNSIPortal |
| National Nanotechnology Initiative (NNI) Nanotechnology Signature Initiative on Nanotechnology Knowledge Infrastructure: Enabling National Leadership in Sustainable Design | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB | This is an interagency effort to provide a community-based, solutions-oriented knowledge infrastructure to accelerate nanotechnology discovery and innovation. http://www.nano.gov/NKIPortal |
| National Ocean Council | Committee, Work group, Advisory group, or Task Force | OS | NIEHS | The National Ocean Council is charged with implementing the National Ocean Policy. As part of President Obama''s National Policy for the Stewardship of the Ocean, Our Coasts, and the Great Lakes, the National Ocean Council has released the Implementation Plan to address some of the most pressing challenges facing the ocean, our coasts, and the Great Lakes. It describes the actions the Federal Government will take to improve the health of the ocean, coasts, and Great Lakes, which support tens of millions of jobs, contribute trillions of dollars a year to the national economy and are essential to public health and national security. https://obamawhitehouse.archives.gov/administration/eop/oceans |
| National Research Action Plan (NRAP) | Research Initiative | CDC | NIDA, NIAAA, NIMH, NINDS | This Executive Order directed the Department of Defense, Veterans Affairs, Health and Human Services, and Department of Education to develop a National Research Action Plan on post-traumatic stress disorder, other mental health conditions, and traumatic brain injury to improve the coordination of agency research into these conditions and reduce the number of affected men and women through better prevention, diagnosis, and treatment. https://www.researchgate.net/publication/268102333_The_National_Research_Action_Plan_NRAP |
| National Robotics Initiative | Research Initiative | FDA | NIBIB, NEI, NIA, NICHD, NIDCD, NINDS, NINR, OD/DPCPSI/OBSSR | Although the National Robotics Initiative MOU has ended, NIH continues to engage and participate with colleagues in other agencies to promote this work. The robotics group engages program officers across NIH and other agencies with an interest in promoting robotics to address health needs. Discussions address topics related to planning trans-NIH initiatives, co-funding grants and contracts, and participating in joint site visits to mutually funded investigators. This working group is also linked to the efforts of the National Robotics Initiative that held a Principal Investigators meeting in November 2016. http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=503641&org=CISE |
| National Science Advisory Board for Biosecurity | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | NSABB is a Federal Advisory Committee established in 2004 to provide advice to the USG and leadership on biosecurity and issues related to dual-use research. The NSABB is an influential committee and its reports and recommendations have shaped policy development. The NSABB also undertakes domestic and international outreach and education efforts to raise awareness of issues related to biosecurity. http://osp.od.nih.gov/office-biotechnology-activities/biosecurity/nsabb |
| National Science and Technology Council Committee on Science | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP | The NSTC Committee on Science (CoS), operated out of OSTP, aims to coordinate all Federal efforts in science by establishing a structure to improve Federal government planning and coordination of R&D and by ensuring that Federal R&D efforts are balanced, integrated, and comprehensive. One of the goals of CoS is to ensure that science is considered in development and implementation of Federal policies and programs. CoS membership includes : USDA, DoC, DoD, ED, HHS, DHS, DOI, DOJ, DOL, State, DoT, Treasury, VA, EPA, NASA, NSF, and the Smithsonian, as well as OSTP and OMB. In addition to the activities of the main committee, CoS oversees about a dozen interagency subcommittees and working groups on topics ranging from the microbiome to research business models. These subgroups often involve staff from other NIH ICs that have the appropriate subject matter expertise. https://obamawhitehouse.archives.gov/administration/eop/ostp/nstc/committees/cos |
| National Security Staff Combatting Antibiotic-Resistant Bacteria sub-Interagency Policy Committee (NSS CARB sub-PCC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID, NLM | This Sub-Policy Coordinating Committee develops policy options for US government oversight of dual-use research of concern (DURC) and serves under the NSS DURC PCC. |
| National Security Staff Dual Use Research of Concern Interagency Policy Committee (NSS DURC PCC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP, NIAID | This Policy Coordinating Committee develops policy options for US government oversight of dual-use research of concern (DURC). |
| National Security Staff Dual Use Research of Concern Sub-Interagency Policy Committee (NSS DURC Sub-PCC) | Committee, Work group, Advisory group, or Task Force | CDC, OS | OD/OSP, NIAID | Develops policy options for US government oversight of dual-use research of concern (DURC). |
| National Survey of Family Growth | Health Survey | ACF, CDC | NICHD | The National Survey of Family Growth (NSFG) gathers information on family life, marriage and divorce, pregnancy, infertility, use of contraception, and men’s and women’s health. The survey results are used by the US Department of Health and Human Services and others to plan health services and health education programs and to do statistical studies of families, fertility, and health. The NSFG is used by: scholars in the behavioral sciences (e.g., sociology, demography, and economics) to study marriage, divorce, fertility, and family life; scholars in public health to study reproductive, maternal and infant health topics; agencies of the US Department of Health and Human Services to brief senior officials and to inform program decision-making; in research programs and in health and social service programs; state and local governments to plan health and social service programs; and the press, to prepare articles on a number of topics related to health and family life. https://www.cdc.gov/nchs/nsfg/index.htm |
| National Toxicology Program (NTP) Executive Committee | Committee, Work group, Advisory group, or Task Force | ATSDR, CDC, FDA | NIEHS, NCI | The National Toxicology Program (NTP) was established as a department-wide effort within the Public Health Service (PHS) on November 15, 1978. The program is comprised of the relevant PHS activities within the US Food and Drug Administration, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention, and the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health. The NIEHS Director serves as NTP Director and reports to the Assistant Secretary for Health. The NTP Executive Committee reviews progress on NTP activities directed toward carrying out its mission. http://ntp.niehs.nih.gov/about/org/ec/index.html |
| Native American Research Center for Health (NARCH) | Research Initiative | IHS | NIGMS, CSR, NCI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NIMH, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | The Native American Research for Health (NARCH) program is a trans-NIH collaboration with the Indian Health Service (IHS) that supports collaborations between federally-recognized American Indian/Alaska Native (AI/AN) Tribes or Tribal organizations and research-intensive academic institutions that support health research projects prioritized by the Tribal communities. NARCH supports competitive research linked to the health priorities of AI/AN organizations and health disparities; increasing the capacity of both AI/AN organizations and research-intensive institutions to reduce distrust by AI/AN communities and people toward research; and developing a cadre of AI/AN scientists and health professionals engaged in biomedical, clinical, behavioral, and health services research who will be competitive in securing NIH funding. https://www.nigms.nih.gov/Research/CRCB/NARCH/Pages/default.aspx |
| Natural Compounds to Reduce Nitrate in Meat Products: Phytome | Research Initiative | CDC | NCI | NCI and the CDC are collaborating on a longitudinal human feeding study of processed meats and drinking water nitrate conducted by Maastricht University. CDC researchers are measuring volatile nitrosamines (NOCs) and nitrate concentrations in urine samples taken before and after consumption different types of processed meats with and without the intake of nitrate in drinking water. NCI will also evaluate nitrate and nitrosamine excretion levels in relation to the oral microbiome. Results from this study will characterize NOC formed from water nitrate and processed meat ingestion. |
| Natural Experiments and Effectiveness Studies in the Prevention and Control of Diabetes | Research Initiative | CDC | NIDDK | This project will focus on population-targeted interventions that health systems, communities, and governments can undertake to reduce the incidence of diabetes and its complications. This project will also strengthen the capacity of CDC and NIDDK to conduct vital health services and health policy research related to diabetes prevention and care. |
| NCI Clinical Trials and Translational Research Advisory Committee (CTAC) | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NCI | The Clinical Trials and Translational Research Advisory Committee makes recommendations on the National Cancer Institute-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trial process. The Committee will provide advice on matters related to the conduct, oversight, and implementation of clinical trials and translational research across the Institute. http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm |
| NCI National Cancer Informatics Program (NCIP) Nanotechnology Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NHLBI, NIBIB, NIEHS | The National Cancer Institute National Cancer Informatics Program (NCIP) Nanotechnology Working Group (NCIP Nano WG) was established in 2008 for researchers with a specific interest in informatics and computational approaches to nanotechnology, with a particular emphasis on nanomedicine. The goal of this Working Group is to demonstrate the scientific potential of federating nanotechnology databases through pilot projects aimed at integrated semantic search and retrieval of nanomedicine and nanotoxicology datasets that are applicable across nanoscience. The NCIP Nano WG comprises over 20 active participants from academia, government, and industry with diverse interests. https://nciphub.org/groups/nanowg |
| NCI/CCR-FDA Clinical Investigator Program | Research Initiative | FDA | NCI | Multilateral Benefit in a Joint Program to Recruit Combined FDA and NCI/CCR Clinical Investigators: the FDA gains an academic oncologist with disease-specific expertise who is actively involved and understands critical nuances of the field; NCI gains a clinical investigator and leader who understands regulatory considerations in drug development; and the oncologic community gains a regulator/academic who will provide a leadership voice to help design trials with regulatory endpoints in mind https://deainfo.nci.nih.gov/advisory/joint/0615/03%20Pazdur.pdf |
| NCI/FDA Memorandum of Understanding for Drug Related Information | Resource Development | FDA | NCI | The National Cancer Institute (NCI) Enterprise Vocabulary Services is working with the US Food and Drug Administration (FDA) to develop and support controlled terminology in several areas. More than 10,000 FDA terms and codes are stored in the NCI Thesaurus. http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/fda |
| NCI/FDA Memorandum of Understanding for Proteomics | Research Initiative | FDA | NCI | This Memorandum of Understanding (MOU), signed in 2007 and renewed in 2012, establishes an official relationship in clinical proteomic regulatory science between NCI''s Office of Cancer Clinical Proteomics Research and the FDA. Active areas of research collaboration include sample collection, preparation, storage and processing; bioinformatics and data analysis; discovery and validation of biomarkers; and surrogate biomarkers of cancer development and drug response, including standardization among technology platforms and assay standards development. https://proteomics.cancer.gov/news_and_announcements/nci-and-fda-study-cancer-proteogenomics-together |
| NEI Stem Cell Meeting: Clinical Applications of Stem Cell Therapies for Patients with Eye Disease | Meeting/ Workshop | FDA | NEI | Stem cells have the potential to treat many diseases, including eye diseases. On December 5-6, 2016, the National Eye Institute (NEI) convened 75 leading stem cell researchers, clinicians, and relevant stakeholders from private foundations, the Food and Drug Administration (FDA) and the National Institutes of Health (NIH), to discuss the state of the science, progress, challenges, and the pathways necessary to translate the science and technology of stem cells to clinical trials for therapy. Cell types discussed included bone marrow (BMSCs), adult stem cells, embryonic (ESCs), corneal limbal stem cells, neural, and retinal progenitors and induced pluripotent stem cells (iPSCs). https://nei.nih.gov/content/clinical-applications-stem-cell-therapies-patients-eye-disease |
| Networking and Information Technology Research and Development (NITRD) | Research Initiative | AHRQ | NIGMS | The Networking and Information Technology Research and Development (NITRD) Program provides a framework in which many Federal agencies come together to coordinate their networking and information technology (IT) research and development (R&D) efforts. https://www.nitrd.gov/Index.aspx |
| New Molecular Methods for Evaluation of Antibody Responses Following RSV Vaccination and Infection | Other | FDA | NIAID | The goal of the project is to identify the key protective epitopes in F and G membrane proteins and to develop new tools to measure virus neutralization and antibody affinity. |
| Newborn Screening Coding and Terminology Guide | Resource Development | CDC, HRSA, OS | NLM, NHGRI, NHLBI, NICHD | This ongoing collaboration develops, supplements, and publicizes a free online resource with guidance to help promote the efficient electronic exchange of standardized newborn screening data. Related efforts include studying the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD), and developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Uniform Recommended Screening Panel by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. https://newbornscreeningcodes.nlm.nih.gov/ |
| Newborn Screening Federal Partners Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | NICHD, NHLBI, NLM | The National Institutes of Health, Health Resources and Services Administration, Centers for Disease Control and Prevention (CDC), the American College of Medical Genetics and the Genetic Alliance meet monthly, in person or online, to discuss and coordinate current activities and initiatives in newborn screening. Topics include the activities of the Newborn Screening Translational Research Network Coordinating Center, the Clearinghouse of Newborn Screening Information, Sickle Cell Screening Programs, the CDC Newborn Screening Quality Assurance Program, and the Regional Newborn Screening Collaboratives. |
| NEWSteps Steering Committee | Committee, Work group, Advisory group, or Task Force | HRSA | NICHD | This steering committee supports the mission of NEWSteps, which is to achieve the highest quality for newborn screening systems by providing relevant, accurate tools and resources and to facilitate collaboration between state programs and other newborn screening partners. |
| NEXT Longitudinal Study 2009-2016: Health Behavior in School-Age Children | Research Initiative | HRSA | NICHD, NHLBI, NIAAA, NIDA | NEXT is a 7-year longitudinal assessment of a representative sample of US adolescent and young adults starting at grade 10. The goals of the study are to identify the trajectory of adolescent health status and health behaviors; to examine predictors of key adolescent risk behaviors; to identify factors that promote or sustain positive health behaviors; to identify transition points in health risk and risk behaviors; and to examine the role of potential gene-environment interactions. https://www.nichd.nih.gov/about/org/diphr/officebranch/hbb/next |
| NGSP (formerly the National Glycohemoglobin Standardization Program) | Resource Development | CDC | NIDDK | The purpose of the NGSP (formerly the National Glycohemoglobin Standardization Program) is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. http://www.ngsp.org/ |
| NIAID Universal Influenza Vaccine Working Group | Committee, Work group, Advisory group, or Task Force | CDC, OS | NIAID | HHS working group established to facilitate the development of universal influenza vaccines and move them toward clinical trials. |
| NIAID-CDC Joint US Partnership Implementing TB Elimination Research (JUPITER) | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | Through weekly teleconferences, the Joint US Partnership Implementing TB Elimination Research (JUPITER) facilitates cooperation, communication, and collaboration on tuberculosis between the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC). This approach helps ensure that Federal activities are coordinated and not duplicated, and stimulates collaborations where appropriate. |
| NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews | Other | CDC | NIAID | The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database. |
| NIAID/NASA Medical Countermeasures Working Group | Committee, Work group, Advisory group, or Task Force | BARDA, FDA | NIAID, NCI, NHLBI | The purpose of this WG is to bring together experts in radiation countermeasures to look for complementary areas of research across agencies in the following areas: medical countermeasure selection, repurposing, research strategies, and animal models for select endpoints. |
| Nicotine Research Cigarettes (SPECTRUM) | Committee, Work group, Advisory group, or Task Force | FDA | NIDA | This partnership with the Food and Drug Administration (FDA) is for the production of research cigarettes. |
| NIH Guide for Grants and Contracts | Resource Development | AHRQ, CDC, FDA | OD/OER, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI | The National Institutes of Health (NIH) Guide for Grants and Contracts is the official publication for NIH medical and behavioral grant policies, guidelines, and funding opportunities. Other US Department of Health and Human Services agencies also use the Guide to disseminate Funding Opportunity Announcements to its 60,000 subscribers. http://grants.nih.gov/grants/guide/index.html |
| NIH Recombinant DNA Advisory Committee (RAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NCI, NHGRI, NIAID, NINDS | The Recombinant DNA Advisory Committee (RAC) advises the National Institutes of Health on the safe and ethical conduct of basic and clinical research involving recombinant or synthetic nucleic acid molecules. The Committee reviews and provides recommendations for exceptional human gene transfer protocols to enhance scientific and ethical design. The RAC also provides biosafety guidance for emerging technologies or agents. This year RAC members participated in a meeting to consider the biosafety oversight framework, and whether certain emerging technologies and other areas of life science research may raise scientific, safety, and ethical concerns that should be included in such a system. https://osp.od.nih.gov/biotechnology/recombinant-dna-advisory-committee/ |
| NIH Scientific Data Council for the Common Data Elements (CDE) Task Force | Committee, Work group, Advisory group, or Task Force | AHRQ | NICHD, CC, CIT, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH, OD/OER, OD/OSP | The Common Data Elements (CDE) Task Force is charged by the NIH Scientific Data Council to advise it concerning how to improve the communication and coordination of NIH efforts to identify, develop, and promote the use of CDEs in NIH-supported research. Previously, as a working group under the aegis of the Trans-NIH BioMedical Informatics Coordinating Committee (BMIC), the group provided advice to the development of a CDE Repository that serves as a platform for searching, harmonizing, developing, and disseminating CDEs used by NIH Institutes and Centers; Task Force members continue to work with the National Library of Medicine (NLM) to improve this publicly available platform. The Task Force also maintains a web portal with information about NIH-supported CDE initiatives that are intended for use by NIH-funded researchers. The Task Force continues to take steps to encourage the use of CDEs by NIH-funded researchers, minimize overlap and redundancy in CDE initiatives, improve interoperability and compatibility between and among CDE initiatives and with other standards development activities (e.g., related to electronic health records), and assist NIH Institute and Center staff and researchers in identifying and using CDEs that are relevant to their projects. https://www.nlm.nih.gov/cde/ |
| NIH Translational Research Interest Group | Committee, Work group, Advisory group, or Task Force | FDA | NCI, CC, CIT, CSR, NCATS, NCCIH, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI, OD/OER, OD/OIR, OD/OSP | As Chair of the National Institutes of Health (NIH) Translational Research Interest Group (TRIG), National Cancer Institute (NCI) staff have coordinated forums, workshops, NIH Bench-to-Bedside Awardees’ Lecture Series, and the Monthly Seminar Series to help bridge the gap between laboratory research and clinical applications; suggest topics and speakers for the Annual NIH Research Festivals; and nominate speakers for the NIH Wednesday Afternoon Lecture Series and the NIH Director’s Lecture Series. NCI staff have informed TRIG members of scientific events coordinated with other NIH scientific interest groups and working groups. with https://oir.nih.gov/sigs/translational-research-interest-group-trig |
| NIH-CDC-IDSA Guidelines for Treatment of HIV Related Opportunistic Infections Among Adults and Adolescents | Committee, Work group, Advisory group, or Task Force | CDC | CC, OD/DPCPSI/OAR | The National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, and the Centers for Disease Control and Prevention (CDC) have developed guidelines for treatment of opportunistic infections (OIs) among adults and adolescents infected with human immunodeficiency virus (HIV). These guidelines are intended for clinicians and other health-care providers who care for HIV-infected adults and adolescents, including pregnant women; they complement companion guidelines for treatment of OIs among HIV-infected children and previously published guidelines for prevention of OIs in these populations. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5315a1.htm |
| NIH-FDA Interagency Clinical Outcome Assessments (ICOA) Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NICHD | The Interagency Clinical Outcome Assessments Working Group (ICOA WG) works to foster the development, evaluation, and qualification of Clinical Outcomes Assessments (COAs) for use in both medical product development and clinical research. Leveraging the unique strengths, knowledge, and resources at both the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH), the objectives of the ICOA WG are: (1) To increase communication between the relevant groups at FDA and the many separate efforts at NIH to advance measurement science by exchanging information about specific COA projects of common interest, thereby improving the knowledge base for COA development; (2) To clarify and disseminate information about the regulatory processes for evaluation of medical product development tools; (3) To foster appropriate interagency scientific efforts to generate evidence toward the development and potential qualification of novel COAs; and (4) To leverage public and private efforts toward consensus and standards development in this area. The ICOA WG is composed of representatives and selected senior staff of each agency |
| NIH-FDA Joint Leadership Council | Committee, Work group, Advisory group, or Task Force | FDA | OD/OSP, NCATS, NCCIH, NCI, NHLBI, NIAID, NIDDK, NIMH, NINDS | The NIH-FDA Joint Leadership Council work together to help ensure that regulatory considerations form an integral component of biomedical research planning and the latest science is integrated into the regulatory review process. Such collaboration and integration will advance the development of new products for the treatment, diagnosis, and prevention of common and rare diseases and enhance the safety, quality, and efficiency of the clinical research and medical product approval enterprise. The formation of the Leadership Council represents a commitment on the part of both agencies to forge a strong partnership and to leverage the strengths of each agency toward this common goal. http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm201654.htm |
| NIH-FDA Medical Device Research Interest Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIBIB, NCATS, NCI, NEI, NHLBI, NIA, NIAID, NICHD, NIDDK, NINR, OD/DPCPSI/ORIP | The Medical Device Research Interest Group (MDRIG) meets quarterly to share information and ideas on supporting research throughout the development pipeline. Recent topics of interest include an early feasibility supplement for SBIR grantees that would facilitate grantee-FDA meetings and communication in the formative years in order to increase appropriate planning during the development of their technologies toward FDA approval. NHLBI is supporting a pilot of this concept and the group will incorporate feedback from this pilot into their planning. MDRIG is also planning to conduct a portfolio analysis to inform future grant funding. |
| NIH/BMGF Collaboration - Point of Care Testing Working Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIBIB, NCI, NIAID, NICHD | NIBIB co-chairs the NIH-Bill and Melinda Gates Foundation Working Group on Point of Care (POC) Diagnostics. This group of government and private partners is working to identify and collaborate on projects to develop diagnostic tests for low resource areas. One area of focus is to leverage resources for the development of a rapid POC diagnostic test for viral infections such as HIV or influenza. NIBIB hosted a working group session on March 30, 2017, that focused on patient access to health diagnostics. Ideas from this session were presented at the larger NIH-BMGF meeting on June 30, 2017, hosted by NIH. |
| Northwest Portland Tribal Registry Project | Resource Development | IHS | NCI | Over the past 10 years, health care delivery for Northwest American Indians and Alaska Natives (AI/AN) has evolved from a centralized system maintained by the Indian Health Service (IHS) to a diverse and complex environment. The Northwest Tribal Registry Project was developed in January 1999 by the Northwest Tribal Epidemiology Center, a tribally operated program located at the Northwest Portland Area Indian Health Board (NPAIHB) in Portland, Oregon. The Project works with state health organizations to correct racial misclassification for AI/AN in disease registries, obtain accurate estimates of the cancer burden, and to generate health status information for tribes and health programs. NCI contributes funding to the IHS for this project through the Native American Research Centers for Health (NARCH) program. http://surveillance.cancer.gov/disparities/native/portland.html |
| Nutrition Research Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, OS | NIDDK, CC, CIT, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ODP, OD/DPCPSI/ODS | The Nutrition Research Coordinating Committee (NRCC) was established by the NIH Office of the Director in 1975 to improve communication and research coordination of nutrition activities within the NIH and across the federal government. Today it provides an open forum for members to discuss current and future nutrition research challenges and opportunities. The NRCC has broad representation from the NIH institutes and centers. In addition, liaisons from other federal offices and agencies also participate. The NRCC meets monthly, alternating between intra-NIH and interagency meetings. NRCC membership is open to any federal staff member interested in carrying out any trans-NIH or trans-agency nutrition research efforts. NRCC meetings are chaired by the Director of the NIDDK Office of Nutrition Research. Scientific seminars and discussions are featured during the NRCC meetings as a means of disseminating information on nutrition research efforts and to stimulate new research in priority areas. The NRCC operates as an NIH-wide forum to review, stimulate, and encourage the support of nutrition research and training to better define the role of nutrition in the promotion and maintenance of health and in the prevention and treatment of disease. The NRCC also plays a key role in the development of nutrition research policy at the NIH. The goal of the NRCC is to review, stimulate, and encourage the necessary support of nutrition research and training and to define the role of nutrition in health promotion and disease prevention and management. https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/nutrition-research-coordinating-committee/Pages/default.aspx |
| Obesity Prevention and Control: Combined School-Based Interventions to Increase Healthier Food and Beverage Consumption and Physical Activity | Meeting/ Workshop | CDC | NHLBI | Ongoing participation on monthly calls by the Community Guide Coordinating Team. https://www.thecommunityguide.org/ |
| Office for Human Research Protections/Office of Extramural Research Training Initiative | Meeting/ Workshop | OS | OD/OER | The National Institutes of Health collaborated with the Office for Human Research Protections to provide comprehensive training at both NIH Regional Meetings for the extramural community. |
| Office of AIDS Research Advisory Council (OARAC) | Committee, Work group, Advisory group, or Task Force | CDC | OD/DPCPSI/OAR, NCI, NIAID, NIDA, NIMH | The Office of AIDS Research Advisory Council advises the Director of the Office for AIDS Research, the Director of the NIH, and the Secretary of the Department of Health and Human Services on the planning, coordination, and evaluation of all HIV/AIDS research programs and related activities at the NIH. The OARAC also advises on the AIDS research policies and priorities, the development of an annual plan for HIV-related research, and the coordination of trans-HHS agency HIV/AIDS efforts. http://www.oar.nih.gov/oarac/ |
| Office of Science and Technology Mo99 Stakeholders Working Group | Committee, Work group, Advisory group, or Task Force | CMS, FDA, OSG | NIBIB, NCI | The purpose of this working group is to coordinate the efforts of multiple stakeholders (Department of State, Department of Energy, Department of Homeland Security, Department of Health and Human Services, private sector) to establish a stable, long-term domestic supply of Mo99 (molybdenum-99) for medical purposes. Such a supply needs to be consistent with current international goals (to which the US is an active participant) of reduction in the use of high-enriched uranium in all reactors, including Mo99 production facilities, as well as full cost recovery solutions. |
| Oral Health, Cancer Care, and You | Public Education Campaign | CDC | NIDCR, NCI, NINR | Information for healthcare providers and patients about steps they can take to reduce the risk and impact of oral complications of cancer treatment. http://www.nidcr.nih.gov/OralHealth/Topics/CancerTreatment/ |
| OS PCORTF Leadership Council | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, HRSA, OS | OD/OSP, NCCIH, OD/DPCPSI/ODP, OD/OER | The Patient Protection and Affordable Care Act of 2010 created the Patient-Centered Outcomes Research Trust Fund (PCORTF) to help build the national capacity and infrastructure needed to conduct patient-centered outcomes research (PCOR), and to enable PCOR findings to be integrated into clinical practice. The Office of the Secretary (OS) of the US Department of Health and Human Services (HHS) receives 4 percent of the PCORTF to build data capacity for PCOR. ASPE convenes a Leadership Council of HHS principals or their designees to develop a strategy for use of these funds and to determine yearly investments https://aspe.hhs.gov/patient-centered-outcomes-research-trust-fund |
| Osteoporosis and Related Bone Diseases—National Resource Center | Resource Development | OS | NIAMS, NIA, NICHD, NIDCR, NIDDK, OD/DPCPSI/ORWH | Provides patients, health professionals, and the public with an important link to resources and information on metabolic bone diseases, including osteoporosis, Paget’s disease of the bone, and osteogenesis imperfecta. http://www.bones.nih.gov |
| OSTP Interagency Working Group on Medical Imaging | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NIBIB, NCI, NIAMS, NICHD, NIDDK | The IWMI is co-chaired by NIH and NIST and is working to identify gaps and develop a roadmap to accelerate technology development that is more effective, improves patient care, and has the potential to lower cost. The working group, which includes twelve federal agencies, has determined key strategic directions through a series of stakeholder meetings. Areas identified as important for joint focus include deep/machine learning, quantitative and high-value imaging, and inter-agency collaboration to accelerate translation. The working group released its final report on December 22, 2017. As of February 2018, the charter for this working group will not be renewed. https://www.whitehouse.gov/wp-content/uploads/2017/12/Roadmap-for-Medical-Imaging-Research-and-Development-2017.pdf |
| P63, P13K and RAS oncogenes in tumorigenesis, immune deregulation and therapy of squamous cell carcinoma | Research Initiative | FDA | NIDCD | At the FDA, Dr. Weinberg is transducing murine keratinocytes with combinations of oncogenes found in human squamous cell carcinomas to determine if they generate transformation and tumors in laboratory conditions. Dr. Van Waes’ laboratory at NIDCD will study how these oncogene-driven tumors in mice deregulate keratinocytes and host immune responses, as well as response to various standard, molecular, and immune therapies. |
| Palliative Care: Maximizing Patient Preferences and Cost Savings | Research Initiative | AHRQ | CC | The goal of the study is to provide rational, patient-defined, evidence-based recommendations to inform the redesign of the Medicare hospice benefit, transitioning policy from the current hospice benefit to a more patient-centered palliative care model. http://grantome.com/grant/NIH/R01-HS018360-01 |
| Partners in Information Access for the Public Health Workforce | Resource Development | AHRQ, CDC, HRSA, OS | NLM | Partners in Information Access for the Public Health Workforce is a collaboration of US government agencies, public health organizations, and health sciences libraries that provides timely, convenient access to selected public health resources on the Internet. http://phpartners.org/ |
| Partnership for Tuberculosis (TB) and TB/HIV Research -2 | Resource Development | CDC | NIAID | Support for whole genome sequencing (WGS) of isolates and bioinformatics/analytic support for WGS to characterize TB drug resistance mutations. This is a joint CDC/NIAID effort to develop a comprehensive database of resistance polymorphisms and phenotypic correlations from clinical samples from various sites worldwide. |
| Partnerships for Accelerating Cancer Therapies (PACT) | Other | FDA | OD/OSP, NCI | The Partnership for Accelerating Cancer Therapies (PACT) is a public-private partnership between NIH, FDA, the private sector, foundations, and cancer advocacy organizations to accelerate progress in cancer research and bring cancer therapies to patients in less time as part of the Cancer Moonshot. Following in the models of successful existing partnerships, PACT will support jointly funded research through a collaborative decision-making structure and ensure open data sharing with partners and the public. |
| Pathogen Detection Project and Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS) | Resource Development | CDC, FDA | NLM | The Pathogen Detection Project is a multi-agency collaboration that is combining data from pathogen outbreaks with other information to determine the major source of contamination. The project is conducted via a centralized system that integrates sequence data for bacterial pathogens obtained from food, the environment, and human patients. A number of public health agencies in the US and internationally are collecting samples from these sources to facilitate active, real-time surveillance of pathogens and foodborne disease. The agencies sequence the samples and submit the data to NCBI/NLM/NIH, which analyzes the sequences against others in its database to identify closely related sequences. The aim is to uncover potential sources of contamination by linking isolates from food or the environment to human illness and to quickly report the sequence relationships to public health scientists in order to aid traceback investigations and outbreak response. Collaborating agencies include FDA, CDC, USDA-Food Safety and Inspection Service, and Public Health England. The US agencies formalized their collaboration in a charter document (Interagency Collaboration on Genomics for Food and Feed Safety (Gen-FS)) that includes coordinating activities on antimicrobial resistance. http://www.ncbi.nlm.nih.gov/pathogens/ |
| Pathways to Prevention (P2P) Workshop Program | Meeting/ Workshop | AHRQ | OD/DPCPSI/ODP | The Pathways to Prevention (P2P) program is a workshop series hosted by the Office of Disease Prevention (ODP) to identify research gaps in a selected scientific area, identify methodological and scientific weaknesses in that scientific area, suggest research needs, and move the field forward through an unbiased, evidence-based assessment of a complex public health issue. P2P workshops are designed for topics that have incomplete or underdeveloped research and for which it is difficult to produce a report synthesizing published literature. ODP collaborates with various NIH ICs and Offices as well as other federal partners to sponsor the workshops. https://prevention.nih.gov/programs-events/pathways-to-prevention/ |
| Patient-Centered Outcomes Research Clinical Decision Support Learning Network (PCOR CDS-LN) Advisory Council | Committee, Work group, Advisory group, or Task Force | AHRQ, OS | NLM | This council provides a forum for stakeholders to assess both barriers and facilitators to implementing PCOR findings in CDS and make recommendations for optimizing PCOR-enabled CDS to facilitate improvements in care and outcomes. The PCOR CDS-LN is funded through a cooperative agreement with the Agency for Healthcare Research and Quality https://www.pcorcds-ln.org/about |
| Pediatric Device Consortia Grant Program | Other | FDA | NICHD | FDA funds consortia which provide expert advising and support services to innovators of children''s devices. These services include business and regulatory consulting, as well as device testing capabilities. Specific areas of expertise provided by the consortia include intellectual property advising; prototyping; engineering; laboratory and animal testing; grant-writing; and clinical trial design. A successful Pediatric Device Consortium brings together individuals and institutions that can support pediatric medical device progression through all stages of development—concept formation, prototyping, preclinical, clinical, manufacturing, marketing, and commercialization. The consortia are expected to support a mix of projects at all stages of development, particularly the later stages of clinical, manufacturing, and marketing. To accomplish this work, the consortia unite individuals, groups, or institutions to provide the following capabilities: knowledge of the clinical needs for pediatric devices, business planning, regulatory advising, intellectual property protections and other legal expertise, as well as scientific, engineering, pre-clinical, and clinical capabilities. This program is intended to further the development of multiple pediatric devices; thus, grants are not awarded to support the development of a single device project. Although administered by the Office of Orphan Products Development, this grant program is intended to encompass devices that could be used in all pediatric conditions and diseases, not just rare diseases. https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/PediatricDeviceConsortiaGrantsProgram/ |
| Physical Activity and Healthcare Utilization and Costs in Older Adults | Research Initiative | CDC | NCI | Through this initiative, CDC and NCI plan to investigate the association between physical activity over the life-course on later life health care utilization and costs in Medicare recipients in the AARP Cohort. |
| Pink Ribbon Red Ribbon | Meeting/ Workshop | CDC | NCI | Pink Ribbon Red Ribbon (PRRR) is a partnership to leverage public and private sector investments to address breast and cervical cancers in developing countries. It is being implemented in several countries in sub-Saharan Africa. The National Cancer Institute and Centers for Disease Control and Prevention provide technical assistance in implementation strategies to the PRRR countries. This assistance involves drafting guidelines for monitoring and evaluation of prevention and treatment services as well as developing communication strategies. http://www.ncbi.nlm.nih.gov/pubmed/24101785 |
| Planning and Design for Post-Acute Care Assessment Instruments and Data Elements | Resource Development | CMS | NLM | The ultimate goal of this work is to improve quality of care and interoperability of computerized data in acute hospitals and post-acute care (PAC) settings through the use of health informatics and real-time transfer of patient information. The National Library of Medicine (NLM) and Centers for Medicare & Medicaid Services (CMS) collaborate on planning and design for the Continuity Assessment Record & Evaluation (CARE) instrument and its data elements, and those of other CMS post-acute care assessment tools; develop logical data model and software applications that promote compliance and compatibility with Federal Health Architecture consolidated health informatics (CHI) standards; adopt Federal government-wide health information interoperability standards associated with Meaningful Use; and improve data and messaging for the Medicare program. This collaboration benefits from NLM''s role as central US Department of Health and Human Services (HHS) coordinating body for clinical terminology standards, and provides NLM specific and usage-based feedback on the utility of such standards in this environment. |
| Polyhalogenated Aromatic Hydrocarbons (PHAH) and Thyroid Cancer | Research Initiative | CDC | NCI | Polyhalogenated aromatic hydrocarbons are being measured in banked serum/plasma samples from cohort studies to evaluate the association with thyroid cancer incidence. NCI investigators are leading nested case-control studies of thyroid cancer in three cohorts to examine associations between pre-diagnostic concentrations of polychlorinated biphenyls (PCB), polybrominated diethyl ethers (PBDE), and organochlorine insecticides and thyroid cancer risk. |
| Population Assessment of Tobacco and Health (PATH) Study | Health Survey | FDA | NIDA | The Population Assessment of Tobacco and Health (PATH) Study is the first large-scale National Institutes of Health (NIH)/US Food and Drug Administration (FDA) collaboration since Congress granted FDA the authority to regulate tobacco products in the Family Smoking Prevention and Tobacco Control Act (FSPTCA) in 2009. The PATH Study is a national longitudinal cohort study that will follow an estimated 59,000 US household residents ages 12 years and older for at least three years. Objectives are to assess initiation and use patterns; to study trends in tobacco-product use cessation and relapse; to monitor behavioral and health impacts, including in risk perceptions and other tobacco-related attitudes; and to assess differences in tobacco-related attitudes, behaviors, and health outcomes among racial/ethnic, gender, and age subgroups. The PATH Study will also collect biospecimens from adults to analyze biomarkers of tobacco use and related health outcomes. By measuring and accurately reporting on the social, behavioral, and health effects associated with tobacco-product use in the United States, the PATH Study will provide an empirical evidence base to help inform FDA’s decisions about changes in tobacco products in meeting the objectives of the 2009 FSPTCA. http://www.PATHStudyInfo.nih.gov |
| Post-Traumatic Stress Disorder (PTSD)/Trauma Brain Injury (TBI), Suicide Prevention National Research Action Plan (NRAP) Workgroup | Committee, Work group, Advisory group, or Task Force | OS | NIMH, NIAAA, NIDA, NINDS | A 2012 White House Executive Order, emphasizing support of Service Members, Veterans, and their families as a top priority, called for an urgent increase in the Departments of Health and Human Services (HHS), Defense (DoD), and Veterans Affairs (VA) research coordination to address the problems of PTSD, TBI, and suicide. Section 5 of this Executive Order requested a National Research Action Plan (NRAP) to develop biomarkers, define the pathophysiology, and develop new treatments for PTSD. HHS charged the National Institute of Mental Health (NIMH) to lead this effort along with a parallel effort for TBI led by National Institute of Neurological Disorders and Stroke (NINDS), with both Institutes working closely with VA and DoD. The NRAP was published in 2013. Prior investments integrating the molecular, genomic, and brain circuitry changes that give rise to PTSD in the context of environmental factors provide the requisite foundation to respond to this White House request for biomarkers for risk prediction, as well as new targets for medications, and other therapies to treat PTSD. This investment has the potential to revolutionize care for individuals at high risk for PTSD and prevent the development of chronic, complex treatment-resistant PTSD. The agencies meet weekly and produce quarterly progress reports. http://www.whitehouse.gov/the-press-office/2012/08/31/executive-order-improving-access-mental-health-services-veterans-service |
| Practical Oral Care for People with Developmental Disabilities | Public Education Campaign | CDC | NIDCR, NICHD | Fact sheets designed to equip dental professionals in the community with the information they need to deliver quality oral health care to people with special needs. https://www.nidcr.nih.gov/health-info/developmental-disabilities |
| Preclinical Assessment of Phage Therapy for Pathogen Decolonization | Research Initiative | FDA | NIAID | This project addresses key regulatory considerations relevant to using bacteriophages for decolonization of the drug-resistant nosocomial pathogens, vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). These include characterizing pathogen resistance to phage, defining phage mixtures ("cocktails") to circumvent resistance, optimizing mouse models to evaluate pathogen decolonization, and identifying endpoints that support claims for clinical benefit (e.g., reduced risk of disease transmission). |
| Pregnancy and Birth to 24 Months (P/B-24) Project''s Federal Expert Group | Committee, Work group, Advisory group, or Task Force | OS | NICHD | In 2012, the US Department of Agriculture (USDA) and Department of Health and Human Services (HHS) initiated a project informally called the “B-24 project.” This multi-phase project was originally intended to conclude in 2018 with information that could help the Departments develop dietary recommendations for infants and toddlers for release separate from the Dietary Guidelines. The first phase was completed in 2012-2013. In February 2014, Congress passed the Agricultural Act of 2014, also known as the Farm Bill, mandating that the Dietary Guidelines expand to include dietary guidance for infants and toddlers (from birth to age 24 months), as well as women who are pregnant, beginning with the 2020-2025 edition. Thus, USDA and HHS adjusted the purpose, timeline, and scope of the project. Now called the “Pregnancy and Birth to 24 Months project” or “P/B-24 project” to reflect the addition of pregnant women, this project is a joint initiative led by USDA and HHS in collaboration with programmatic and scientific experts. Rather than concluding in 2018 with dietary recommendations, the goal of the current project is to begin examining topics of public health importance for women who are pregnant and infants and toddlers from birth to 24 months of age. The findings from this work will be made publicly available at the completion of the project. https://www.cnpp.usda.gov/birthto24months |
| President''s Commission on the Study of Bioethical Issues | Committee, Work group, Advisory group, or Task Force | OS | CC | The Commission advises the President on bioethical issues arising from advances in biomedicine and related areas of science and technology. The Commission seeks to identify and promote policies and practices that ensure scientific research, healthcare delivery, and technological innovation are conducted in a socially and ethically responsible manner. The Commission undertakes the study of issues presented to them by the President and the Secretary of Health and Human Services. |
| President''s Task Force on Environmental Health Risks and Safety Risks to Children | Committee, Work group, Advisory group, or Task Force | FDA, OSG | NIEHS, NCI, NHLBI, NIAID, NICHD | The Secretary of the Department of Health and Human Services and the Administrator of the Environmental Protection Agency co-chair the President''s Task Force on Environmental Health Risks and Safety Risks to Children which is focused on coordinating Federal actions in this area, and which comprises representatives of 17 federal departments and White House offices. The Task Force currently focuses on priority areas including climate change, asthma disparities, healthy homes, chemical exposures, and lead. NIEHS staff co-chair the climate change, chemical exposures, and lead subcommittees. The Task Force released an inventory of federal activities to reduce children''s lead exposure in October 2016: https://ptfceh.niehs.nih.gov/features/assets/files/key_federal_programs… https://ptfceh.niehs.nih.gov/ |
| Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, FDA, OS | NIAID | In March 2015, HHS announced the establishment of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). This FACA Committee includes public voting members, non-voting liaison representatives from organizations and/or interest groups, and non-voting federal ex-officio members. PACCARB provides advice, information, and recommendations to the Secretary regarding programs and policies intended to support and evaluate the implementation of Executive Order 13676, including the National Strategy for CARB and the National Action Plan for CARB. PACCARB has been reauthorized until Jan 18, 2019 (based on its charter), through Executive Order 13811 on Sept. 29, 2017. https://www.hhs.gov/ash/advisory-committees/paccarb/index.html |
| President’s Emergency Plan for AIDS Relief (PEPFAR) Implementation Science/Combination Prevention | Research Initiative | CDC | NIAID, FIC, NCI, NIAAA, NIDA, NIMH, OD/DPCPSI/OAR | This President’s Emergency Plan for AIDS Relief (PEPFAR) activity focuses on testing treatment as prevention on the population level in South Africa and Zambia. This activity was initiated through the HIV Prevention Trials Network (HPTN), with support of multiple National Institutes of Health (NIH) Institutes and Centers, PEFPAR, and the Bill & Melinda Gates Foundation. The Requests for Application (RFA) was issued concurrently with a Centers for Disease Control and Prevention (CDC) RFA for combination prevention, and the agencies have worked together to ensure that the studies are complementary and do not overlap. http://www.pepfar.gov/ |
| Preventing HIV in Adolescent Girls and Young Women Taskforce | Committee, Work group, Advisory group, or Task Force | CDC | NICHD | In August 2014, the “Preventing HIV in Adolescent Girls and Young Women Task Force” was formed in response to a request from the Office of the Global AIDS Coordinator (OGAC) to articulate PEPFAR/South Africa’s strategy to address the high rates of HIV incidence and infection in 15-24-year-old females. Despite slight HIV prevalence declines over the past decade young South African women continue to experience rapid increases in HIV infection rates beginning in late adolescence. Declining HIV knowledge and increased risk behavior, despite significant treatment scale up and the availability of new prevention tools, are concerning trends among young women. Representatives from NICHD, CDC, and other government agencies joined the OGAC-led task force to develop the strategy and implementation plan. In December 2014, PEPFAR launched the DREAMS initiative, an ambitious partnership to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women. https://www.pepfar.gov/partnerships/ppp/dreams/ |
| Prevention Research Centers | Research Initiative | CDC | NCI | The Prevention Research Centers program funds community-based research projects at 26 academic research centers across the United States. These centers: (1) Conduct research projects that promote health and prevent disease; (2) Build research teams of multidisciplinary faculty; (3) Seek solutions, strategies, and policies that address public health problems; (4) Participate in research networks that address priority health issues, such as healthy aging, cancer prevention & control, and obesity prevention; (5) Build long-term relationships for engaging communities as partners in research; (6) Conduct research in directions guided by advisory boards of community leaders; (7) Develop and deliver trainings that enhance the public health workforce; and (8) Conduct additional research funded by other federal agencies, foundations, and nonprofit organizations. http://www.cdc.gov/prc/ |
| Prevention Research Coordinating Committee (PRCC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, OS | OD/DPCPSI/ODP, CC, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODS, OD/DPCPSI/ORWH, OD/OLPA | The NIH Prevention Research Coordinating Committee (PRCC) serves as a venue for exchanging information on recent scientific advances in disease prevention; examining the impact of new policies on research; planning new or discussing ongoing initiatives; and highlighting program accomplishments. As a trans-NIH, trans-agency committee, the PRCC provides a broad perspective on the current state-of-the-science and actively disseminates information about prevention-related activities sponsored by federal and non-federal organizations to the NIH Institutes and Centers. https://prevention.nih.gov/prevention-research/prcc |
| Priorities for National HIV/AIDS Strategy 2020 Research and Programmatic Agenda for Mental Health and Substance Use Concerns | Committee, Work group, Advisory group, or Task Force | CDC, HRSA, SAMHSA | NIMH, NIAID, NIDA | The Department of Health and Human Services (HHS) Interagency HIV, Mental Health, and Substance Use Concerns Work Group, which grew out of the National HIV/AIDS Strategy (NHAS), updated to 2020, includes participation from the Centers for Disease Control and Prevention (CDC), Health Services Resources Administration (HRSA), Substance Abuse and Mental Health Services Administration (SAMHSA), and National Institutes of Health (NIH). The workgroup identified priorities within four themes: (1) Screening; (2) Integrated Care and Prevention Services; (3) Anti-Stigma/Anti-Discrimination; and, (4) Addressing the Special Needs of Key Populations and Other Populations Heavily Affected by HIV. Priorities were written broadly to allow assessment, assurance, policy, and research strategies to be developed as needed or prioritized by each agency. Improving prevention and treatment outcomes for HIV, mental and substance use disorders, co-occurring disorders, and other problems is inherent in all priorities, as well. HIV prevention is focused on communities and populations with increased HIV incidence and prevalence, and HIV care and treatment is aimed at the HIV care continuum from testing to viral suppression and continued care. Research goals include developing and testing novel and innovative interventions. Another focus is delivery of evidence-based services and practices to the relevant communities and populations. |
| Promoting Semantic Interoperability of Laboratory Data Test Results | Resource Development | CDC, FDA | NLM | CDC and NLM encourage considering ways that FDA could accelerate specifications of LOINC codes that apply to each test result that a lab/test instrument or kit can generate. Availability of the right LOINC codes with each instrument test kit will greatly simplify the correct assignment of codes by a laboratory for sending to clinician''s medical record system. |
| Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, OS, SAMHSA | NIAID, NIAMS, NICHD, NINDS, NLM | The Public Health and Emergency Medical Countermeasures Enterprise (PHEMCE) advances national preparedness for natural, accidental, and intentional threats by coordinating medical countermeasure-related efforts within HHS and in cooperation with PHEMCE interagency partners. NIAID has representatives on many groups within PHEMCE. http://www.phe.gov/Preparedness/mcm/phemce/Pages/mission.aspx |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Chemical Integrated Product Development Team (IPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NINDS, NIAID | The US Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) leads the mission to develop and acquire medical countermeasures that will improve public health emergency preparedness as well as prevent and mitigate the adverse health consequences associated with chemical, biological, radiological and nuclear (CBRN), and naturally occurring threats. https://www.medicalcountermeasures.gov/ |
| Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Pediatrics and Obstetrics Integrated Program Team (IPT) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD, NIGMS | The Public Health Emergency Medical Countermeasures Enterprise''s (PHEMCE) mission is to advance national preparedness for natural, accidental, and intentional threats by coordinating medical countermeasure-related efforts within HHS and in cooperation with PHEMCE interagency partners. The Pediatrics and Obstetrics Integrated Program Team (IPT) provide a complete, end-to-end vision of medical countermeasures for pregnant women, mothers, and their children. The IPT considers requirement-analysis, development and production, stockpiling, delivery and dispensing to the end user, adverse event monitoring, communications, guidance and policy development, and evaluating medical countermeasures'' effectiveness and replacement needs. https://www.phe.gov/Preparedness/mcm/phemce/Pages/default.aspx |
| Quantitative Data Mining for Drug-Adverse Event Safety Signal Detection Using MEDLINE | Research Initiative | FDA | NLM | The objective of this initiative between the National Library of Medicine (NLM) Cognitive Science Branch and the Center for Drug Evaluation and Research at the US Food and Drug Administration (FDA) is to develop a mutually beneficial automated data mining analytical tool in which NLM’s electronic databases and resources (including MEDLINE) are utilized to support the FDA’s mission related to enhancing postmarket drug safety surveillance and safe use. http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162057.htm |
| Radiation Biodosimetry Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This working group is focused on regulatory and scientific issues regarding technologies and devices for radiation biodosimetry. The working group assisted in drafting new Food and Drug Administration (FDA) Center for Device and Radiological Health (CDRH) guidance for industry. |
| Radiation Emergency Medical Management (REMM) | Resource Development | CDC, OS | NLM, NCI | This activity is to develop a comprehensive web resource and mobile app. Radiation Emergency Medical Management (REMM) is a mechanism to collect, evaluate, collate, store, and make available electronically to health care professionals immediate, up-to-date, evidence-based clinical information they would use to treat civilian patients and others affected by radiation incidents. http://www.remm.nlm.gov/ |
| Radiation/Nuclear Biodosimetry Team | Committee, Work group, Advisory group, or Task Force | BARDA | NIAID | Team members participate in the review of white papers as well as proposals and progress reviews for Biomedical Advanced Research and Development Authority (BARDA)-funded contracts supporting the development of novel biodosimetry platforms. |
| Radiation/Nuclear Technical Evaluation Review Panel | Committee, Work group, Advisory group, or Task Force | BARDA | NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) participates on the Radiation/Nuclear Technical Evaluation Review Panel to review white papers and proposals received by the US Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) for the development of radiation and nuclear medical countermeasures. NIAID provides scientific and programmatic critiques and reviews of selected submissions. |
| Radiobiology Bioterrorism Research and Training Group (RABRAT) | Meeting/ Workshop | FDA, OS | NCI | This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications, and other events and information related to preparing the US Government to respond to nuclear terrorism. https://rrp.cancer.gov/programsResources/program_collaborations.htm |
| Reciprocal Educational and Training Partnerships between FDA/CDER and the NIH Clinical Center | Training Initiative | FDA | CC, NCI, NIAID, NIDCR, NIDDK, NIMH, NINDS | This activity is sponsored by the Clinical Pharmacology Program, Office of Clinical Research Training and Medical Education (OCRTME) at The National Institutes of Health (NIH) Clinical Center (CC). It consists of elective rotations at the Office of Clinical Pharmacology (OCP) and the Office of New Drugs (OND) of the US Food and Drug Administration''s (FDA) Center for Drug Evaluation and Research. It is for NIH staff, with a primary focus on clinical fellows and research fellows, who expressed an interest in learning more about FDA regulatory sciences applicable to drug development research. Rotating fellows are mentored by FDA staff on the required elements of an Investigational New Drug (IND) application and the key elements of the FDA review process from a regulatory perspective. This program also established a mechanism for FDA scientific reviewers at the OCP to rotate at the NIH CC and to interact with members of a clinical research team, thus acquiring a better perspective on clinical research protocol implementation and the requirements of an Institutional Review Board (IRB) at the NIH. |
| Recruiting Older Adults into Research (ROAR) Tookit | Research Initiative | ACL, CDC | NIA | The National Institute on Aging (NIA) at NIH, the Centers for Disease Control and Prevention (CDC), and the Administration for Community Living (ACL) are collaborating on the Recruiting Older Adults into Research (ROAR) project to encourage older adults and their family caregivers, including underrepresented populations, to consider participating in research. https://www.nia.nih.gov/health/publication/roar-toolkit |
| Reentry Research Network | Committee, Work group, Advisory group, or Task Force | ACF, SAMHSA | NIDA, OD/DPCPSI/OBSSR | This is a subgroup that reports to the Federal Interagency Reentry Council. The purpose of this group is to bring together numerous federal agencies to make communities safer, assist those returning from prison and jail to becoming productive, tax-paying citizens, and save taxpayer dollars by lowering the direct and collateral costs of incarceration. NIDA serves on the HHS Re-entry/CJ working group. Staff meets by phone monthly. |
| Regenerative Medicine Innovation Project | Meeting/ Workshop | FDA | NHLBI, NCATS, NEI, NIA, NIAID, NIAMS, NIBIB, NIDCD, NIDCR, NIDDK, NIMH, NINDS | The 21st Century Cures Act, passed in December 2016, establishes a Regenerative Medicine Innovation Project (RMIP) to accelerate the field by supporting clinical research on adult stem cells while promoting the highest standards for carrying out scientific research and protecting patient safety. In recognition of the integral role of the Food and Drug Administration (FDA) in the successful development of this field, NIH is leading the RMIP in coordination FDA. https://www.nih.gov/research-training/medical-research-initiatives/rmi |
| RePORT South Africa | Research Initiative | CDC, OS | NIAID | RePORT South Africa is a jointly funded project between the NIH, PEPFAR, and the South African Medical Research Council and Department of Science and Technology to establish a consortium of TB researchers in South Africa. |
| Repurposing Food and Drug Administration Approved Drugs for a Radiation Indication Meeting | Meeting/ Workshop | BARDA, FDA | NIAID | The purpose of the meeting was to bring together medical countermeasures stakeholders, including academic researchers, industry, and funding and regulatory agencies to consider challenges and opportunities of gaining approval for drugs for a radiation indication that have another approved use. Through presentations from industry, academia, and government, and a guided discussion session, information was shared to highlight ways to address potential hurdles. A meeting report will be generated based on the workshop discussions and outcomes. |
| Research and Surveillance Working Group of the HHS LGBT Policies Coordinating Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, CMS, FDA, IHS, OS, SAMHSA | OD/DPSCSI/SGMRO | The Working Group is a cross-Departmental group that initiates dialogue to help harmonize efforts and prevent duplication with respect to LGBT/SGM research. |
| Research Evaluation and Commercialization Hub (REACH) Review Committee | Committee, Work group, Advisory group, or Task Force | CMS, FDA | NICHD, NCI, NHLBI, NIDA | This trans-NIH group helps manage the NIH Research Evaluation and Commercialization Hub (REACH) Awards program to promote dissemination of evidence-based therapeutics, preventatives, diagnostics, devices, and tools into the marketplace. |
| Research in Diabetes Mellitus, Its Complications, and Obesity | Research Initiative | IHS | NIDDK | The objectives are to identify the determinants and understand the progression of type 2 diabetes, obesity, and other chronic diseases in Pima Indians. |
| Research to Guide Practice Enhancing HIV/AIDS Platforms to Address Non- Communicable Diseases in Low Resource Settings (HIV/NCD Integration Project) | Research Initiative | CDC | FIC, NCI, NHLBI, NIAID, NICHD, NIDDK, NIMH, NIMHD, NINDS, NINR, OD/DPCPSI/OAR | Research to guide practice: Enhancing HIV/AIDS platforms to address non-communicable diseases (NCDs) in low-resource settings (the HIV/NCD Integration Project) aims to bring together researchers, implementers, and government representatives to articulate practical goals, approaches, and a related research agenda to incorporate prevention, care, and treatment for NCDs into HIV/AIDS platforms in sub-Saharan Africa. The HIV/NCD Integration Project focuses on people living with HIV, many of whom are being treated successfully for HIV, but who are increasingly experiencing co-morbid diseases or conditions such as cardiovascular disease, diabetes, cancer, and depression. This project has produced landscape analyses, is establishing research agendas and priorities, and supports products, including modeled data, to enhance NCD services through HIV platforms. http://www.fic.nih.gov/About/Staff/Policy-Planning-Evaluation/Pages/pepfar-ncd-project.aspx |
| Research to Inform the Prevention of Asthma in Healthcare | Research Initiative | CDC | NCI | This collaboration between CDC and NCI aims to Characterize the exposure of healthcare workers to disinfectants and other chemicals. |
| Research-Tested Intervention Program Database (RTIPs) | Resource Development | SAMHSA | NCI | The Research-Tested Intervention Program Database (RTIPs) is a searchable database of cancer control interventions and program materials and is designed to provide program planners and public health practitioners easy and immediate access to research-tested materials. http://rtips.cancer.gov/rtips/index.do |
| Respiratory exposure of vaccinated Non-human Primates to Ebola Virus | Other | BARDA, FDA | NIAID | This is an interagency agreement between NIAID and USAMRMC/USAMRIID to investigate the cause of respiratory disease and lung pathology in cynomolgus macaques vaccinated with an Ebola virus vaccine and challenged with Ebola virus by the aerosol route. |
| Revision of CDC Guidelines on Hepatitis B | Committee, Work group, Advisory group, or Task Force | CDC | CC | The collaboration serves to revise guidelines for managing occupational exposures to HIV and managing healthcare workers infected with hepatitis B. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6103a1.htm?s_cid=rr6103a1_e |
| Ruth L. Kirschstein National Research Service Award Program | Training Initiative | AHRQ, HRSA | OD/OER | The National Institutes of Health (NIH) Ruth L. Kirschstein National Research Service Award program provides predoctoral and postdoctoral training to meet the nation’s need for investigators in biomedical, behavioral, and clinical research. In accordance with the Public Health Service Act (Public Law 1118, Section 219), NIH annually transfers a portion of these funds to the Agency for Healthcare Research and Quality and Health Resources and Services Administration to foster the training of health services and primary care researchers. https://researchtraining.nih.gov/ |
| RxNorm | Resource Development | FDA | NLM | RxNorm provides normalized names for clinical drugs and links its names to many of the drug vocabularies commonly used in pharmacy management and drug interaction software. By providing links between these vocabularies, RxNorm can mediate messages between systems not using the same software and vocabulary. http://www.nlm.nih.gov/research/umls/rxnorm/ |
| Sabbatical in Clinical Research Management Program | Training Initiative | FDA, OS | CC, FIC, NCATS, NEI, NHLBI, NIAID, NIDCR, NIDDK | Experienced investigators come to the National Institutes of Health (NIH) to learn about management of a clinical research enterprise, including topics such as planning and budget development, protocol writing and tracking, and scientific review. Sabbaticals are self-directed, meaning that the participant chooses from a list of electives and helps determine how much time to spend studying each topic. The electives are offered by leaders at the NIH and other US Department of Health and Human Services agencies with the NIH Clinical Center being the most heavily involved. http://www.cc.nih.gov/training/sabbatical/index.html |
| Safe to Sleep | Public Education Campaign | CDC, HRSA | NICHD | The Safe to Sleep® campaign seeks to educate parents and caregivers about the importance of placing healthy babies on their backs to sleep, for naps and at night, to reduce the risk of Sudden Infant Death Syndrome (SIDS). The campaign also describes other ways to reduce the risk of SIDS. The NICHD offers print and electronic materials, media resources, toolkits, and continuing education programs for nurses as part of the campaign. The Safe to Sleep® campaign partners with minority organizations serving African American, Asian, Hispanic, and Native American communities. The campaign concentrates outreach efforts in states with high SIDS rates; these states have high minority and low-income populations. https://www1.nichd.nih.gov/sts/Pages/default.aspx |
| SAMHSA Recovery Month | Public Education Campaign | SAMHSA | NIDA | The Substance Abuse and Mental Health Services Administration (SAMHSA) holds an annual public health observance for people in recovery from substance abuse. The National Institute on Drug Abuse (NIDA) is part of SAMHSA''s inter-agency planning committee and a promotional partner. http://www.recoverymonth.gov/ |
| SCOPE (Spinal Cord Injury Outcomes Endeavor) | Other | ACL | NICHD, NINDS | The Spinal Cord Outcomes Partnership Endeavor (SCOPE) aims to enhance the development of clinical trial and clinical practice protocols that will accurately validate therapeutic interventions for spinal cord injury (SCI) leading to the adoption of improved best practices. http://scope-sci.org/ |
| SEARCH for Diabetes in Youth | Research Initiative | CDC | NIDDK | SEARCH is a multi-center study that identifies cases of diabetes in children/youth, providing data on incidence and prevalence in the US as well as data on diabetes management and complications. http://www.searchfordiabetes.org |
| Secretary''s Tribal Advisory Committee (STAC) | Committee, Work group, Advisory group, or Task Force | CDC, CMS, HRSA, IHS, OS, SAMHSA | OD/OSP, OD/DPCPSI/THRO | The STAC’s primary purpose is to seek consensus, exchange views, share information, provide advice and/or recommendations, or facilitate any other interaction related to intergovernmental responsibilities or administration of HHS programs, including those that arise explicitly or implicitly under statute, regulation or Executive Order. This purpose will be accomplished through forums, meetings, and conversations between Federal officials and elected Tribal leaders in their official capacity (or their designated employees or national associations with authority to act on their behalf). https://www.hhs.gov/about/agencies/iea/tribal-affairs/about-stac/index.html |
| Senior Medical Advisor to Assistant Secretary for Preparedness and Response (ASPR) | Committee, Work group, Advisory group, or Task Force | OS | NCI, NIAID | A NCI staff member serves as Senior Medical Advisor to ASPR. As such, NCI helps to develop plans for emergency and disaster responses and plays a role in responses operations as needed. A good number of the Operations plans and models that apply to all hazards have been developed from NCI science and knowledge. http://www.phe.gov/about/aspr/Pages/default.aspx |
| Smokefree.gov | Resource Development | CDC, OS | NCI, OD/DPCPSI/OBSSR | Smokefree.gov is intended to help individuals quit smoking. Different people need different resources as they try to quit. The information and professional assistance available on this website can help to support both immediate and long-term needs as individuals become, and remain, a nonsmoker. Smokefree.gov allows individuals to choose the help that best fits their needs. This collaboration also includes a number of smoking cessation text message programs throughout the world: China, Caribbean, Guam, American Samoa, and Samoa. http://smokefree.gov/ |
| Smoking Cessation Services During CDC TIPS II Campaign | Public Education Campaign | CDC | NCI | This campaign assists in ensuring that 1-800-QUIT-NOW''s counseling services and the National Cancer Institute''s text messaging service and website (Smokefree.gov) have adequate capacity to meet the expected increased demand for services during the Centers for Disease Control and Prevention TIPS Campaigns. |
| Society for Prevention Research Annual Meetings | Meeting/ Workshop | ACF, CDC | NIDA, NCI, NIAAA, NICHD, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The Society for Prevention Research was formed in 1991 and has grown from a small group of researchers focused on drug and alcohol abuse prevention and mental health to become a leading scientific organization devoted to advancing prevention science, with 700+ members and a multidisciplinary prevention focus that emphasizes drug abuse, mental health, and HIV/AIDS prevention in addition to diverse, public health domains (e.g., obesity, violence, translational science). The annual meetings promote cross-fertilization of theory, methods, and intervention and provide an opportunity to enhance understanding of the underlying mechanisms of health-related issues with the goal of building the science of effective strategies, and for prevention and health promotion. http://preventionscience.org |
| Somatic Cell Genome Editing | Research Initiative | FDA | OD/DPCPSI, NCATS, NCI, NHGRI, NHLBI, NIAID, NIAMS, NIDDK, NIMH, NINDS, OD/DPCPSI/ORIP, OD/DPCPSI/OSC | The Somatic Cell Genome Editing (SCGE) program aims to develop quality tools to perform effective and safe genome editing in human patients. These research tools will be made widely available to the research community to reduce the time and cost required to develop new therapies. A representative from FDA/CBER plays an advisory role for the program regarding regulatory issues. The program is also coordinating with the NIST Gene Editing consortium and the DARPA Safe Genes program and is exploring ideas for possible synergistic activities. https://commonfund.nih.gov/editing |
| Specificity and Quality of Influenza-Specific Antibodies | Research Initiative | FDA | NIAID | This collaboration supports the evaluation of specificity and quality of influenza-specific antibodies in human subjects that have been vaccinated or naturally infected with influenza. Specific tasks include the construction of phage display libraries, production of recombinant proteins, development of surface plasmon resonance assays and the use of these technologies to measure antibody affinity maturation. |
| Standardized Machine-Readable Units of Measure | Committee, Work group, Advisory group, or Task Force | OS | NLM | Historically, NLM has been at the nexus of standards needed to make clinical data flow to and from sources for clinical care, biomedical research, and epidemiologic databases. The big new research initiatives such as PCORI, Precision medicine, and the Cancer Moonshot depend heavily on efficient access to rich clinical data. A core problem of clinical data science is the prevalence of local and idiosyncratic coding systems used by individual care institutions. The major enabler of the use of big clinical Data is the standardization of the coding systems and formats (i.e. message standards) that clinical organizations use. On the coding system side, we have been developing, disseminating, and facilitating the adoption of universal standards, i.e., Unified Code for Units of Measure (UCUM) for units of measure so that clinical measures that different institutions report in different units of measure could be converted to a single unit of measure, which would simplify their use in care and research. We are working with NIST (DoL) to promote the use of UCUM as a replacement for ISO-8000. We have also developed a web-based open source tool to enable the conversion of units of measure to standard machine-readable format using UCUM. http://unitsofmeasure.org/trac |
| Standards for Genetic Testing Report | Research Initiative | AHRQ, CDC, OS | NLM, NHGRI | This activity aims to develop a standard reporting format for genetic variations using Logical Observation Identifiers Names and Codes (LOINC) and HL7, for electronic medical records health information exchange, and activities of the Office of the Secretary. |
| State Cancer Profiles | Resource Development | CDC | NCI | The objective of the State Cancer Profiles Website is to provide a system to characterize the cancer burden in a standardized manner in order to motivate action, integrate surveillance into cancer control planning, characterize areas and demographic groups, and expose health disparities. The focus is on cancer sites for which there are evidence-based control interventions. Interactive graphics and maps provide visual support for deciding where to focus cancer control efforts. http://statecancerprofiles.cancer.gov/ |
| Steering Committee of the Scientific Interest Group in Glycobiology | Committee, Work group, Advisory group, or Task Force | FDA | NIGMS, NCI, NHGRI, NHLBI, NIAID, NICHD, NIDCR, NIDDK | The Steering Committee of the Scientific Interest Group in Glycobiology (GlycoSIG) is comprised of NIH intramural scientists and program staff as well researchers from the Food and Drug Administration (FDA) and the National Institute of Standards and Technology (NIST). The committee organizes a seminar series; an annual NIH/FDA Glycosciences Research Day Meeting (averaging 250 people in attendance); and a Mentoring & Networking Luncheon for graduate students and postdoctoral fellows to meet with staff from federal agencies and learn about NIH extramural programs. The Committee also offers a Special Topics in the Glycosciences Course every other year. In addition, the GlycoSIG maintains an email listserve to distribute information on meetings, jobs, funding opportunities, and seminars. The SIG cross posts with other NIH SIG’s that share interests. https://oir.nih.gov/sigs/glycobiology-scientific-interest-group |
| Stimulating Peripheral Activity to Relieve Conditions | Research Initiative | FDA | OD/DPCPSI, NCATS, NCCIH, NEI, NHLBI, NIAID, NIBIB, NICHD, NIDA, NIDCD, NIDDK, NIMH, NINDS, OD/DPCPSI/OSC | The Stimulating Peripheral Activity to Relieve Conditions (SPARC) program''s central goal is to provide an integrated, predictive neural circuit map that illustrates the physiology and biological mechanisms underlying peripheral nervous system control of internal organ function. SPARC is collaborating with the FDA''s CDRH to facilitate discovery of new therapeutic uses for existing neuromodulation devices as well as improvements that make these devices more effective and/or minimally invasive. SPARC also coordinates with DARPA''s ElectRx program to minimize research overlap while ensuring complimentary efforts are undertaken to collectively advance the neuromodulation field as a whole. https://commonfund.nih.gov/sparc/index |
| Structured Data Capture (SDC) Initiative | Resource Development | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS | NLM, NCI | The Structured Data Capture (SDC) Initiative is sponsored by the Department of Health and Human Services, Office of the National Coordinator (ONC), as part of the Standards and Interoperability Framework, a program developed to foster collaboration between the public and private sectors to promote the interoperable exchange of health data and information. The SDC mission is to develop and validate a data architecture and exchange standards so that a structured set of data can be accessed from electronic health record systems, merged with comparable data and made accessible for purposes other than clinical care, such as research, patient safety, and public health. The SDC Working Group on Common Data Elements and Forms, chaired by NLM/NIH with NCI/NIH participation, evaluated and selected two ISO standards to serve as the basis for definitions of Common Data Elements and electronic Case Report Forms (eCRF) under the initiative: ISO/IEC 11179 (Metadata Registries and Data Elements metamodel) and ISO/IEC 19763-13 (Forms metamodel). https://www.nlm.nih.gov/cde/ |
| Study of Cancer Among US Firefighters | Research Initiative | CDC | NCI | A retrospective cohort study to evaluate the relationship between occupational exposures of firefighters and cancer risk. https://www.cdc.gov/niosh/firefighters/injury.html |
| Study to Assess the Incidence of Type 1 Diabetes in Young Adults | Research Initiative | CDC | NIDDK | The goal of this study is to develop, implement, and evaluate a population-based, timely, low-cost surveillance system for the assessment of the incidence of type 1 diabetes among young adults in the United States. The study will determine the incidence of type 1 diabetes among young adults and will include an Islet Autoantibody Standardization Program (ISAP)-certified central laboratory for the measurement of diabetes auto anti-bodies in all individuals identified with newly diagnosed diabetes. Incident cases of diabetes will be identified using electronic health records. |
| Subcommittee for Toxics and Risks | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIEHS, NLM | The Subcommittee for Toxics and Risks (T&R) serves under the National Science and Technology Council’s, Committee on Environment, Natural Resources, and Sustainability (CENRS). The committee consists of 17 federal agencies with public health or regulatory responsibilities involving toxicology, environmental exposure, or epidemiology. NIH/NIEHS has been a co-chair of this committee for the past 8 years in close cooperation with the Environmental Protection Agency and the Department of Defense. The T&R meets bi-monthly to share ongoing issues relevant to research, regulations, and emerging science. Presently, the White House Office of Science and Technology Policy is in the process of reorganization. The present charter for the T&R expires on April 30, 2018 |
| Subcommittee on Disaster Reduction | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The Subcommittee on Disaster Reduction (SDR) is a Federal interagency body of the US National Science and Technology Council under the Committee on Environment, Natural Resources and Sustainability. Chartered in 1988, the SDR provides a unique Federal forum for information sharing; development of collaborative opportunities; formulation of science- and technology-based guidance for policymakers; and dialogue with the US policy community to advance informed strategies for managing disaster risks. Under its mandate, the SDR advises the White House Office of Science and Technology Policy (OSTP) and others about relevant risk reduction resources and the related work of SDR Member Agencies. Additional information about the subcommittee''s mandate is available in the SDR Charter. http://www.sdr.gov/ |
| Subcommittee on Ocean Science and Technology | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | The purpose of the Subcommittee on Ocean Science and Technology (SOST) is to advise and assist the National Science and Technology Council (NSTC)''s Committee on Environment, Natural Resources, and Sustainability on national issues of ocean science and technology. In that capacity, the SOST is the lead interagency entity for Federal coordination on ocean science and technology. The SOST identifies ocean science and technology priorities, fosters and facilitates ocean science and technology activities, and contributes to Federal goals and agency missions in this area, including through collaborative interagency strategies. The SOST’s interagency efforts expand knowledge, provide advice, and offer recommendations regarding the advancement of ocean science and technology across the federal government and with the broader ocean community, including international activities. https://obamawhitehouse.archives.gov/administration/eop/ostp/nstc/oceans |
| Sudden Death in the Young (SDY) Registry | Resource Development | CDC, HRSA | NINDS, NHLBI | The Sudden Death in the Young (SDY) Registry is a surveillance system to track sudden deaths in youths less than or equal to 19 years of age in up to 10 states and to gather clinical data and a DNA sample to be used for research to explore the causes and risk factors for sudden death in the young. The SDY Registry is a collaboration between the National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and Centers for Disease Control and Prevention (CDC). https://www.sdyregistry.org/research/ |
| Suicide Mortality Surveillance | Other | CDC | NIMH | Through the Suicide Mortality Surveillance project, the Centers for Disease Control and Prevention (CDC) will develop and refine a rapid suicide mortality surveillance system. Monitoring the trends in cause-specific mortality is critical for identifying emerging public health problems and in generating evidence for health policy development, implementation, and evaluation. Timely information is important for monitoring severity of the disease or condition, allocating resources, and facilitating preventive and control programs. The results from this study will yield valuable information about the validity, feasibility, and timeliness of the enhanced vital statistics system for rapid suicide surveillance. |
| Support for Implementation of Agency Public Access Policies | Resource Development | AHRQ, CDC, FDA, OS | NLM | NIH Public Access Policy was created by NIH and established in statute by Congress in the Consolidated Appropriations Act 2008, P. L. 110-161, enacted on 12/26/2007. It ensures that the public can access without charge peer-reviewed journal articles arising from NIH-funded research. Since 2008, the PubMed Central (PMC) database has served as the repository for journal articles subject to the NIH Public Access Policy. The Office of Science and Technology Policy (OSTP) coordinated the development of public access policies across federal science agencies, and OSTP released a directive in February 2013 to increase public access to scientific publications and digital data. NIH is collaborating with five divisions and offices in HHS and four agencies outside HHS to use PMC and related services in support of their public access policies. Interagency agreements have been signed with AHRQ, ASPR, CDC, FDA and ACL within HHS, as well as with NASA, NIST, VA, and EPA. Researchers funded by CDC, VA, NIST, AHRQ, FDA, and NASA have begun depositing manuscripts in PMC. |
| Surveillance, Epidemiology and End Results (SEER) - Medicare Database | Resource Development | CMS | NCI | The Surveillance, Epidemiology, and End Results (SEER) - Medicare Database data are a unique resource that can be used for research related to the health care provided to persons with cancer. The database results from the linkage of two large population-based data sources: the SEER cancer registries data and Medicare enrollment and claims files. http://healthservices.cancer.gov/seermedicare/ |
| Surveillance, Epidemiology, and End Results (SEER) Program | Resource Development | CDC | NCI | The Surveillance, Epidemiology, and End Results (SEER) program is the premier source for cancer statistics in the US. It collects information on incidence, prevalence, and survival from specific geographic areas representing 26 percent of the US population. Through SEER, NCI develops reports on all of these information areas plus cancer mortality for the entire country. The site is intended for anyone interested in US cancer statistics or cancer surveillance methods. http://seer.cancer.gov/ |
| Sync for Science (S4S) | Committee, Work group, Advisory group, or Task Force | OS | OD/AoU | Sync for Science (S4S) is a collaboration with Harvard Medical School, various electronic health record (EHR) vendors, and the United States Federal Government (National Institutes of Health and the Office of the National Coordinator for Health Information Technology (ONC)). Sync for Science (S4S) is a technology for enabling individuals to donate electronic clinical and health data to biomedical research studies. S4S is working towards a provider pilot in conjunction with the All of Us Research Program (formerly known as the Precision Medicine Initiative Cohort Program), a national, large-scale research enterprise designed to support discoveries that increase our ability to better treat and prevent disease by enrolling one million or more volunteers. The health data to be gathered by All of Us will support research across a breadth of disciplines. The Harvard team is funded through a grant supplement supported by NIH. ONC has provided various levels of guidance including the development of privacy and security considerations for the S4S technology implementation, an effort contracted to ESAC Inc. S4S provides participants the ability to share electronic health record-based clinical-health data with a research program of their choice via an open, read-only application programming interface (API). The S4S API is based on the Health Level 7 (HL7) Fast Healthcare Interoperability Resources (FHIR) and OAuth 2.0 standards. The S4S API requires implementers to use technology that describes how app developers can access FHIR resources using OAuth 2.0. OAuth 2.0 is used to provide access control based on rules set to enforce a vendor site’s security policy. The S4S API was developed to use OAuth 2.0 to allow an application to have read-only access to all or a portion of electronic personal health information about a patient made available through an HPOs patient portal, via the patient’s authentication credentials. The S4S API enables a health provider organization (HPO) to share a subset of the Certified EHR Technology (CEHRT) Common Clinical Data Set (CCDS) data elements, consistent with the Argonaut Project FHIR profile. The S4S API was developed with the intention that it can be used in the future for other research applications. Future applications may use additional or different subsets of the CCDS data elements, as their applications require. |
| Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) | Resource Development | AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA | NLM | This activity provides support for SNOMED CT, a systematically organized computer processable collection of medical terminology covering most areas of clinical information such as diseases, findings, procedures, microorganisms, pharmaceuticals, etc. It allows a consistent way to index, store, retrieve, and aggregate clinical data across specialties and sites of care. It also helps to organize the content of medical records, reducing the variability in the way data is captured, encoded and used for clinical care of patients and research. http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html |
| Targeting of Interleukin-13 Receptor a2 for Treatment of Head and Neck Squamous Cell Carcinoma Induced by Conditional Deletion of TGF-ß and PTEN Signaling | Research Initiative | FDA | NIDCR, NIDCD | This activity is testing new animal models of head and neck squamous cell cancer with targeted treatments using Interleukin-13 Receptor alpha 2 antagonists. |
| Task Force for Combating Antibiotic-Resistant Bacteria (CARB) | Committee, Work group, Advisory group, or Task Force | AHRQ, BARDA, CDC, CMS, FDA, HRSA | NIAID | Established by Executive Order 13676, the Task Force facilitates implementation of the CARB Action Plan and provides progress reports and quarterly updates describing key achievements. The Task Force is an internal government committee comprised of federal representatives and co-chaired by the Secretaries of Defense, Agriculture, and HHS. |
| Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, OS | NICHD, NCATS, NHLBI, NIAID, NIDDK, NIMH, OD/DPCPSI/ORWH | The 21st Century Cures Act established PRGLAC to advise the Secretary of Health and Human Services (HHS) regarding gaps in knowledge and research on safe and effective therapies for pregnant women and lactating women. PRGLAC is tasked with identifying these gaps and will report its findings back to the Secretary. In addition to providing advice and guidance to the Secretary, the Task Force will prepare and submit to the Secretary and Congress a report that includes each of the following: a plan to identify and address gaps in knowledge and research regarding safe and effective therapies for pregnant women and lactating women, including the development of such therapies; ethical issues surrounding the inclusion of pregnant women and lactating women in clinical research; effective communication strategies with healthcare providers and the public on information relevant to pregnant women and lactating women; and recommendations to improve the development of safe and effective therapies for pregnant women and lactating women. The report will also include identification of Federal activities, including the state of research on pregnancy and lactation; recommendations for the coordination of, and collaboration on research related to pregnant women and lactating women; dissemination of research findings and information relevant to pregnant women and lactating women to providers and the public; and existing Federal efforts and programs to improve the scientific understanding of the health impacts on pregnant women, lactating women, and related birth and pediatric outcomes, including with respect to pharmacokinetics, pharmacodynamics, and toxicities. https://www.nichd.nih.gov/About/Advisory/PRGLAC |
| Technical and Clinical Consultation to Indian Health Service in Kidney Disease | Other | IHS | NIDDK | A National Institute of Diabetes and Digestive and Kidney Diseases senior staff member serves as Chief Clinical Consultant for Nephrology for the Indian Health Service. |
| Technical Consultation on Viral Hepatitis (HCV) Infection in Young Injection Drug Users | Meeting/ Workshop | CDC, OS, SAMHSA | NIDA, NIAID, NIDDK | This collaboration brings Federal and non-Federal clinician/researchers from academia, state public health departments, and communities together to present and discuss current research and other information on an emerging epidemic of viral hepatitis (HCV) infection in the 15-30 year group of Injection Drug Users (IDUs). |
| Technical Working Group on National Security Risks Associated with the Applications Enabled by Advancements in Genome Editing and Synthesis Technologies and Other Related Enabling Technologies | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | OD/OSP, NIAID | The purpose of the TWG is to discuss and evaluate current and emerging risks associated with applications enabled by advancements in genome editing and synthesis technologies and other related enabling technologies. These efforts are intended to support US government national security decision making, including the adjustment or development of policies and actions to address the national security risks associated with the applications of technologies under its purview. |
| Technologies for Donating Medicare Beneficiary Claims Data to Research Studies | Research Initiative | CMS, OS | OD/AoU | This project is a collaboration between NIH and CMS to leverage the Sync for Science™ (S4S) and Blue Button® API (BB API) programs to enable Medicare beneficiaries to donate their medical claims data for scientific research studies using S4S data donation workflow. NIH will be the lead agency, developing the technical guidelines and CMS will contribute significant support by converting the Medicare claims to HL7’s Fast Healthcare Interoperability Resources (FHIR®) data standard and adapting the BB API to allow Medicare beneficiaries to donate up to three years’ worth of their Medicare claims data to align with the S4S specification. |
| Technology Transfer Policy Board | Committee, Work group, Advisory group, or Task Force | CDC, FDA | OD/OIR/OTT, CC, CIT, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM, OD/OER, OD/OIR | The purpose of the Public Health Service (PHS) Technology Transfer Policy Board (TTPB) is to serve as the principal advisory board to the National Institutes of Health (NIH) as lead agency in the PHS technology transfer program, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) in establishing PHS technology transfer policies and modifying existing policies, as applicable. |
| Terminology Standards for Medicare Assessment Instruments | Resource Development | CMS | NLM | NLM is working with CMS to develop LOINC codes for all of the CMS Medicare assessment instruments. http://loinc.org |
| Text4baby | Public Education Campaign | ACF, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA | NIDCR, NICHD, NIDA, NIDDK | Free health text messaging service for pregnant women and new mothers. Those who text "BABY" (or “BEBE” for Spanish) to 511411 receive weekly text messages, timed to their due date or their baby''s birth date through the baby’s first year. Messages, which have been vetted by both government and non-profit health experts, deal with topics such as nutrition, immunization, birth defect prevention, and oral health. http://www.text4baby.org |
| The Agricultural Health Study | Research Initiative | CDC | NIEHS, NCI | The Agricultural Health Study (AHS) is a prospective study of cancer and other health outcomes (e.g. Parkinson’s disease, diabetes, thyroid disease, respiratory diseases, rheumatoid arthritis and other autoimmune disorders, and reproductive health) in a cohort of licensed pesticide applicators and their spouses from Iowa and North Carolina. The AHS began in 1993 with the goal of answering important questions about how agricultural lifestyle and genetic factors affect the health of farming populations. The study is a collaborative effort involving investigators from National Cancer Institute, the National Institute of Environmental Health Sciences, the Environmental Protection Agency, and the National Institute for Occupational Safety and Health. More than 89,000 pesticide applicators and spouses in Iowa and North Carolina have participated in the study. Their participation has provided, and continues to provide, the data researchers need to help the current and future generations of farmers and their families live healthier lives. Between 1993 and 1997, 52,394 licensed private pesticide applicators (mostly farmers) from Iowa and North Carolina enrolled, as did 32,345 of their spouses. The study also included 4,916 commercial pesticide applicators in Iowa in its first two phases. The average ages at enrollment were 47.1 years, 38.0 years, and 46.9 years for private applicators, commercial applicators, and spouses. The study began by collecting baseline information from participants when they enrolled (1993-1997). Follow-up telephone interviews were conducted in the second (1999-2003), third (2005-2010), and fourth phases (2013-2015) of the study. At Phase 2, participants provided updated information on farming practices, lifestyle, and health and were asked to complete a dietary questionnaire and provide a sample of cheek cells as a source of DNA. The Phase 3 interview also updated information on farming practices, lifestyle, and health while Phase 4 focused on changes in health status. The cohort continues to be followed via linkages with cancer registries and vital statistics. Participants periodically participate in comprehensive sub-studies, including an investigation of genetic and environmental risk factors for asthma and other respiratory diseases and studies of Parkinson’s disease, neurobehavioral function, and cognitive decline. Biological and environmental samples are being collected from a subset of the cohort to facilitate mechanistic studies that might explain links between pesticide and other exposures and increased risk for cancer and other conditions. http://www.aghealth.nih.gov/ |
| The American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NICHD | The NIH advises The American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice research advances that can inform gynecologic clinical practice. |
| The Assistant Secretary for Preparedness and Response (ASPR)''s chemical, biological, radiological and nuclear defense team | Committee, Work group, Advisory group, or Task Force | OS | NCI, NIAID | NCI and NIAID participate in Assistant Secretary for Preparedness and Response (ASPR)''s chemical, biological, radiological and nuclear defense team. Both NCI and NIAID provide expertise on radiation topics and for the Biomedical Advanced Research and Development Authority (BARDA), within the Office of ASPR in the U.S. http://www.phe.gov/about/aspr/Pages/default.aspx |
| The Effect of Various Drugs on the Retina | Research Initiative | FDA | NEI | Using powerful in vivo imaging technology, it is possible to view the retina at the cellular level. This collaboration with the FDA seeks to monitor changes to the retina for drugs that are known to cross the blood/retina barrier to better understand possible toxicity. |
| The Environmental Determinants of Diabetes in the Young (TEDDY) | Research Initiative | CDC | NIDDK, NIAID, NICHD, NIEHS | This consortium is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. The study enrolled over 8,000 newborns and is following them for 15 years to identify environmental triggers of type 1 diabetes. http://www.teddystudy.org |
| The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) | Research Initiative | CDC | NCI | The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM) initiative provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma (BL) epidemiology. Study data will help characterize or investigate: (1) The association of malaria-resistance genes with endemic BL. (2) Host genetic polymorphisms associated with BL using genome-wide association methods. (3) The role of the Epstein-Barr virus (EBV) genetic variants in endemic BL. (4) The role of malaria immunology and phenotype of inflammation in BL. (5) The complexity of coinfection with different P. falciparum malaria genotypes in BL. (6) The interaction between helminthic parasites, HIV, malaria, and EBV in BL. (7) The immunohistochemistry and molecular pathology of BL. (8) The impact of malaria, helminthic parasites, and HIV on childhood BL. http://emblem.cancer.gov/ |
| The Federal Tuberculosis Task Force | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, OS | NIAID, NICHD | The Federal Tuberculosis (TB) Task Force is a coalition composed of the Federal agencies and organizations involved in US TB control efforts. Established in 1991, the Task Force facilitates coordination of activities between Federal agencies. It was created by the Director of the Centers for Disease Control and Prevention (CDC) to address the outbreaks of multidrug-resistant (MDR) TB occurring during the 1985-1992 surge in TB cases. The TB Task Force is co-chaired by CDC and NIAID. http://www.cdc.gov/tb/about/taskforce.htm |
| The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study | Research Initiative | CDC | NIDDK, NHLBI | The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) is a long-term study of different treatments for type 2 diabetes. A major challenge in diabetes treatment is to determine which of the many possible drugs is the best choice among people already treated with metformin, the most commonly used diabetes drug. GRADE is a randomized clinical trial of participants diagnosed with type 2 diabetes within the past 10 years who are already on metformin. Participants will be randomly assigned to one of four commonly-used glucose-lowering drugs (glimepiride, sitagliptin, liraglutide, and basal insulin glargine), plus metformin, and will be followed for up to 7 years. The goal of the GRADE Study is to determine which combination of two diabetes medications is best for achieving good glycemic control, has the fewest side effects, and is the most beneficial for overall health in long-term treatment for people with type 2 diabetes. https://portal.bsc.gwu.edu/web/grade |
| The Healthy Brain Initiative | Public Education Campaign | ACL, CDC | NIA | The Healthy Brain Initiative, or Roadmap, is a project of the Centers for Disease Control and Prevention (CDC) and the Alzheimer''s Association. NIA, along with other HHS participation and a representative from the Administration for Community Living/Administration on Aging, help refine recommendations for state and local governments, with use of Federal resources, to address brain health/dementia in communities. http://www.cdc.gov/aging/healthybrain/index.htm |
| The Impact of Tobacco Use on Oral Health and the Oral Microbiome | Research Initiative | CDC, FDA | NCI | The US Food and Drug Administration Intramural Center of Tobacco Regulatory Science Award Program funded a project examining how tobacco affects oral health and the oral microbiome in the National Health and Nutrition Examination Survey (NHANES) study. https://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/Research/ucm404564.htm |
| The Incidence of Breast and Other Cancers Among Female Flight Attendants | Research Initiative | CDC | NCI | A cohort study of approximately 10,000 Pan Am flight attendants to determine cancer incidence (primarily breast cancer) associated with cosmic radiation and circadian disruption from their work. |
| The Interagency Committee on Human Nutrition Research (ICHNR) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NIDDK | The Interagency Committee on Human Nutrition Research (ICHRN) is charged with improving the planning, coordination, and communication among federal agencies engaged in nutrition research. https://www.nal.usda.gov/fnic/interagency-committee-human-nutrition-research |
| The Interagency Committee on Human Nutrition Research (ICHNR) Dietary Guidelines Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NICHD, NIDDK, OD/DPCPSI/ODS | The Interagency Committee on Human Nutrition Research (ICHNR) dietary guidelines subcommittee serves to improve planning, coordination, and communication among federal agencies engaged in research in nutrition and/or nutrition policies, surveillance, technologies, and related issues. The key focus of the Subcommittee on Dietary Guidelines is to gain perspectives from Federal stakeholders regarding the Dietary Guidelines Advisory Committee''s (DGAC) deliberations and identify any gaps or concerns that are important to Federal programs and to engage USDA and HHS agencies in the DGA policy development process. |
| The MDEpiNet TMJ RoundTable | Meeting/ Workshop | AHRQ, FDA | NIDCR | This workshop facilitated collaboration of stakeholders to address data on implant performance, surgical outcomes, and adverse events in an effort to: develop outcome and assessment and reporting tools based on patient input, the intersection of patient biology, anatomy, genetics, physiology with TMJ medical devices, and clinical patient-centered outcomes to better target therapies. |
| The Mental Health Block Grant Ten Percent Set Aside (MHBG) Evaluation | Other | SAMHSA | NIMH | The Substance Abuse and Mental Health Services Administration (SAMHSA) is sponsoring an evaluation of first episode psychosis treatment programs funded through the federal 10 percent Mental Health Block Grant Set Aside. Through an inter-agency agreement, the National Institute of Mental Health (NIMH) is co-funding the evaluation and is actively involved in all phases of the evaluation design and planning. |
| The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIBIB, OD/OSP | This subcommittee of the National Science and Technology Council''s Committee on Technology is responsible for coordinating the National Nanotechnology Initiative (NNI). The NNI was established in 2001 to coordinate federal research and development in nanotechnology by providing a vision of the long-term benefits and opportunities offered by nanotechnology and acting as a locus for communication, cooperation, and collaboration between federal agencies involved in nanotechnology research and development. In 2016, the NSET updated its strategic plan to reflect the fact that nanotechnology is now a broadly enabling technology, not simply an area of research at the nanoscale. The new strategic plan outlines four goals: (1) advance a world-class nanotechnology research and development program, (2) foster the transfer of new technologies into products for commercial and public benefit, (3) develop and sustain educational resources, a skilled workforce, and a dynamic infrastructure and toolset to advance nanotechnology, and (4) support responsible development of nanotechnology. http://www.nano.gov/nset |
| The Science of Sex and Gender in Human Health | Training Initiative | FDA | OD/DPCPSI/ORWH | This is a Web-based course that offers a scientific understanding of the major physiological differences between the sexes, their influence on illness and health outcomes, and their implications for policy, medical research, and health care. The course is under active review and revision, including the development of a new module that focuses on incorporating epidemiologic observations, basic/pre-clinical research findings, and clinical research results, with an emphasis on the basic science to highlight sex/gender-based influences for particular disease entities. http://sexandgendercourse.od.nih.gov/ |
| The SMART Vaccines 2.0 Platform: Decision-Support for Prioritizing Vaccine R&D and Introduction (SMART Vaccines 2.0) | Resource Development | OS | FIC | The prototype decision-support tool, SMART Vaccines, was delivered to the National Vaccine Program Office (NVPO) by the Institute of Medicine (IOM) in early 2015. In support of the National Vaccine Action Plan, NVPO charged the IOM to develop a tool that reflected the dynamic and complex nature of decision-making among multiple stakeholders within the vaccine decision-making space—comprising the different interests, roles, and priorities of individuals engaged in vaccine research, research funding, purchasing, immunization programs, and policy. The current design of the tool seeks to capture the components of this decision-making process and to model how those elements interact to ultimately influence how an individual or an organization might prioritize its strategic and financial investments in new research and targets for vaccines or newly available vaccines for introduction into national immunization schedules. By attempting to more uniformly define the components of the process and allowing individuals to rank the importance of each, the tool generates a score that allows for a comparison among different inputs of vaccine targets and/or existing vaccines and the impact of each on the resulting score. NVPO and FIC are collaborating in support of both agencies’ missions related to developing and implementing strategies for increasing the prevention of human diseases through immunization. As part of a process to build a fully functional tool, SMART Vaccines 2.0, the NVPO and FIC are engaging relevant stakeholder organizations and individuals to assist in the prototype’s transformation to a more widely-accessible, relevant, and responsive tool for use in support of prioritizing the scientific, technical, and financial commitments of decision makers in the broad vaccine development and delivery community. Collaboration efforts support the following objectives: 1) Provision of capabilities to transform the existing SMART Vaccines tool to a web-based platform (html open-source model) that can be supported and sustained for public access; 2) Iterative adaptation and refinement of the tool -or suite of tools- that is responsive to: - dynamic and emerging information/inputs (e.g., disease burden, antigen-specific technology, and economic data); - ongoing assessment/validation of methodologies; and, - user/stakeholder feedback 3) Expansion and updating of the data warehouse (model supporting data) and standardized formats for data sharing; 4) Dissemination and use of the tool (and/or derivative tools) supported by direct engagement and training of the public sector, academic, and private sector stakeholders and decision-makers associated with vaccine development, purchasing, and deployment/implementation programs; and, 5) Identifying an external hosting organization for the tool that is sustainable and provides global access to the tool by embedding it an infrastructure that utilizes existing resources for maintenance of standards and capabilities. To support these objectives, at least two piloting opportunities have been identified in which the relevant organizational stakeholders have agreed to utilize the SMART Vaccines 2.0 web-based tool in support of a targeted decision-making process. The focus of these decision-making efforts is related to the prioritization of resource-allocation for vaccine research and development and/or the introduction of new or existing vaccines into current immunization schedules. NVPO and FIC are supporting the following deliverables: 1) Provision of capabilities to utilize the web-based SMART Vaccines 2.0 platform in support of piloted applications; 2) Direct engagement of NVPO/FIC (and partner organizations) technical assets, staffing, and training in support of the pilot organization’s use of the SMART Vaccines 2.0 tool; 3) Modification and enhancement of the tool’s back-end model supporting algorithms and data-sourcing and acquisition capabilities for alignment with the pilot organizations specific decision-support needs; 4) Evaluation of the implementation and outcome of the piloted projects and the responsive of the SMART Vaccines 2.0 platform in this process; 5) Assessment of the long-term sustainability of the SMART Vaccines initiative based on the following: - an evaluation of the tool produced from the pilot project and the feasibility of its on-going adaptation for other related decision-making processes; - the opportunities and limitations associated with data availability in support of the SMART Vaccines approach; - an evaluation of the likelihood of use by key decision-makers in the vaccine research, development, and delivery communities; - the viability of commitments from external technical experts and organizations to continue to support the ongoing and dynamic modifications that will be required to adapt the SMART Vaccines tool for individual decision-making needs; and, - the likelihood of external stakeholder funding opportunities to support the sustained human, technical, and financial needs required for long-term viability of a publicly accessible SMART Vaccines tool. |
| The United States Renal Data System (USRDS) | Resource Development | CMS, HRSA | NIDDK | The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the United States. The missions of USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients. http://www.usrds.org |
| Therapeutics for Rare and Neglected Diseases (TRND)/FDA Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NCATS | A group of Therapeutics for Rare and Neglected Diseases (TRND) Program staff and US Food and Drug Administration (FDA) staff from the Center for Drug Evaluation and Research (CDER) meet on a monthly basis to discuss projects for the TRND program. The purpose of this working group is to discuss regulatory science toward the eventual goal of an Investigational New Drug Application. Results of experiments are discussed, and TRND staff and FDA/CDER staff exchange ideas that are taken into consideration when developing TRND project plans. https://ncats.nih.gov/trnd |
| Tissue Chip Testing Centers | Research Initiative | FDA | NCATS | NCATS-funded Tissue Chip Testing Centers (TCTC) scientists will use a reference set of validation compounds vetted by pharmaceutical representatives through an NCATS partnership with the IQ Consortium and the Food and Drug Administration (FDA) and will run tests to determine functionality, reproducibility, robustness, and reliability in these organ platforms. The TCTC scientists will coordinate activities among Tissue Chip program-funded investigators and the FDA to support the progress of these chips, with the goal of getting chips to be used widely as a validated research tool and qualified for use in pre-clinical drug testing. https://ncats.nih.gov/tissuechip/projects/centers |
| Tobacco and Nicotine Research Interest Group (TANRIG) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | NCI, NHGRI, NHLBI, NIAAA, NIAID, NICHD, NIDA, NIEHS, NIMH, NINR, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant US Department of Health and Human Services agencies. https://oir.nih.gov/sigs/tobacco-nicotine-research-interest-group-tarnig |
| Tobacco and Reproductive Health Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD, NCI, NIAAA, NIDA, NINR | The purpose of this working group is to exchange information across agencies about research efforts concerning tobacco and reproductive health. |
| Tobacco Centers of Regulatory Science (TCORS) | Research Initiative | FDA | OD/DPCPSI/ODP | The Tobacco Regulatory Science Program located in the NIH Office of Disease Prevention coordinates the trans-NIH collaboration effort with the Food and Drug Administration Center for Tobacco Products to conduct research that is needed to ensure that US tobacco regulatory actions and activities are based on sound and relevant scientific evidence. The P50 Tobacco Centers of Regulatory Science (TCORS) are the centerpiece of this NIH-FDA collaboration. The TCORS are expected to demonstrate research excellence and leadership in tobacco regulatory science that will contribute to the science base that FDA will use to develop meaningful product regulation, which will, in turn, reduce the toll of tobacco-related disease, disability, and death in the United States. Essential elements of the TCORS include at least three theoretically grounded, strong research projects with an integrative theme; an Administrative Core and other cores as needed; the ability to conduct developmental/pilot and time-sensitive research; and a program for career development and training Fourteen TCORS, made up of scientists with a broad range of expertise (e.g., epidemiology, economics, toxicology, addictions, and marketing) have been funded. https://prevention.nih.gov/tobacco-regulatory-science-program/research-portfolio/centers |
| Tobacco Product Disease Risks | Research Initiative | FDA | NCI | NCI and the FDA-Center for Tobacco Products, in collaboration with the US Census Bureau, co-lead this study, which harmonizes data on cigarette, cigar, and pipe use from various Tobacco Use Supplements that have been administered over the years as part of the Current Population Survey. The participants in these surveys have been followed for mortality by linkage to the National Death Index. These data are used to provide contemporary estimates of the mortality risks of daily and non-daily use of cigarettes, pipes, and cigars. The first manuscript from the project is in press. |
| Tobacco Products Scientific Advisory Committee (TPSAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA, SAMHSA | OD/DPCPSI/ODP | TPSAC advises the FDA Commissioner or designee in discharging responsibilities as they relate to the regulation of tobacco products. The Committee reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides appropriate advice, information and recommendations to the Commissioner of Food and Drugs. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisoryCommittee/default.htm |
| Tobacco Regulatory Science Program (TRSP) | Research Initiative | FDA | OD/DPCPSI/ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIDCR, NIEHS, OD/OER | Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources. https://prevention.nih.gov/tobacco-regulatory-science-program |
| Tox21 - Memorandum of Understanding on High Throughput Screening, Toxicity Pathway Profiling, and Biological Interpretation of Findings | Research Initiative | FDA | NIEHS, NCATS | This Memorandum of Understanding sets in place mechanisms to strengthen existing collaborations in the research, development, validation, and translation of new and innovative test methods that characterize key steps in toxicity pathways. This includes the exploration of high throughput screening assays and tests using phylogenetically lower animal species as well as high throughput whole genome analytical methods, to evaluate mechanisms of toxicity. Ultimately, the data generated by these new tools is to be provided to risk assessors to use in the protection of human health and the environment. Success is expected to result in test methods for toxicity testing that are more scientifically and economically efficient and models for risk assessment that are more biologically based. http://www.ncats.nih.gov/tox21 |
| Training on Implementing Collaborative Care Model for Behavioral Health Conditions in Nurse-Led Safety-Net Clinics. | Training Initiative | HRSA | NIMH | NIMH and HRSA are partnering on an initiative to assist the implementation of a Collaborative Care model in nurse-led safety net clinics supported by HRSA. NIMH is supporting this initiative via a contract to provide training to the 11 2017 HRSA-funded Nurse Education, Practice, Quality and Retention- Interprofessional Collaborative Practice Program: Behavioral Health Integration (NEPQR-IPCP: BHI) awardees who choose to take part in this initiative. Training will be aimed at ensuring awardees implement the IMPACT Collaborative Model of Depression Care with fidelity. The training will be composed of two phases: Phase I –Establishing and delivering an initial training program for successful implementation of Collaborative Care. All activities up to and including the In-Person Training; Phase II – Providing follow up training and implementation support after the In-Person Training to ensure fidelity of Collaborative Care Delivery. |
| Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) | Committee, Work group, Advisory group, or Task Force | BARDA, CDC, FDA | NIAID | The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of US and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration in order to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation. http://www.cdc.gov/drugresistance/tatfar/ |
| Trans-NIH American Indian and Alaska Native Health Communications and Information Workgroup | Committee, Work group, Advisory group, or Task Force | ACL, IHS | NIAMS, CC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORWH, OD/OCPL | Formed in 2005, the Trans-NIH AI/AN Health Communications and Information Work Group provides a forum for health education and communications staff from National Institutes of Health (NIH) Institutes, Centers, and Offices to share strategies and effective communication approaches to develop and disseminate health information to American Indian and Alaska Native communities. In partnership with the Indian Health Service (IHS) and the Administration on Aging/Administration for Community Living (AoA/ACL), the Work Group conducts outreach to approximately 1,600 IHS Community Health Representatives (CHRs) and 600 AoA/ACL Title VI grantees nationwide through seasonal e-newsletters featuring NIH health information. The e-newsletter, which replaced quarterly hard-copy mailings, features a wide range of health topics and is distributed to IHS CHRs and AoA/ACL grantees that provide services to Native elders. The purpose of the project is to increase awareness among CHRs and Title VI grantees about the availability of free or low-cost, science-based health information for patients and the general public. http://www.niams.nih.gov/About_Us/Mission_and_Purpose/Community_Outreach/Multicultural_Outreach/AIAN_WG/default.asp |
| Trans-NIH Structural Birth Defects Working Group (SBDWG) | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDCD, NIDCR, NIDDK, NIEHS, NINDS | The Trans-NIH SBDWG brings together extramural program officials from NIH components whose missions include research into structural birth defects, with the ultimate goal of facilitating advances in our understanding of the etiology, mechanisms, epidemiology, prevention, and treatment of structural birth defects. https://www.nichd.nih.gov/about/org/der/branches/dbsvb/programs/trans_NIH_SBDWG |
| Trans-NIH Tuberculosis (TB) Working Group | Committee, Work group, Advisory group, or Task Force | CDC | NICHD, FIC, NCATS, NCI, NHLBI, NIAAA, NIAID, NIDA, NIGMS, OD/DPCPSI/OAR | The TB Working Group provides a forum for sharing information about NIH-specific TB projects, including both ongoing and proposed research, including extramural funding initiatives. In addition, the working group fosters continual open communication about TB research being conducted across NIH and maintains a consistent message about the importance of NIH intramural and extramural TB research. It also provides an avenue for the introduction of new technology programs of interest and importance for TB research (such as the "human on a chip"). The working group invites guests/speakers from outside NIH and convenes invitations for teleconference participation to other US Government agencies including the Centers for Disease Control and Prevention (CDC) and the US Agency for International Development (USAID). |
| Transformation of PROWL Survey into Electronic Form. | Health Survey | FDA | NEI, NLM | In 2016, the FDA posted the final version of the Patient-Reported Outcomes with Lasik (PROWL) survey instrument developed in collaboration with the National Eye Institute (NEI) and the Department of Defense (DoD). The survey is intended to collect data to help better understand the potential risk of severe problems that can result from LASIK. The NEI is collaborating with the National Library of Medicine (NLM) to recreate the form in an electronic format to allow for incorporation in electronic data capture systems. The collaboration worked to make the raw data more accessible and deposited in the Biomedical Research Informatics Computing System (Jan 2018). |
| Transplant Cancer Match Study | Research Initiative | HRSA | NCI | A study linking databases of US transplant recipients, donors, and waitlist candidates to multiple US cancer registries to evaluate the spectrum of cancer risk in transplant recipients. http://transplantmatch.cancer.gov/ |
| Traumatic Brain Injury Common Data Elements Standards - Interagency Steering Committee | Resource Development | CDC | NINDS, CIT | The Traumatic Brain Injury (TBI) Common Data Elements (CDE) Standards - Interagency Steering Committee provides oversight to a Federal scientific initiative to develop and utilize common data elements for TBI. http://www.commondataelements.ninds.nih.gov/TBI.aspx#6 |
| Treating for Two: Safe Medication Use in Pregnancy Initiative | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA | OD/DPCPSI/ORWH, NICHD | The initiative provides expert input for the development of a conference on systematic, evidence-based review of specific medications used during pregnancy and adverse fetal outcomes. http://www.cdc.gov/pregnancy/meds/treatingfortwo/index.html |
| Trial to Assess Chelation Therapy 2 (TACT2) | Research Initiative | CDC | NIDDK, NCCIH, NHLBI, NIEHS | Trial to Assess Chelation Therapy 2 (TACT2) is a randomized, double-blind controlled factorial clinical trial of edetate disodium-based chelation and high-dose oral vitamins and minerals to prevent recurrent cardiac events in diabetic patients with a prior myocardial infarction. http://tact2.org/ |
| Tribal Epidemiology Centers Program | Research Initiative | IHS | NIMHD | The Tribal Epidemiology Centers Program develops Epidemiology Centers and public health infrastructure for American Indian/Alaska Native communities. http://www.ihs.gov/epi/index.cfm?module=epi_tec_tecs |
| Tribal Health Research Advisory Council (HRAC) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA | NIMHD | NIH supports the activities of the Tribal Health Research Advisory Council (HRAC), including obtaining input from tribal leaders on health research priorities and needs, and dissemination of information. http://minorityhealth.hhs.gov/hrac/ |
| Tularemia Animal Model Qualification Working Group | Committee, Work group, Advisory group, or Task Force | FDA | NIAID | This working group is collaborating on the qualification of a primate model of pneumonic tularemia under FDA''s Animal Model Qualification/Drug Development Tools Program. Animal model qualification is a regulatory decision and will be published on the FDA website when final. The collaboration includes the exchange of study data, study reports, and agreements on regulatory strategy for model qualification. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284078.htm |
| TUS-CPS (Tobacco Use Supplement to Current Population Survey) | Health Survey | CDC | NCI | The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an NCI-sponsored survey of tobacco use that has been administered as part of the US Census Bureau''s Current Population Survey approximately every 3-4 years since 1992-93. https://cancercontrol.cancer.gov/brp/tcrb/tus-cps/ |
| Understanding and Identifying the Needs for Medical Devices | Committee, Work group, Advisory group, or Task Force | FDA | NCATS | The Institute of Medicine Rare Diseases and Orphan Products 2010 Report recommended that the FDA and NIH perform an assessment of unmet devices needs, and determine the impediments, and options for overcoming these impediments. The assessment was completed and analyzed in 2017. A manuscript and report have been written and will be published soon. The assessment will document examples of compelling unmet needs across sections of medical specialties. Collaborating are the Office of Rare Diseases Research at NCATS, and the Office of Orphan Product Development and other parts of the FDA. |
| Unified Medical Language System Metathesaurus (UMLS) | Resource Development | AHRQ, CDC, CMS, FDA | NLM | NLM''s Unified Medical Language System (UMLS®) facilitates the development of computer systems that behave as if they understand the meaning of the language of biomedicine and health. To that end, NLM produces and distributes the UMLS Knowledge Sources (databases) and associated software tools (programs) for use by system developers in building or enhancing electronic information systems that create, process, retrieve, integrate, and/or aggregate biomedical and health data and information, as well as in informatics research. By design, the UMLS Knowledge Sources are multi-purpose. http://www.nlm.nih.gov/pubs/factsheets/umls.html |
| United States Breastfeeding Committee | Committee, Work group, Advisory group, or Task Force | AHRQ, CDC, FDA, HRSA, IHS, OS | NICHD | The United States Breastfeeding Committee (USBC) is an independent nonprofit organization that was formed in 1998 in response to the Innocenti Declaration of 1990, of which the United States Agency for International Development was a co-sponsor. Among other recommendations, the Innocenti Declaration calls on every nation to establish a multisectoral national breastfeeding committee comprised of representatives from relevant government departments, non-governmental organizations, and health professional associations to coordinate national breastfeeding initiatives. The USBC is now a coalition of more than 50 organizations that support its mission to drive collaborative efforts for policy and practices that create a landscape of breastfeeding support across the United States. http://www.usbreastfeeding.org/ |
| United States Government Global Nutrition Coordination Plan | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA | NICHD | The purpose of the US Government Global Nutrition Coordination Plan is to strengthen the impact of the many diverse nutrition investments across the US Government through better communication and collaboration and through linking research to program implementation. Through coordination mechanisms, the US Government will maximize its support to country-led programs, continue its global leadership and partnerships, and generate, share, and apply knowledge and evidence in the nutrition sector in order to accelerate progress toward shared nutrition goals. The US Government is committed to improving nutrition throughout the world in order to enhance health, productivity, and human potential. https://www.usaid.gov/what-we-do/global-health/nutrition/usgplan |
| United States Government International Assistance for Children in Adversity Working Group | Committee, Work group, Advisory group, or Task Force | ACF, CDC, FDA, HRSA, OS | NICHD, NIAAA, NIDA, NIMH, OD/DPCPSI/OBSSR, OD/DPCPSI/ORWH | United States Government International Assistance for Children in Adversity Working Group seeks to improve the coordination and coherence of the overall United States Government portfolio of assistance for children in adversity. The US Government will help ensure that children under 5 survive and thrive by supporting comprehensive programs that promote the sound development of children through the integration of health, nutrition, and family support. US Government assistance will support and enable families to care for their children; prevent unnecessary family-child separation; and promote appropriate, protective, and permanent family care. The US Government will facilitate the efforts of national governments and partners to prevent, respond to, and protect children from violence, exploitation, abuse, and neglect. The US Government will support partners to build and strengthen holistic and integrated models to promote the best interests of the child. Finally, the US Government will devote resources to building and maintaining a strong evidence base on which future activities to reach and assist the most vulnerable children can be effectively planned and implemented. The US Government will institutionalize and integrate the components of this plan in its diplomatic, development, and humanitarian efforts overseas. https://www.childreninadversity.gov/home |
| Update to Health and Human Services AIDS Strategy | Committee, Work group, Advisory group, or Task Force | CDC, FDA, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/OAR, NIAID, NIDA, NIMH | The National HIV/AIDS Strategy (NHAS) is a five-year plan that details principles, priorities, and actions to guide our collective national response to the HIV epidemic. First released on July 13, 2010, the Strategy identified a set of priorities and strategic action steps tied to measurable outcomes for moving the Nation forward in addressing the domestic HIV epidemic. In 2015 the NHAS was updated to 2020 and reflects the work accomplished and the new scientific developments. |
| Urban Waters Federal Partnership | Committee, Work group, Advisory group, or Task Force | CDC | NIEHS | This partnership will reconnect urban communities, particularly those that are overburdened or economically distressed, with their waterways by improving coordination among federal agencies and collaborating with community-led revitalization efforts to improve our Nation''s water systems and promote their economic, environmental, and social benefits. https://www.epa.gov/urbanwaterspartners |
| Urinary Luteinizing Hormone and Fibroid Development | Research Initiative | CDC | NIEHS | This collaboration is an examination of the association between basal luteinizing hormone levels and fibroid development. |
| US Agency for International Development Antiretroviral Optimization Program Advisory Committee (USAID ART Optimization PAC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NIAID | The goal of the USAID Project Advisory Committee is to guide USAID''s efforts in the area of ART optimization as part of their Cooperative Agreement "Antiretroviral Therapy Simplification – Drug Regimen,” which was awarded to Wits Reproductive Health and HIV Institute with a total estimated ceiling of $50.2 million over five years (October 2015 to October 2020). The Committee has members from the US government, WHO, UNITAID, Paediatric European Network for Treatment of AIDS, Clinton Health Access Initiative, Gates Foundation, Global Fund, university clinical programs, and community representatives. Industry representatives provide background information without sitting on the Project Advisory Committee. https:/www.usaid.gov/what-we-do/global-health/hiv-and-aids/information-center/hiv-and-aids-research-corner/top-10 |
| US Government Inter agency Working Group on Nanotechnology Environmental, and Health Implications (NEHI), of the Nanoscale Science, Engineering, and Technology Subcommittee (NSET) of the National Science and Technology Council (NSTC) | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NCI, NIEHS | The Nanoscale Science, Engineering, and Technology (NSET) Subcommittee and Nanotechnology Environmental, and Health Implications (NEHI) Working Group provide leadership in establishing the national nanotechnology environmental, health, and safety research agenda and in communicating data and information related to environmental and health aspects of nanotechnology between National Nanotechnology Initiative (NNI) agencies and with the public. NNI activities support the development of new tools and methods required for the research that will enable risk analysis and assist in regulatory decision-making. NNI agencies engage and interact with regional, state, and local groups, educational institutions, industry-supported groups, and non-governmental organizations to enhance the impact and value of NNI efforts and to provide a collaborative approach. http://www.nano.gov/nehi |
| US Government Zika Vaccine Development Working Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA, OS | NIAID | NIAID established the Zika Vaccine Development Working Group, which includes representatives from various US Government agencies (BARDA, CDC, FDA) to coordinate research efforts, mobilization of domestic and international research infrastructure, and partnerships with industry to accelerate the development of a safe and effective Zika vaccine. |
| US Preventive Services Task Force (USPSTF) | Resource Development | AHRQ | OD/DPCPSI/ODP, NCI | The US Preventive Services Task Force (USPSTF) is an independent panel of non-Federal experts in prevention and evidence-based medicine and is composed of primary care providers. The USPSTF conducts scientific evidence reviews of a broad range of clinical preventive health care services (such as screening, counseling, and preventive medications) and develops recommendations for primary care clinicians and health systems that are published in the form of "Recommendation Statements." The Agency for Healthcare Research and Quality (AHRQ) has been authorized by the US Congress to convene the Task Force and to provide ongoing scientific, administrative, and dissemination support to the Task Force. The NIH Office of Disease Prevention (ODP) works closely with AHRQ and the USPSTF to provide scientific input from NIH Institutes and Centers on draft research plans, draft evidence reviews, and clinical practice guidelines to be included in the Guide to Clinical Preventive Services. The ODP also disseminates information to NIH Institutes and Centers about high-priority evidence gaps for clinical preventive services that have been identified by the USPSTF. http://www.uspreventiveservicestaskforce.org/ |
| US Public Health Service (USPHS) Physicians Professional Advisory Committee (PPAC) | Committee, Work group, Advisory group, or Task Force | ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA | NIAID | The purpose of this committee is to provide advice and consultation to the Surgeon General on issues relating to the professional practice and personnel activities, civil service, and Commissioned Corps of the Medical Category. The committee provides advisory assistance to the Chief Professional Officer and to the Agency and/or Program Heads of the USPHS and to non-PHS programs that routinely use USPHS personnel. |
| USDA-HHS Birth to 24 Months & Pregnant Women Project Federal Expert Group | Committee, Work group, Advisory group, or Task Force | CDC, FDA | NHLBI, NCI, NICHD, NIDDK, OD/DPCPSI/OBSSR, OD/DPCPSI/ODP | The current work includes identifying topics of public health importance and conducting a small number of systematic reviews on diet and health for infants, toddlers, and women who are pregnant; it will not include specific dietary recommendations or advice. The scientific basis for dietary guidance for these population groups will be informed by the advisory report of the next (2020) Dietary Guidelines Advisory Committee. https://www.cnpp.usda.gov/birthto24months |
| Value Set Authority Center (VSAC) | Resource Development | AHRQ, CDC, CMS, OS | NLM | The National Library of Medicine (NLM) provides an online repository of value sets (code sets from standardized medical vocabularies) that are used for clinical quality measurement in the CMS EHR Incentive Program (meaningful use). The Value Set Authority Center (VSAC) provides downloadable access to all official versions of vocabulary value sets contained in the 2014 Clinical Quality Measures (CQMs). Each value set consists of the numerical values (codes) and human-readable names (terms), drawn from standard vocabularies such as SNOMED CT ®, RxNorm, LOINC, and ICD-10-CM, which are used to define clinical concepts used in clinical quality measures (e.g., patients with diabetes, clinical visit). http://vsac.nlm.nih.gov |
| Violence Against Women Steering Committee (DHHS VAW) | Committee, Work group, Advisory group, or Task Force | ACF, AHRQ, CDC, HRSA, IHS, OS, SAMHSA | OD/DPCPSI/ORWH, NIA, NIAAA, NICHD, NIDA, NIMH, NLM, OD/DPCPSI, OD/DPCPSI/OAR, OD/DPCPSI/OBSSR | The DHHS Violence Against Women Act (VAWA) steering committee is chaired by the Office on Women’s Health (OWH). The VAWA committee has the responsibility for coordinating the Department of Health and Human Services (DHHS) response to issues related to violence against women and their children, and also coordinates DHHS violence-related activities with those of other Federal agencies. The members of the committee establish links with professional societies in the health and social service fields to increase attention to women’s health and violence issues. The members of the committee also serve as resource experts for the National Advisory Committee on VAW, which is chaired by the HHS Secretary and the DOJ Attorney General. http://womenshealth.gov/about-us/who-we-are/groups-committees/steering-committee.html |
| Vitamin D Standardization Program (VDSP) | Research Initiative | CDC | OD/OSP, OD/DPCPSI/ODS | The NIH Office of Dietary Supplements (ODS) collaborates with CDC and others on the VDSP, which is an international collaborative effort to standardize the laboratory measurement of vitamin D status. The goal of the program is to improve the detection, evaluation, and treatment of vitamin D deficiency and insufficiency by promoting the standardized laboratory measurement of serum total 25-hydroxyvitamin D [25(OH)D]. VDSP promotes the standardized laboratory measurement of total 25(OH)D (a measure of vitamin D status) to improve clinical and public health practice worldwide. https://ods.od.nih.gov/Research/vdsp.aspx |
| White House Task Force on Research and Development for Technology to Support Aging Adults | Other | ACL, AHRQ | NHLBI, NCI, NIA, NIBIB, NIDCD | The Task Force on Research and Development for Technology to Support Older Adults (Tech4Aging) was established by action of the National Science and Technology Council (NSTC) Committee on Technology (CoT). In the 2016 Report on Independence, Technology, and Connection in Older Age, the President’s Council of Advisors on Science and Technology (PCAST) focused on the loss of social engagement and connectivity, cognitive change, and physical change that aging Americans often experience. Tech4Aging is to advise and assist the Assistant to the President for Science and Technology and the CoT on science and technology policy, procedures, and plans related to research and development (R&D) that will lead to technology that enhances aging Americans’ ability to be independent and engage with society as they age. These technologies may be appropriate for anyone regardless of age with the relevant functional limitations. https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/NSTC/NSTC%20TF%20Tech4Aging%20Charter%20final%20signature.pdf |
| Work Group on Harmonizing Hemoglobinopathy Data Sets | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | NLM, NCATS, NHLBI, NICHD, NIGMS, OD/OER | The mission of the Workgroup for Harmonizing Hemoglobinopathy Data Sets is to create a resource for federal programs and extramural communities to use in data systems that incorporate data elements in hemoglobinopathies. Specifically this entails establishing a Hemoglobinopathies Uniform Medical Language including: identifying specific goals and objectives for the kind of data that are required by these programs; case definitions for electronic data systems at all levels; consensus about conditions and data elements to be included; and differentiation between data needs for surveillance and for registries/biorepository. |
| Working Groups to Develop Department of Health and Human Services (DHHS) HIV/AIDS Treatment and Prevention Guidelines | Committee, Work group, Advisory group, or Task Force | CDC, HRSA | OD/DPCPSI/OAR, NIAID, NICHD | There are five working groups to develop Department of Health and Human Services (DHHS) HIV/AIDS treatment and prevention guidelines. The five working groups are the 1) HHS Panel on Antiretroviral Guidelines for Adults and Adolescents, 2) HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, 3) HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV, 4) HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, and 5) Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. The DHHS HIV/AIDS Treatment and Prevention Guideline Panels update guidelines for HIV/AIDS care providers with the most current information on combination antiretroviral therapy, treatment and prevention of opportunistic infections for people living with HIV, and the emergence of new knowledge on safety and efficacy in the general population as well as in pregnant women and children. http://www.aidsinfo.nih.gov/Guidelines/?MenuItem=Guidelines&Search=On |
| Workshop on Zika therapeutics | Meeting/ Workshop | BARDA, FDA | NIAID, NCATS, NICHD | The goals of the workshop, held in September 2017, were to: • Discuss possible therapeutic approaches for Zika Virus (ZIKV) and the ideal properties for each therapeutic • Discuss the optimal clinical trial design for different indications and achievable endpoints • Review animal models that might be used to support pre-clinical development of therapeutics • Review current ZIKV therapeutic development efforts http://www.cvent.com/events/niaid-zika-virus-therapeutics-workshop/event-summary-19d468800cf3469ba224bf9275d95464.aspx |
| World Health Organization (WHO) Programme on Prevention of Deafness and Hearing Loss | Committee, Work group, Advisory group, or Task Force | CDC | NIDCD | Stakeholders’ meeting for the WHO Programme on Prevention of Deafness and Hearing Loss to explore mechanisms to offer financial support for a World Report on Hearing (prepared and disseminated through WHO). http://www.who.int/pbd/deafness/activities/hearing_care_programme/en/ |
| Zika Supplement for Virus Tissue Tropism During Pregnancy | Resource Development | FDA, HRSA | NIAID | This activity addressed a time-critical public health crisis to understand Zika virus (ZIKV) and HIV in the Americas. This supplement leverages unique existing collaborations and resources from the parent award to develop models for ZIKV pathogenesis that currently do not exist. The investigators have the ideal expertise in virology, immunology, primate models of pregnancy, and pediatrics to quickly establish a relevant animal model for ZIKV infection of pregnant women. This supplement will perform initial studies of virus replication and pathogenesis in pregnant female macaques and their offspring. This will directly address a rapidly expanding public health emergency in the Americas that may threaten vulnerable HIV+ populations. https://zika.labkey.com/project/OConnor/begin.view? |
| Zoster Working Group of the CDC Advisory Committee for Immunization Practices | Committee, Work group, Advisory group, or Task Force | CDC | NIAID | The Working Group discusses new zoster vaccines and makes recommendations to the Advisory Committee for Immunization Practices (ACIP) on how to use zoster vaccines. |
An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government
organization in the United States.
A .gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.
A lock (🔒) or https:// means you've safely connected to the .gov website.
Share sensitive information only on official, secure websites.